The Role of the HIV-1 Accessory Proteins Nef and Vpu in Subverting Host Cellular Immunity by Pawlak, Emily N
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
9-25-2018 2:00 PM 
The Role of the HIV-1 Accessory Proteins Nef and Vpu in 
Subverting Host Cellular Immunity 
Emily N. Pawlak 
The University of Western Ontario 
Supervisor 
Dikeakos, Jimmy D. 
The University of Western Ontario 
Graduate Program in Microbiology and Immunology 
A thesis submitted in partial fulfillment of the requirements for the degree in Doctor of 
Philosophy 
© Emily N. Pawlak 2018 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Virology Commons 
Recommended Citation 
Pawlak, Emily N., "The Role of the HIV-1 Accessory Proteins Nef and Vpu in Subverting Host Cellular 
Immunity" (2018). Electronic Thesis and Dissertation Repository. 5751. 
https://ir.lib.uwo.ca/etd/5751 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
i 
 
Abstract 
The HIV-1 accessory proteins Nef and Vpu have no known enzymatic activity, yet these viral 
proteins are critical for HIV-1 viral spread and pathogenicity. To mediate this, these viral 
proteins bind to and hijack host cellular proteins, including proteins implicated in the 
membrane trafficking machinery. Key to the effects of these proteins is their ability to alter the 
subcellular localization of a plethora of cell surface receptors, including the key immune cell 
receptors CD28 and MHC-I. However, the mechanism utilized by Nef and Vpu to modulate 
these proteins is not fully understood. Herein, we demonstrated that Nef and Vpu mediate a 
decrease in both cell surface and total CD28 protein levels in CD4+ T cells. We have implicated 
the endosomal degradation machinery in this process, as we observed that in the presence of 
these viral proteins CD28 localizes to LAMP-1 positive compartments in an endosomal 
acidification-dependent manner. Moreover, in investigating the mechanisms utilized by Nef 
and Vpu to mediate CD28 downregulation we implicated the Nef LL165 and DD175 and Vpu 
S52/56 motifs, which interact with specific cellular membrane trafficking machinery, in CD28 
downregulation. Furthermore, upon infection with viruses encoding or lacking Nef and Vpu, 
we observed differential effects on cellular activation upon stimulation. In seeking to 
understand the mechanism of MHC-I downregulation by Nef, we examined the roles of 
membrane trafficking mediators in the sorting nexin family of proteins. Namely, we identified 
a novel direct Nef binding partner, SNX18, and mapped this interaction with Nef to the SH3 
domain of SNX18 and a polyproline PxxP75 motif on Nef. Additionally, using shRNA knock-
downs we have implicated SNX18 in Nef-mediated MHC-I downregulation, a key mechanism 
for HIV-1 viral immune evasion. Overall, this work sheds light on the mechanism of Nef- and 
Vpu-mediated mis-localization of host cellular proteins, processes key to the pathogenic 
effects of these viral proteins.  
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Chapter 1  
1 Introduction 
1.1 General thesis overview 
The Oxford English Dictionary defines a virus as “an infectious, often pathogenic agent or 
biological entity which is typically smaller than a bacterium, which is able to function only 
within the living cells of a host animal, plant, or microorganism, and which consists of a 
nucleic acid molecule (either DNA or RNA) surrounded by a protein coat, often with an 
outer lipid membrane”[1]. Indeed, viruses require host cells they can infect, as they are 
obligate intracellular parasites and require eukaryotic or bacterial host cells to replicate. 
Thus, as will be highlighted in this thesis, viruses have evolved ingenious mechanisms to 
make use of host cellular machinery to turn their hosts into efficient virus production 
factories. Moreover, given their generally minute size, many viruses have small genomes 
with limited coding capacity. Therefore, they must encode proteins which function in 
numerous different ways to make the host a prime location for replication.  
1.2 Introduction to lentiviruses 
In the early 1980’s a new illness appeared in North America which baffled medical 
professionals. This ailment was characterized by an increased incidence of opportunistic 
infections and rare malignancies that resulted in a rapid death [2]. This illness was later 
recognized as being caused by a severe immune deficiency, thus it was termed acquired 
immune deficiency syndrome (AIDS) by the Centers for Disease Control. Originally, AIDS 
was falsely believed to only affect men who have sex with men, however it was later proven 
that this illness could be acquired through exposure to contaminated bodily fluids through 
transfusion of blood products, heterosexual sex, and mother to child transmission during 
childbirth or breastfeeding [3-7].  
In 1983, Dr. Luc Montagnier’s laboratory at the Institut Pasteur in France isolated a virus 
from the lymph node of a patient exhibiting lymphadenopathy. This patient was considered 
high risk for developing the above mentioned novel immune deficiency syndrome [8]. 
Montagnier’s group named the isolated virus lymphadenopathy-associated virus (LAV) 
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and classified it as a retrovirus belonging to the human T-leukemia virus (HTLV) family. 
These findings were published in Science concurrently with an article by Dr. Robert Gallo 
and colleagues at the National Cancer Institute in Bethesda, Maryland. In the latter 
publication, Gallo’s group identified a virus within an AIDS patient they believed to be 
HTLV, thus they termed this virus HTLV-III [9].  
The following year, Gallo and colleagues published a series of articles illustrating that this 
novel virus was the causative agent of the acute immune deficiency termed AIDS [10-12]. 
By 1986, it was widely recognized that LAV and HTLV-III were the same virus, hence 
this newfound consensus in the virology community resulted in the creation of a new virus 
name: human immunodeficiency virus (HIV) [13]. In the three decades since its initial 
discovery, this deadly virus has spread to millions of people globally [14], making it a 
major area of research interest. 
Extensive phylogenetic analysis of HIV viral genomes has demonstrated that the 
transmission of HIV to humans occurred many years prior to the first documented cases of 
AIDS, most likely around the 1930’s in what is now known as Kinshasa in the Democratic 
Republic of the Congo [15-17]. Specifically, the epidemic is believed to have arisen from 
transmission of the primate simian immunodeficiency virus (SIV) from an infected 
chimpanzee to a human, likely through the act of bush meat hunting [18-20]. Interestingly, 
phylogenetic studies suggest that there have been multiple transmission events of SIV from 
infected primates to humans, however a single transmission event led to the group of HIV-
1 viruses that is responsible for the vast majority of infections world-wide. Specifically, 
the human immunodeficiency virus type 1 (HIV-1) is classified into four phylogenetically 
related clusters termed groups M, N, O and P [21-23]. Group M is so named as it is the 
“major” group of HIV-1, having caused the majority of HIV cases in the global epidemic. 
This group is believed to have arisen through transmission from an SIV infected 
chimpanzee [24, 25]. Similar to Group M, Group N likely arose from a single transmission 
event of SIV from an infected chimpanzee [25], while HIV-1 groups O and P are thought 
to have arisen from two independent transmission events from SIV infected gorillas [23, 
26]. In addition to HIV-1, there is also human immunodeficiency virus type 2 (HIV-2), 
which is distinct from HIV-1 and is derived from transmission of SIV from infected sooty 
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mangabeys [27-29]. Similar to HIV-1, HIV-2 is separated into numerous groups which 
derived from independent transmission events [19]. However, in contrast to HIV-1, HIV-
2 exhibits decreased transmissibility [30, 31], and only the minority of HIV-2 infected 
individuals develop immunodeficiency [32-34]. Since HIV-1 Group M is responsible for 
the vast majority of HIV infections globally, it is the primary focus of most current HIV 
research and much of what we know about HIV is from experiments using Group M 
viruses.  
As a result of a highly error prone viral replication apparatus, HIV viruses are highly 
diverse. Indeed, HIV-1 group M itself can be classified into numerous phylogenetically 
related subtypes or clades [35-37]. However, most HIV research has been performed using 
HIV-1 group M subtype B viruses as a result of these being the most prominent viruses in 
the developed world [38]. However, it is becoming increasingly clear that there are 
functional differences between group M subtypes, specifically in relation to transmission 
and disease progression [39-42]. Therefore, while the majority of this thesis will describe 
work primarily completed using HIV-1 Group M subtype B viruses, it must be 
acknowledged that there may be differences between HIV-1 viruses of different subtypes.  
HIV-1, and the related HIV-2 and SIV, are all classified as retroviruses in the genus 
Lentivirus. The family Retroviridae are enveloped viruses, which carry positive sense RNA 
in their virions [43]. These viruses are unique in that they encode a viral reverse 
transcriptase enzyme, which transcribes a double stranded DNA copy of the viral RNA 
genome [43]. The viral genome encoding DNA, known as pro-viral DNA, becomes 
permanently integrated into the host cell genome, a characteristic which has driven interest 
in the use of retroviral vectors in gene therapy [44]. From the integrated pro-viral DNA, 
viral RNAs and their encoded proteins can be produced to facilitate the production of 
progeny viruses and all retroviruses encode the structural and enzymatic proteins required 
to make virions [43]. However, the retroviruses in the genus Lentivirus are generally quite 
complex, as they have evolved a larger repertoire of proteins to ensure optimal virus 
replication [45, 46]. Specifically, lentiviruses have evolved regulatory proteins, such as 
HIV-1 Tat and Rev, which ensure enhanced gene expression [47]. Moreover, select 
lentiviruses, in particular lentiviruses that infect primates, have evolved multiple accessory 
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proteins which enhance viral spread and persistence within the host [48]. As such, primate 
lentiviruses are highly successful at hijacking host cells to facilitate viral spread.  
1.3 Biology of HIV-1 
1.3.1 Clinical course of infection 
Unlike in the 1980’s, when the virus was first discovered, infection with HIV-1 no longer 
presages certain death. Typically, when an individual becomes infected with HIV-1, an 
immune response is mounted against this foreign invasion. Patients experience flu-like 
symptoms during the first few weeks of the acute infection, as the virus disseminates, 
primarily infecting the CD4+ T cell component of the immune system [49, 50]. 
Unfortunately, unlike for many other viruses, the immune system in unable to clear HIV-
1. If left untreated, the virus continues to replicate and this chronic infection slowly 
depletes the CD4+ T cells of infected individuals. During this period, which can last up to 
a decade, infection often lacks visible symptoms [51, 52]. Eventually, infected individuals 
experience a drastic and catastrophic loss in immune system function, which leads to 
opportunistic infections and malignancies. Clinically, AIDS is defined in adults as a CD4+ 
T cell count lower than 200 cells per microliter of blood [53]. However, since the mid-
1990’s, with the implementation of a combination therapy called highly active anti-
retroviral therapy (HAART) that targets different aspects of the viral life cycle, progression 
of HIV-1 infection to the immunocompromised state can be prevented [54]. Yet, it is 
important to note that HIV-1 infected individuals must remain on therapy for the remainder 
of their lives, as a pool of latently infected cells branded the “latent reservoir” remains 
present during HAART treatment. This latent reservoir can re-populate the body with virus 
upon cessation of anti-retroviral treatment [55]. Thus, a significant amount of the current 
HIV-1 research is focused on finding an HIV-1 cure through targeting this latent reservoir. 
Finally, it is important to acknowledge that while the implementation of effective HAART 
means that HIV-1 infection can be treated, access to HAART is not universal and The Joint 
United Nations Programme on HIV/AIDS estimates that approximately half of all HIV 
infected individuals world-wide are currently not on treatment [56]. 
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1.3.2  HIV-1 virions and replication cycle 
 HIV-1 virions are enveloped and contain two copies of the viral genome which is 
comprised of 9 genes that encode for 15 proteins (Figure 1.1). The HIV-1 proteins are 
classified as: structural, enzymatic, regulatory or accessory (Table 1; [43, 45]). Within 
virions, the RNA genome is associated with the viral nucleocapsid protein, which is further 
surrounded by the capsid protein to form the viral core complex [57]. This core is 
surrounded by a host cell derived lipid envelope, which associates with the viral matrix 
protein and contains the membrane-embedded viral glycoproteins gp120 and gp41. 
To initiate the viral replication cycle (reviewed in [45]), the HIV-1 virion surface 
glycoproteins engage the viral entry receptor, CD4, and the co-receptors, CCR5 or CXCR4. 
These virus-host interactions facilitate fusion of the virion envelope with the host cell 
envelope, thereby ensuring entry [58]. The strict requirement for CD4 and CCR5 or 
CXCR4 to enter cells implies that HIV-1 infections are limited to CD4+ cells, namely the 
following immune cell types: monocytes, dendritic cells (DCs) and CD4+ T cells [59-62]. 
Post-entry, the viral core dissociates and the HIV-1 RNA genome is reverse transcribed to 
DNA by the viral reverse transcriptase. The resulting double stranded DNA, or pro-viral 
DNA, is transported into the nucleus and integrated into the host cell genome via the viral 
integrase enzyme. Ultimately, the integrated viral DNA will be transcribed and the 
resulting mRNAs generate HIV-1 proteins that fulfill specific functions within infected 
cells. Specifically, the HIV-1 regulatory proteins Tat and Rev enhance transcription and 
transport of RNA encoding viral proteins out of the nucleus for translation [47]. In this 
manner, the RNA and proteins necessary to form new virions are produced and bud from 
the host cell plasma membrane, after which the viral protease enzyme mediates proteolytic 
cleavage of viral protein precursors to form mature, infective virions. Overall, the process 
of replication is promoted by the HIV-1 accessory proteins Nef, Vif, Vpr and Vpu, which 
will be discussed in further detail below. 
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Figure 1.1 HIV-1 genome organization 
The 5’ and 3’ ends of the HIV-1 genome encode the long terminal repeats (LTRs), 
repeating sequences necessary for integration of the viral genome into the host cell 
genome. The LTRs also contain host cell transcription factor binding regions that 
enhance viral gene transcription [63]. The gag, pol and env genes encode the viral 
enzymatic and structural proteins. The rev and tat genes encode regulatory elements that 
enhance viral gene expression. The accessory proteins are encoded by the vif, vpr, vpu 
and nef genes. 
  
3’ LTR gag pol 
tat
rev
env5’ LTR
vif vpu nef
vpr
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Table 1 The HIV-1 genes and their encoded proteins 
 Gene Protein Function 
Structural 
gag p17/matrix  Targets viral proteins to sites of viral 
assembly at the plasma membrane 
p24/capsid  Constitutes the major structural 
components of the viral core 
p7/nucleocapsid Incorporation of viral genomic RNA 
into virions and coating of viral RNA 
within the virion core 
p6 Virion budding and incorporation of 
Vpr into budding virions 
env gp120/surface Binding to viral entry receptor/co-
receptors 
gp41/transmembrane Facilitates fusion of the virion 
envelope with the host cell membrane 
during viral entry 
Enzymatic 
pol Integrase Integration of viral genome into host 
cell genome 
Reverse transcriptase Transcription of pro-viral DNA from 
virion-derived viral RNA 
Protease Proteolytic cleavage of viral proteins 
within virions to form mature virus  
Regulatory 
rev Rev Regulates viral mRNA expression via 
shuttling of viral mRNA from the 
nucleus 
tat Tat Enhances transcription of viral 
genome 
Accessory 
vpu Vpu Mediates immune evasion and 
increases viral release and spread 
vpr Vpr Enhances viral replication 
vif Vif Prevents viral genome hypermutation 
nef Nef Mediates immune evasion and 
increases virion infectivity 
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1.4 HIV-1 accessory proteins 
Unlike other lentiviruses, HIV and the related SIV encode multiple accessory proteins. 
These proteins were originally termed “accessory” as they were not required for viral 
replication in vitro. However, the accessory proteins have since been deemed necessary to 
facilitate viral spread and to mediate evasion of the immune response during infections in 
vivo [48]. Indeed, the importance of HIV-1 accessory proteins for viral dissemination and 
pathogenicity has been demonstrated using both mouse and non-human primate infection 
models [64-68]. Moreover, these proteins fulfill their functions without possessing any 
known enzymatic activity and therefore function solely by interacting with and hijacking 
host cell proteins. Specifically, these proteins primarily mediate their effects by co-opting 
the host cell’s protein degradation or membrane trafficking machinery (reviewed in [48, 
69]). In this way, they sequester host cellular proteins within specific locations in the cell 
or target them for degradation via the lysosome or proteasome. Given their reliance on the 
host cellular machinery to fulfill their functions, the accessory proteins exemplify viruses’ 
strict requirement for a host. 
1.4.1 HIV-1 Vpr and Vif 
HIV-1 Vpr, or viral protein R, is an ~14 kDa protein that is actively incorporated into 
budding virions through its association with the HIV-1 p6 protein [70-73]. Multiple effects 
have been attributed to Vpr (reviewed in [74]), but this accessory proteins’ functions still 
remain poorly defined. Notably, Vpr is critical for efficient viral replication in 
macrophages in vitro [75], but it remains scantily understood how this is mediated. It has 
been postulated that this effect in macrophages may relate to Vpr’s ability to facilitate 
degradation of an as of yet undefined host anti-viral factor which inhibits virion envelope 
incorporation [76-78]. Moreover, during infection of lymphoid cells, Vpr inhibits G2 to S-
phase cell cycle progression by inducing G2 cycle arrest, resulting in cells lagging in G2 
phase, during which HIV-1 transcription is highly active [79, 80]. In addition, Vpr has been 
implicated in modulating cell survival [81]. While the mechanisms that mediate the above 
described consequences of Vpr expression remain poorly defined, these effects may be 
related to Vpr’s ability to readily hijack the host cellular ubiquitin ligase machinery to 
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mediate the ubiquitination and subsequent degradation of DNA repair pathway proteins 
[82-86].  
Similar to Vpr, the HIV-1 Viral infectivity factor (Vif) protein contributes to efficient viral 
replication by targeting host cellular proteins for ubiquitination. Specifically, Vif mediates 
the poly-ubiquitination of host cell restriction factors, cellular apolipoprotein B mRNA 
editing complex 3 (APOBEC3) proteins, leading to their degradation [87, 88]. Members of 
the APOBEC3 family of proteins limit viral replication by inducing viral genome 
hypermutations during synthesis of cDNA from viral RNA. Specifically, APOBEC3 
proteins mediate deamination of viral RNA, such that upon reverse transcription the newly 
transcribed viral cDNA contains G to A mutations, which impede the viral life cycle [89]. 
Vif counteracts this by targeting APOBEC3 proteins for degradation, thereby preventing 
their incorporation into budding virions [88]. Alternatively, degradation-independent 
mechanisms of APOBEC3 protein counteraction by Vif have also been proposed [90]. 
1.4.2 HIV-1 Nef and Vpu 
In contrast to the relatively small number of host cell proteins currently described as targets 
for intracellular sequestration or degradation by Vif or Vpr, the accessory proteins Nef and 
Vpu modulate the expression, localization, and function of an exorbitant number of host 
cellular proteins. Large scale screens have identified >30 host cell proteins that are 
modulated by Nef or Vpu [91-93]. Thus, Nef and Vpu have evolved the amazing ability to 
mediate numerous functions within host cells. Due to the sheer number of host cellular 
proteins that are altered by Nef and Vpu, we have only begun to understand the functions 
of Nef and Vpu, how these functions are mediated, and the complex interplay between 
these two proteins. The accessory proteins Nef and Vpu will be the focus of this thesis, 
with their functions described in more detail below.  
1.5 Biological effects of HIV-1 Nef and Vpu 
HIV-1 Nef and Vpu are viral proteins that, despite their lack of enzymatic activity, facilitate 
the creation of highly efficient virus production factories within their host. These proteins 
are especially interesting as they have distinct, but sometimes overlapping functions. HIV-
1 Nef, or negative factor, so named due to initial descriptions of it negatively affecting viral 
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replication [94-96], and viral protein u (Vpu), are small membrane associated proteins of 
~27 and ~16 kDa, respectively [97-99]. Vpu is a type-I transmembrane protein [100], 
whereas Nef is post-translationally modified through the addition of a lipid myristoyl 
group, which mediates Nef’s association with membranes [101]. Due to their membrane 
association, it is unsurprising that these proteins primarily usurp host cellular membrane 
trafficking pathways in order to alter the host cell environment [69]. As with the accessory 
proteins Vpr and Vif, many of these functions are mediated by sequestering host cellular 
proteins within the cell or targeting host proteins for degradation, with many of the proteins 
targeted by Nef and Vpu being cell surface associated (Figure 1.2). A critical role for HIV-
1 Nef and Vpu during infection is their contributions to viral immune evasion. Both 
proteins actively contribute to counteracting the innate and adaptive immune response. 
Collectively, these Nef and Vpu functions antagonize immune responses to promote viral 
spread and persistence.  
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Figure 1.2 Immune cell surface proteins that are targeted by the HIV-1 accessory 
proteins Nef and Vpu 
Multiple cell surface associated proteins undergo modifications in their subcellular 
localization within HIV-1 infected immune cells through the activities of HIV-1 Nef and 
Vpu. These modifications reduce the abundance of these molecules on the cell surface 
and can alter immune responses. Molecules can be targeted by Nef (blue), Vpu (purple) 
or both Nef and Vpu (green). Modifications include: decreases in cell surface MHC-I 
thereby preventing detection by cytotoxic T cells [102-104], Nef-mediated decreases in 
the cell surface chemokine receptors CCR5 and CXCR4 [105], Nef and Vpu evasion of 
NK cell responses by downregulation of ligands that bind to NK cell activating receptors 
[106-109], and decreases in cell surface CD4 to prevent detection of infected cells by 
NK cells through inducing exposure of antibody-dependent cellular cytotoxicity 
(ADCC)-mediated epitopes on the HIV-1 envelope protein [110-112]. Nef and Vpu 
decrease cell surface levels of the host cell restriction factors serine incorporator 
(SERINC) 5 and bone marrow stromal cell antigen 2 (BST-2; also called tetherin), 
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respectively, inhibiting incorporation of these anti-viral factors into budding virions 
[113-116]. Finally, the activation of infected T cells by antigen presenting cells is 
inhibited by the downregulation of activating cell surface molecules in both infected 
CD4+ T cells and in infected antigen presenting cells [117-119]. 
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1.5.1 Evasion of cell-mediated adaptive immune responses 
During viral infections, the primary immune cell type that target infected cells are CD8+ 
cytotoxic T lymphocytes (CTLs). Specifically, CTLs recognize and eliminate cells which 
present virus-derived peptides or antigens on major histocompatibility complex class I 
(MHC-I) molecules (reviewed in [120]). Mature MHC-I molecules are heterodimers 
composed of a common β2-microglobulin light chain and a variable heavy chain that binds 
to 8-10 amino acid peptide antigens [120]. To prevent detection of infected cells by CTLs, 
Nef and Vpu mediate decreases in cell surface levels of MHC-I. Specifically, Nef mediates 
the endocytosis of cell surface MHC-I, followed by its sequestration in the cellular 
paranuclear region [102, 121-123]. In contrast, Vpu disrupts the formation of newly 
synthesized MHC-I in the endoplasmic reticulum (ER) [103]. Interestingly, Nef 
preferentially targets HLA-A and HLA-B [124], while Vpu targets HLA-C [125]. 
Ultimately, the downregulation of MHC-I molecules by HIV-1 has been implicated in 
reducing CTL killing of infected cells [104]. 
The second arm of cell-mediated adaptive immune responses is comprised of helper CD4+ 
T cells, which function during infection to regulate the immune response [126]. CD4+ T 
cells are activated comparably to CD8+ CTLs, through the presentation of antigens on 
MHC class II (MHC-II) molecules by antigen presenting cells (APCs), including HIV-1 
infected monocytes and dendritic cells. Mature MHC-II molecules are presented on the cell 
surface subsequent to being loaded with peptide antigen in an endocytic cellular 
compartment. Prior to this, MHC-II molecules are complexed with the MHC-II invariant 
chain (CD74; Ii), which is degraded when the MHC-II molecule is loaded with a peptide 
antigen [127]. Both Nef and Vpu alter the expression of mature MHC-II molecules on the 
cell surface [119, 128-130], owing to their ability to interact with the MHC-II invariant 
chain. Briefly, Nef induces accumulation of the invariant chain on the cell surface or in 
intracellular compartments [129, 131]. Alternatively, Vpu may decrease the levels of cell 
surface invariant chain, though there are conflicting reports [92, 128]. Taken together, these 
alterations in invariant chain subcellular localization likely contribute to Nef- and Vpu-
mediated decreases in the quantity of peptide-loaded mature MHC-II molecules on the cell 
surface [119, 128, 130]. This decrease has been associated with a diminished ability of 
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monocytic cells to activate T cells [128]. Moreover, a correlation has been observed 
between rapid disease progression in HIV infected children and increased Nef-mediated 
up-regulation of cell surface invariant chain and downregulation of mature MHC-II [132]. 
1.5.2 Evasion of humoral and innate immune responses 
In addition to cell-mediated adaptive immune responses, a large antibody-mediated or 
humoral response is developed during HIV-1 infection. Of particular importance is the 
humoral response targeting the HIV-1 surface glycoprotein, or envelope, which is present 
on the surface of virions and infected cells. Notably, during virion entry the envelope 
glycoprotein interacts with the viral entry receptor CD4 and undergoes a conformational 
change to allow for virion envelope fusion with the host cellular membrane [133-135]. We 
have recently begun to appreciate that the envelope glycoprotein conformational change 
induced upon CD4 binding exposes epitopes that are targeted by antibodies that can be 
detected by innate immune cells to facilitate antibody-dependent cellular cytotoxicity 
(ADCC) [111, 112, 136, 137]. During ADCC, innate immune cells, such as natural killer 
(NK) cells, detect infected cells that have been bound by specific antibodies and 
subsequently mediate their lysis. Importantly, Nef and Vpu counteract this effect through 
their ability to decrease cell surface and total cellular CD4 levels [111, 112, 138], via 
targeting CD4 for lysosomal or proteasomal degradation [139-141]. This is believed to 
limit the interactions between the viral envelope and CD4 on the surface of infected cells, 
thereby reducing the exposure of CD4-induced epitopes that are targeted by ADCC-
mediating antibodies. Ultimately, this leads to a reduction in ADCC in the presence of Nef 
and Vpu [111, 112], with lower levels of cell surface CD4 correlating with a decreased 
susceptibility to ADCC [138].  
The ability of NK cells to target and eliminate HIV-1 infected cells is not solely dependent 
on ADCC-mediating antibodies binding to infected cells. Indeed, viral infections can alter 
the cell surface levels of NK cell activating or inhibitory receptors, allowing for NK cells 
to detect and lyse virally infected cells [142]. However, viruses have evolved the ability to 
counteract this innate immune mechanism by directly altering these receptors. Briefly, 
upon infection with HIV-1 lacking a functional nef gene, Jurkat T cells exhibit increases in 
receptors that are detected by the NK cell activating receptor, NKG2D [106]. However, 
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upon infection with viruses encoding Nef, Nef mediates the downregulation of NKG2D 
ligands, such that infection does not increase the abundance of these receptors on the cell 
surface [106]. This activity can prevent NK cell-mediated targeting of infected cells, as a 
correlation exists between the increased ability of Nef alleles to downregulate NKG2D 
ligands and decreases in NK cell mediated-ADCC [110]. Nef has also been implicated 
through an undefined mechanism in the downregulation of NKp44L, the ligand for the NK 
cell activating receptor NKp44, with Nef expression reducing NKp44L-mediated killing 
of infected CD4+ T cells [107].  
The modulation of NK activating receptors is also attributable to Vpu. Specifically, Vpu 
mediates decreases in cell surface levels of the NK cell activating receptor NTB-A through 
altering the processing and glycosylation of newly translated NTB-A [143]. This activity 
decreases NK cell-mediated effects against virally infected cells [108]. Moreover, 
reductions in NK cell lysis of infected T cells has also been linked to the ability of Vpu to 
decrease surface levels of the adhesion molecule intracellular adhesion molecule 1 (ICAM-
1), which limits the formation of adhesions between T cells and NK cells that are necessary 
for NK cell-mediated killing [144]. Finally, both Nef and Vpu target the NK cell activating 
receptor PVR (CD155), limiting cell surface levels to decrease susceptibility to NK cell 
killing [109, 145]. Overall, the presence of a functional Nef and Vpu protein has been 
shown to reduce NK cell-mediated killing of HIV infected CD4+ T cells [106-109]. 
1.5.3 Alterations in immune cell homing 
Critical to immune responses in vivo is the ability of immune cells to survey an organism 
for infections and be recruited to sites where immune cell responses are established. 
Adhesion molecules are essential for homing of immune cells to the secondary lymphoid 
organs, namely the lymph nodes, where immune responses are developed (reviewed in 
[146]). Nef and Vpu independently contribute to decreases in cell surface levels of the 
adhesion molecule L-selectin (CD62L; [147]), which mediates entry of T cells into lymph 
nodes. This is accomplished by interactions between the viral proteins and L-selectin, 
which facilitates the inhibition of L-selectin transport to the cell surface via Nef-mediated 
decreases in total L-selectin protein levels and Vpu-mediated intracellular sequestration of 
L-selectin [147]. Viral protein induced reductions in cell surface L-selectin results in 
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decreased adhesion of infected CD4+ T cells to the L-selectin ligand fibronectin and 
reduces L-selectin-mediated immune cell activating signaling [147]. Moreover, 
recruitment of immune cells to sites of infection is often mediated by migration in response 
to various stimuli, including chemokines. Nef and Vpu can limit this migration in response 
to chemokines by decreasing cell surface levels of chemokine receptors, including the HIV-
1 viral entry co-receptors CCR5 and CXCR4, or by altering the ability of cells to migrate 
in response to chemokines [105, 148-153]. Notably, Nef inhibits migration of infected T 
cells in response to the CXCR4 ligand SDF1 alpha [152, 153]. Additionally, Vpu reduces 
cell surface levels of CCR7 on HIV-1 infected cells, reducing migration in response to the 
CCR7 ligand [154]. The above-mentioned alterations in the migration and homing of HIV-
1 infected immune cells may alter the ability of infected cells to be detected by the immune 
system and may increase viral dissemination by promoting continued circulation of 
infected cells throughout the body.  
1.5.4 Counteraction of host cell restriction factors 
In addition to the aforementioned mechanisms mediated by HIV-1 Nef and Vpu to evade 
adaptive and innate immune responses, these viral proteins also mediate evasion of intrinsic 
antiviral proteins known as restriction factors. Restriction factors are key components of 
innate immunity and function to impede viral replication [155]. Specifically, Vpu’s most 
recognized function is undoubtedly its ability to counteract BST-2, an interferon induced 
protein. BST-2 inhibits release of enveloped viruses by incorporating into the budding 
virions’ envelope to tether these virions to the surface of infected cells [156]. Indeed, in 
cells expressing endogenous BST-2 the presence of Vpu can increase HIV-1 virion release 
by 20-fold [113, 115]. Vpu mediates increased virion release through interacting with BST-
2 and preventing its incorporation into budding virions. This is facilitated through 
numerous proposed mechanisms, including removing BST-2 from sites of viral assembly 
[157, 158], and decreasing cell surface levels of BST-2 [113]. Decreases in the abundance 
of cell surface BST-2 are achieved through inhibiting transport of newly synthesized BST-
2 to the cell surface [159], sequestering BST-2 away from the plasma membrane [160], 
and degrading BST-2 in lysosomes [161-163]. Moreover, it was recently shown that 
decreases in cell surface BST-2 are important for evasion of ADCC, as the tethering of 
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virions on the cell surface increases the exposure of CD4-induced envelope epitopes to 
which ADCC-mediating antibodies may bind [164]. Finally, the counteraction of BST-2 
has been implicated in facilitating viral dissemination early in infection [165]. 
Similar to Vpu, Nef also counteracts restriction factors, specifically the newly identified 
restriction factors belonging to the SERINC family of proteins, SERINC3 and SERINC5 
[114, 116]. Nef has long been known for its’ ability to increase virion infectivity [166, 
167], but it was not until 2015 that it was discovered that this is primarily due to the ability 
of Nef to counteract SERINC5 [114, 116]. Specifically, Nef limits the incorporation of 
SERINC5 into budding virions [114, 116, 168]. This action is facilitated by binding to 
SERINC5, which results in the redirection of SERINC5 from viral assembly sites at the 
plasma membrane to the lysosome where it is degraded [168, 169]. How SERINC5 limits 
infectivity of virions is not yet clear, but it may be related to effects on the virion envelope 
proteins as some HIV-1 envelopes appear to confer increased resistance, or alternatively 
sensitivity, to the effects of SERINC5 [170, 171]. 
1.5.5 Modulation of immune cell activation 
CD4+ T cells, the primary cell type infected by HIV-1 [172], are classically activated 
through signaling provided by APCs, including B cells, dendritic cells and monocytic cells. 
Specifically, the T cell receptor (TCR) is engaged by binding to antigen presented in the 
context of MHC-II molecules on the surface of APCs. Subsequent to initial TCR 
engagement, additional cell surface receptors and intracellular signaling molecules are 
recruited to the site of the TCR: MHC-II complex. This forms the immunological synapse, 
the sum of interactions between T cells and APCs that mediate T cell activation (Figure 
1.3; reviewed in [173]). When the immunological synapse is formed, intracellular signaling 
pathways and transcription factors are activated, leading to increased cytokine production. 
These effects can result in immune cell proliferation, which is essential for amplification 
of the immune response. Nef and Vpu can influence CD4+ T cell activation, which is 
particularly important for HIV-1 as viral gene transcription and subsequent virion 
production can be induced by transcription factors that are upregulated upon T cell 
activation [174-176]. Therefore, HIV-1 propagation may be optimized by promoting an 
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environment in which activation is sufficient to mediate viral replication and 
dissemination, whilst also preventing anti-viral immune responses and cell death.   
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Figure 1.3 Schematic of select molecules found in the immunological synapse  
Immunological synapses form between T cells and antigen presenting cells to mediate 
sustained T cell activating signaling (reviewed in [173]). In CD4+ T cells, these 
interactions include TCR binding to antigen presented in the context of MHC-II 
molecules, which is facilitated by the co-receptor CD4. TCR-mediated signaling is also 
enhanced or inhibited by binding of the co-stimulatory or co-inhibitory receptors CD28 
and CTLA-4, respectively, to B7.1/B7.2 on antigen presenting cells. Engagement of the 
TCR allows for recruitment of downstream signaling molecules, including Zap70 and 
Lck. Moreover, to ensure sustained interactions between T cells and antigen presenting 
cells, adhesion molecules, such as ICAM-1, bind to their ligands on the cognate cell. 
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1.5.5.1 Disruption of the immunological synapse 
Alterations in immune cell activation may be facilitated by changes in the cell surface 
architecture of HIV infected CD4+ T cells, as cell surface associated molecules can 
influence the formation, maintenance, and downstream signaling of the immunological 
synapse. Indeed, these processes are thwarted by HIV-1 Nef. Specifically, Nef reduces the 
formation of immunological synapse-like complexes between T cells and peptide loaded 
APCs [177]. This is facilitated by changes to immunological synapse-associated molecules 
that are mediated by HIV-1 Nef and these changes are briefly described below. 
Cell surface co-stimulatory or co-inhibitory receptors and their cognate ligands are key 
components of the immunological synapse. Thus, they are commonly targeted by 
intracellular parasites to evade immune responses [178]. Specifically, T lymphocytes 
express cell surface CD28, which functions as a co-stimulatory molecule to initiate a 
signaling cascade that acts in concert with TCR signaling to promote T cell activation 
[179]. This is facilitated by the binding of CD28 on T cells to the ligands B7.1/B7.2 
(CD80/CD86) on the surface of APCs (Figure 1.3). However, following T cell activation, 
the co-inhibitory molecule CTLA-4 is also upregulated to prevent over-activation of T 
cells. Consequentially, CTLA-4 competes with CD28 for binding to B7.1/B7.2 on APCs. 
However, HIV-1 alters these responses, as Nef reduces T cell surface levels of CTLA-4 
and CD28 [118, 180], as well as B7.1/B7.2 on monocytic cells [117]. Specifically, HIV-1 
Nef interacts with CD28 and decrease its abundance on the cell surface [118, 181]. In 
addition, Nef decreases total cellular CTLA-4 protein levels, presumably by mediating 
CTLA-4 degradation [180]. Finally, Nef also subverts the immunological synapse by 
sequestering B7.1/B7.2 within an intracellular compartment to limit availability for binding 
to CD28 or CTLA-4 [117, 182, 183]. Moreover, cellular receptors outside of the 
immunological synapse can act as co-stimulatory molecules by mediating signaling upon 
ligand binding. This includes L-selectin, which is downregulated from the cell surface by 
Nef and Vpu, a function that is associated with decreased T cell proliferation [147].  
In addition to altering cell surface receptors that modulate T cell activation, Nef can alter 
molecules that facilitate signaling downstream of these receptors. Specifically, Nef 
sequesters Lck, a kinase that plays a key role in signaling downstream of the TCR, in the 
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trans-Golgi network to prevents its recruitment to the immunological synapse [177, 184-
186]. Moreover, Nef impedes the immunological synapse recruitment of phosphoproteins 
that facilitate downstream signaling. Namely, Nef inhibits the clustering of phosphorylated 
neural Wiskott-Aldrich syndrome protein (N-WASP), an actin cytoskeleton regulator, near 
the immunological synapse, which may contribute to Nef’s ability to reduce actin ring 
formation and spreading subsequent to TCR stimulation [184, 187]. This process has been 
linked to the ability of Nef to form a Nef:kinase complex, called the Nef-associated kinase 
(NAK) complex, which contains the Nef-binding serine-threonine kinase p21 activated 
kinase 2 (PAK2) [188]. These Nef-induced changes to the mediators that potentiate 
signaling upon TCR engagement likely limit the signaling pathways that classically occur 
upon TCR activation. Overall, limiting the association of the aforementioned molecules 
with the immunological synapse may inhibit the formation of fully competent 
immunological synapses, and thus inhibit the activation of T cells by external stimuli [189]. 
1.5.5.1 Inhibition of immune cell proliferation 
HIV-1 can also modulate immune cell activation independently of its ability to alter 
immunological synapses or signaling pathways. Namely, HIV-1 can inhibit the key 
downstream consequence of T cell activation, T cell proliferation, which serves to amplify 
the immune response. These effects are mediated through HIV-1 altering amino acid 
metabolism. Specifically, a proteomic screen for host cell plasma membrane proteins that 
are modulated by Nef and Vpu identified the amino acid transporter SNAT1 as being 
downregulated in the presence of Vpu [91]. This is mediated by the ability of Vpu to bind 
to SNAT1 and facilitate its degradation in lysosomes [91]. SNAT1 depletion results in 
decreased alanine uptake and reduced proliferation upon T cell stimulation [91].  
1.5.5.2 Alterations in transcription factor activation 
Despite the ability of Nef to limit T cell activation by APCs in a classical TCR-dependent 
manner, Nef is paradoxically known to facilitate increases in T cell activation. Specifically, 
Nef lowers the threshold for activation of pathways that lead to stimulation of the activities 
of transcription factors NF-κB and NFAT [185, 190-193]. This function induces expression 
of antiviral mediators and cytokines, including IL-2 [185, 190-193]. The exact mechanism 
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by which Nef alters the threshold for activation of these pathways remains enigmatic, but 
is likely through Nef’s ability to modulate intracellular kinases and actin cytoskeleton 
regulators [186, 187, 194]. Moreover, it has been proposed that Nef reduces the threshold 
for activation to stimulate these specific pathways while alternatively limiting the 
activation of others [195]. 
In contrast to the effects of Nef, Vpu inhibits the immune cell activating transcription factor 
NF-κB. Briefly, HIV-1 Vpu counteracts NF-κB through its’ ability to downregulate BST-
2, thereby preventing clustering of virion-bound BST-2 on the cell surface [196]. 
Otherwise, BST-2 would initiate a signaling cascade activating NF-κB. Moreover, Vpu has 
BST-2-independent effects on NF-κB, whereby it prevents the nuclear translocation of 
functional NF-κB in part through inhibiting degradation of the NF-κB inhibitor IκB [197, 
198]. It has been proposed that the seemingly opposing effects of Nef and Vpu are due to 
differences in Nef and Vpu expression patterns during infection. Indeed, Nef is expressed 
early in infection, while Vpu is expressed at later time points [199-201]. In this way, early 
in infection Nef can activate NF-κB, which facilitates HIV-1 viral genome transcription, 
while later in infection Vpu reverses this Nef-mediated effect to mitigate hyper activation 
[202, 203].  
1.5.6 Modulation of cell death pathways 
While HIV-1 may increase immune cell activation in order to enhance viral gene 
transcription, the virus ensures that cellular activation is controlled to guarantee viral 
immune evasion and to prevent excessive activation which may lead to programmed cell 
death, or apoptosis [189]. Nef and Vpu can regulate this balance between activation and 
cell death through their effects on cellular activation, as well as their described pro- and 
anti-apoptotic functions. Indeed, both Nef and Vpu have ascribed pro- and anti-apoptotic 
effects, rendering it difficult to conclude if these proteins are pro- versus anti-apoptotic. 
However these differential effects may be related to differences that occur in cell types and 
time points post infection [204]. Namely, it was proposed that these viral proteins may act 
in an anti-apoptotic manner early in infection to allow for viral replication, followed by 
acting in a pro-apoptotic manner later in infection [204]. Both Nef and Vpu are implicated 
in influencing the tumour suppressor p53 which activates apoptosis. Specifically, Vpu was 
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shown to increase p53 protein levels [205], while Nef is reported to bind to p53 and prevent 
p53-induced apoptosis [206]. Nef also inhibits apoptosis through its ability to bind to the 
kinase PAK2, as this induces PAK-mediated phosphorylation of BAD, inhibiting this pro-
apoptotic protein [207]. Moreover, Nef binds to and inhibits the apoptosis signal-regulating 
kinase 1, a kinase that functions to induce apoptosis [208]. Finally, Nef inhibits apoptosis 
by binding to the membrane trafficking adaptor protein AP-2 [209]. In contrast to these 
anti-apoptotic effects, both Nef and Vpu contribute to increases in Fas/Fas ligand mediated 
apoptosis, whereby Vpu induces increased sensitivity to Fas-mediated apoptosis [210], 
while Nef increases Fas ligand expression to induce apoptosis in neighbouring cells [211]. 
Interestingly, AIDS disease progression is correlated with increased Fas expression on T 
cells [212]. Finally, Nef inhibits the anti-apoptotic proteins Bcl-2 and Bcl-XL to promote 
apoptosis [213].  
The effects of Nef on the secretion of the cytokine transcription necrosis factor-alpha 
(TNFα) is a prime example of HIV-1 balancing cellular activation with induction of 
apoptosis. Specifically, through formation of the Nef-associated kinase complex, Nef can 
induce the secretion of extracellular vesicles containing Nef, Vpu, TNFα and A disintegrin 
and metalloprotease (ADAM)-17 [214], the metalloproteinase which cleaves pro-TNFα to 
facilitate TNFα shedding [215, 216]. Surprisingly, vesicles containing these components 
are detectable in the plasma of HIV-1 positive individuals who are on anti-retroviral 
therapy [217]. Nef-induced secretion of these vesicles is associated with TNFα-mediated 
cell activation, which promotes viral transcription and enhances HIV-1 replication [214]. 
Nef thus induces TNFα production to enhance viral replication, despite TNFα being a pro-
apoptotic mediator [218]. 
1.5.7 Functional redundancy of HIV-1 Nef and Vpu 
The relationship between HIV-1 Vpu and Nef is complex and dynamic. Clear examples 
exist of these viral proteins functioning together to achieve the same effect. Specifically, 
Nef and Vpu both contribute to decreasing levels of cell surface MHC-I, CD4, MHC-II, 
PVR and L-selectin [102, 103, 109, 119, 124, 125, 128-130, 139-141, 147]. This 
redundancy may be due to the sheer importance of these modifications for successful 
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dissemination and persistence of the virus. In this way, Nef and Vpu could compensate for 
each other should defects in the other protein arise.  
Given the ability of Nef and Vpu to perform similar or related functions, there are 
interesting evolutionary dynamics between them. Specifically, in SIVs closely related to 
HIV-1, Nef counteracts the effects of the restriction factor BST-2 [219]. However, small 
differences between the primate and human BST-2 protein prevent chimpanzee SIV Nef 
proteins from counteracting human BST-2 [219-221]. Therefore, HIV-1 Vpu took over this 
SIV Nef function by evolving the ability to counteract human BST-2 [219], a function 
which was likely essential for the zoonotic transmission of SIV from chimpanzees to 
humans. Moreover, while most HIV-1 Group M viruses encode Vpu proteins that 
counteract this restriction factor, there have been viruses identified in which Vpu has lost 
the ability to counteract BST-2 and the Nef protein from these viruses performs this 
function [222]. Moreover, in the case of HIV-1 Groups O and N, viruses have been 
identified that encode either Nef or Vpu proteins that counteract BST-2 [219, 223-225]. 
Thus, the counteraction of BST-2 by Nef and Vpu clearly demonstrate the close 
relationship between these proteins’ functions and their ability to compensate for each 
other to facilitate key tasks.  
Another example of compensation is through the control of cellular activation. Specifically, 
SIV viruses encode Nef proteins capable of downregulating cell surface levels of CD3, a 
protein which functions to stabilize the TCR [226, 227]. The ability of SIV Nef proteins to 
downregulate CD3 is key to limiting extensive cell activation and may contribute to the 
decreased pathogenicity associated with SIV infections, relative to HIV-1 infections [202, 
228, 229]. Interestingly, Nef-mediated downregulation of CD3 is a function that was often 
lost when SIV viruses gained a vpu gene [229-231]. With the recent demonstration that 
HIV-1 Vpu can reduce T cell activation through its ability to suppress NF-κB activity, it 
was proposed that Vpu may be compensating for the loss of CD3 downregulation ability 
in HIV-1 Nef proteins to prevent overly pathogenic effects [202, 203]. Ultimately, the 
control of cellular activation may represent another example of the functional 
interrelatedness of Nef and Vpu.  
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1.5.8 The importance of Nef and Vpu in vivo 
Overall, the HIV-1 accessory proteins Nef and Vpu mediate a plethora of effects in HIV-1 
infected cells. These effects can in turn impact pathogenicity and viral spread in vivo. 
Evidence for the importance of Nef in HIV-1 pathogenicity first came from a cohort of 
individuals who were infected with HIV-1 via transfusion of blood products obtained from 
an HIV-1 positive donor who was infected with a virus lacking a functional nef gene. 
Interestingly, individuals infected with Nef defective virus exhibited extremely slow 
disease progression [232]. Moreover, transgenic mice that were developed to express Nef 
in CD4+ cells in the absence of all other HIV-1 proteins exhibited an AIDS-like phenotype 
[233], illustrating the pathogenic potential of this protein in the absence of infection. A 
more recently developed mouse model for studying the effects of HIV-1 was also utilized 
to demonstrate that nef-deficient viruses replicate less rapidly and induce loss of a lower 
number of T cells [234]. In addition, the importance of Nef has been illustrated through the 
use of SIV infections in non-human primate models, as nef genes encoding a premature 
stop codon readily revert to nef genes that encode a functional Nef protein [235]. 
 In the case of Vpu, multiple groups have illustrated the importance of Vpu for viral 
replication and dissemination using humanized mouse models [68, 236, 237]. A recent 
study suggested that this effect is primarily mediated though the ability of Vpu to 
counteract the restriction factor BST-2 [165]. Moreover, in infections of pig-tailed 
macaques with chimeric simian-human immunodeficiency viruses, the inhibition of Vpu 
protein production, the scrambling of the amino acids in the Vpu transmembrane domain, 
or the mutation of functionally important Vpu residues, all resulted in decreased viral 
pathogenicity [66, 67, 238]. Thus, despite Nef and Vpu being classified as “accessory” 
proteins, they are critical for infection and pathogenicity of the virus in vivo. 
1.6 How do HIV-1 Nef and Vpu mediate their functions? 
HIV-1 Nef and Vpu mediate their multiple effects without possessing their own enzymatic 
activity. This is amazing given their relatively small size, with the prototypical HIV-1 
laboratory strain NL4.3 encoding Nef and Vpu proteins containing 206 and 81 amino acids, 
respectively. This capacity to facilitate many modifications within host cells is due to their 
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ability to co-opt ubiquitous trafficking pathways. The net result of subverting trafficking 
pathways is typically the modification of the subcellular localization of many host cell 
proteins, which in turn alters their function. 
Nef and Vpu can co-opt host trafficking pathways due to the presence of a number of motifs 
that allow them to bind cellular proteins by mimicking signals utilized by host proteins 
(Figure 1.4). Importantly, despite the high diversity observed within the HIV-1 Group M 
viruses, these Nef and Vpu motifs are often very well conserved [239-243]. Additionally, 
both proteins contain regions that lack structure, and this intrinsic disorder may facilitate 
an increased number of host cell protein interactions.  
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Figure 1.4 Structure of HIV-1 Nef and Vpu and motifs that interact with host cell 
proteins 
Left: Cartoon illustrations of the Nef (A; blue) and Vpu (B; purple) proteins. Right: 
schematics illustrating motifs within NL4.3 Nef (A) or Vpu (B). The location of the 
protein motifs and their binding partners or functions are indicated. (A) NL4.3 Nef is a 
206 amino acid cytoplasmic protein which is associated with membranes through 
myristoylation of G2 [99, 244-246]. Nef associates with the membrane trafficking 
adaptor proteins AP-1 and AP-2 through interactions mediated by the 
W13/V16/M20/EEEE65 and ExxxLL165/DD175 motifs, respectively [247-249]. The 
vesicular coat protein β-COP interacts with Nef R17/19 [181, 250, 251]. The membrane 
trafficking regulators phosphofurin acidic cluster sorting (PACS)-1 and -2 bind to the 
Nef acidic cluster, EEEE65, and W113/Y120 [122, 123, 252]. The v-ATPase mediates 
interactions with DD175 [253, 254]. The Nef-targeted cargo protein CD4 interacts with 
Nef via WL58 [255]. The kinases PAK2 and SFKs bind to H89/F191 and PxxP75, 
respectively [256-262]. Nef dimerizes via an interface comprised of 
R105/I109/L112/Y115/F121/D123 [257, 263]. (B) The NL4.3 Vpu protein is an 81 amino acid 
transmembrane protein containing a short luminal domain and two cytoplasmic helixes. 
The transmembrane domain amino acids A10/A14/A18/W22 mediate interactions with the 
Vpu targeted cargo BST-2 [264, 265]. The RL45 and ExxxLV64 motifs mediate binding 
to the adaptor proteins AP-1 and AP-2 [266]. The E3 ubiquitin ligase component β-TrCP 
binds to the Vpu DSGpS56 motif upon serine phosphorylation [267].  
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The host cell machinery that Nef and Vpu hijack are primarily involved in membrane 
trafficking. This fundamental cellular process can be defined as the movement of cargo 
molecules from one location to another in membrane bound vesicles. Nef and Vpu may 
have a specific preference for these cellular processes as they themselves are membrane 
associated proteins [246, 268]. Specifically, the host cell proteins to which Nef and Vpu 
bind are proteins which facilitate trafficking through the endosomal trafficking network 
(Figure 1.5), or the ubiquitin ligase machinery which modifies cargo proteins to target them 
for trafficking to specific locations [69]. The movement of vesicle-associated molecules 
around the cell requires a large number of trafficking proteins which not only facilitate the 
physical movement of cargo along the cellular cytoskeleton, but also dictate directionality 
and specificity. These processes unambiguously determine where vesicles from one 
compartment fuse with vesicles from another compartment (Figure 1.6; [269]). Notably, 
this process is regulated in part by sequences within proteins or post translational 
modifications, such as ubiquitination, that serve to direct where cargo go by giving 
specificity to interactions with cellular trafficking proteins. The importance of regulating 
vesicular trafficking led to the 2013 Nobel prize in Physiology or Medicine being award to 
Drs. James Rothman, Randy Schekman and Thomas Südhof, who were recognized for their 
invaluable contributions to understanding how these membrane trafficking processes occur 
[270]. Importantly, viruses and viral proteins, including HIV-1 Nef and Vpu, have evolved 
the ability to mimic or alter these trafficking signals and thereby alter the localization of 
their target proteins to fulfill their functions [271]. 
  
30 
 
 
Figure 1.5 The endosomal trafficking network 
Proteins destined for the cell surface or compartments in the endocytic network are 
translated on the rough ER and trafficked through the Golgi complex to the trans-Golgi 
network wherein proteins are processed. From here, proteins can be shuttled in 
membrane enclosed vesicles to the plasma membrane and various intracellular 
compartments, including: early endosomes, recycling endosomes, late endosomes or 
multivesicular bodies (MVBs), and lysosomes. Arrows indicate the pathways through 
which vesicle transport can occur. 
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Figure 1.6 General mechanism of vesicle transport 
(1) Signals in the cytoplasmic tail of cargo proteins recruit adaptor proteins to specific 
membrane regions. This process can be further regulated by changes in membrane 
phospholipids. Other proteins necessary for subsequent stages of transport may also be 
recruited, including v-SNAREs. (2) Adaptor proteins contain specific sequences 
mediating recruitment of vesicular coat proteins which oligomerize at sites of vesicle 
budding. This oligomerization can be regulated by the ADP-ribosylation factor family 
of GTPases. (3) Membrane bending ensues and the scission of the vesicle membranes 
from the donor membrane occurs, often assisted by host cell enzymes that polymerize 
along the neck of budding vesicles and through regulated actin polymerization. Once a 
transport vesicle buds, the associated coat and adaptor proteins disassociate and recycle 
back to the donor membrane to be used in future vesicle budding events. (4/5) At 
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acceptor membranes, various tethering factors bring the vesicle into proximity of the 
acceptor membrane and proteins known as t-SNAREs interact with vesicle incorporated 
v-SNAREs to reduce the energy barrier needed to fuse membranes. Tethering factors or 
protein complexes, SNARE proteins, and enzymes in the Rab GTPase family all function 
to mediate specificity of transport, such that they ensure vesicle fusion occurs with the 
correct target membranes. Figure is modified from [269]. 
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1.6.1 Nef: host cell protein interactions 
In order for Nef to mediate its effects it associates with host cell membranes. This is 
facilitated by the post-translational modification of Nef on glycine residue two, which is 
modified by the addition of a lipid myristoyl group derived from myristic acid and 
effectively functions as a lipid anchor [99, 244-246]. When HIV-1 Nef myristoylation is 
inhibited through mutation of glycine residue two to alanine, virtually all of Nef’s functions 
are inhibited, including downregulation of CD4, MHC-I, mature MHC-II, NK cell 
activating receptors, and SERINC5 [106, 109, 114, 119]. The association of Nef with 
membranes presumably brings this protein within close proximity of host cell membrane-
associated proteins, to which Nef must bind to facilitate its functions. 
1.6.1.1 Vesicular adaptor proteins: AP-1 and AP-2 
Key membrane-associated proteins to which Nef binds are the membrane trafficking 
adaptor proteins adaptor protein 1 (AP-1) and adaptor protein 2 (AP-2). AP-1 and AP-2 
are heterotetrameric protein complexes that function as vesicular adaptors to connect cargo 
to vesicular coat proteins [272]. These proteins are recruited to specific cargo based on 
sorting signals present in the cytoplasmic tail of cargo proteins. Two prototypical sorting 
signals recognized by AP-1 and AP-2 are the tyrosine (YxxØ, where x is any amino acid 
and Ø is any amino acid with a bulky hydrophobic amino acid) and dileucine 
([D/E]xxxL[L/I], where x is any amino acid) based sorting signals (reviewed in [272]). 
These distinct signals are bound by different subunits of the adaptor protein complexes, 
with the μ subunits typically recognizing tyrosine based motifs and the combination of γ –
σ (AP-1) or α– σ (AP-2) subunits recognizing dileucine motifs. Nef has evolved the ability 
to hijack these signals to forms complexes with specific cargo and adaptor proteins. 
Namely, Nef can bind the cytoplasmic tail of MHC-I molecules by facilitating recognition 
of an unconventional tyrosine-based sorting signal (Y320SQA) in the MHC-I cytoplasmic 
tail by the AP-1 μ subunit [247]. Specifically, a crystal structure containing Nef, the AP-1 
μ subunit, and the cytoplasmic tail of MHC-I revealed that these proteins form a ternary 
complex which allows for AP-1 to bind the MHC-I Y320SQA motif despite it lacking the 
hydrophobic residue normally found in canonical tyrosine sorting signals [247]. Formation 
of the ternary complex is facilitated through the creation of a hydrophobic pocket 
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containing Nef W13, V16, M20 and an acidic cluster, Nef EEEE65, which together mediate 
interactions with AP-1 [247, 248]. Moreover, mutation of Nef M20 and EEEE65 inhibit 
MHC-I downregulation [247, 248, 273, 274], indicating that the ability of Nef to form this 
Nef: AP-1: MHC-I ternary complex is essential for the ability of Nef to downregulate 
MHC-I.  
In addition to hijacking AP-1 complexes, Nef hijacks AP-2 in a similar manner. 
Specifically, Nef forms a ternary complex with AP-2 and the cytoplasmic tail of the host 
cell receptor CD4 [275]. Unlike the Nef: AP-1: MHC-I ternary complex, the Nef: AP-2: 
CD4 ternary complex can be formed through the recognition of a dileucine based motif in 
Nef (ExxxLL165) by the AP-2 α and σ subunits, as defined by a crystal structure of Nef and 
AP-2 α and σ [249]. The Nef: AP-2 structure also revealed a surface wherein CD4 could 
bind to form a Nef: CD4: AP-2 ternary complex [249]. This predicted CD4 binding site 
contained Nef WL58 [249], which has been previously implicated in the interaction between 
Nef and the cytoplasmic tail of CD4 [255]. The recruitment of AP-2 to the CD4 
cytoplasmic tail by Nef is believed to facilitate the recruitment of the vesicular coat protein 
clathrin to mediate endocytosis of CD4-containing vesicles from the cell surface, thereby 
decreasing cell surface levels of CD4. Indeed, mutation of the Nef AP-2 binding motif 
(LL165) or CD4 binding motif (WL58) abolishes the ability of Nef to downregulate cell 
surface CD4 [276, 277].  
The Nef: AP-2 α and σ structure also suggested that the Nef diacidic motif (DD175), which 
takes the form of aspartic or glutamic acid residues depending on the Nef protein, functions 
to stabilize the interaction between Nef and AP-2 [249]. This may explain, to some extent, 
the requirement of this motif in the downregulation of CD4 [278]. However, the Nef 
diacidic motif has also been implicated in the binding of Nef to the vacuolar ATPase (v-
ATPase) [253, 254], a proton pump which acidifies endosomes [279]. It has been proposed 
that since v-ATPase binds to both Nef and the μ subunit of AP-2 it connects Nef to AP-2 
to mediate CD4 downregulation [253]. Interestingly, the mechanisms utilized by Nef to 
hijack AP-2-mediated trafficking to downregulate CD4 may also be co-opted to 
downregulate other cell surface receptors. Indeed, mutation of the Nef dileucine motif 
(LL165) and the Nef diacidic motif (DD175) have been shown to abolish the ability of Nef 
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to alter the subcellular localization of other cell surface proteins including: the MHC-II 
invariant chain [131, 280], CD28 [118, 280], CTLA-4 [180], and the restriction factor 
SERINC5 [114, 281]. Overall, the ability of Nef to co-opt classical membrane trafficking 
adaptors, namely AP-1 and AP-2, are key to Nef’s functions. 
1.6.1.2 Vesicular coat proteins and their regulators: Arf1 and β-COP  
The oligomerization of adaptor protein-containing vesicular coats is a highly regulated 
process. Indeed, the GTPase ADP-ribosylation factor 1 (Arf1) regulates the formation of 
AP-1 containing coats by interacting with AP-1 and promoting formation of an “open 
complex” wherein the cargo-binding regions are exposed [282]. Interestingly, a functional 
Arf1 protein is necessary for Nef-mediated MHC-I downregulation in T cells [283]. 
Moreover, the expression of a constitutively active Arf1 increased the ability of MHC-I to 
co-immunoprecipitate with AP-1 in the presence of Nef [283]. A more recent cryo-electron 
microscopy study revealed that Arf1 may be contributing to Nef-mediated MHC-I 
downregulation [284]. This study illustrated that a Nef: MHC-I cytoplasmic tail fusion 
protein could form a trimeric complex with Arf1 and AP-1, implicating Arf1 in promoting 
the formation of AP-1 coated vesicles [284]. Arf1 is also known to regulate the formation 
of vesicular coats containing the coat protein coatomer protein I (COPI) [285, 286], which 
Nef has also been implicated in hijacking. Indeed, it was demonstrated that 
immunoprecipitation of Nef can pull down the COPI subunit β-COP from CHO cell lysate 
[287]. While this Nef: β-COP interaction was initially mapped to the Nef diacidic motif 
[287], this was later challenged and the interaction mapped to Nef R17/19 [181, 250, 251]. 
Through the use of short hairpin RNAs to deplete β-COP and the overexpression of Nef 
R17/19 mutants, β-COP was implicated in Nef-mediated degradation of MHC-I and CD4, 
presumably in lysosomes [181, 251]. Generally, Nef may utilize components of the COPI 
trafficking pathway, including Arf1 and β-COP to mediate its distinct functions.  
1.6.1.3 Vesicular trafficking regulators: PACS-1 and PACS-2 
There are many proteins that regulate membrane trafficking by promoting or inhibiting the 
association of specific cargo with trafficking adaptors or coat proteins. A prime example 
of trafficking regulators are PACS-1 and PACS-2, which link acidic cluster containing 
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cargo molecules with membrane trafficking machinery [288]. Specifically, PACS-1 and 
PACS-2 link cargo to the vesicular adaptor proteins AP-1 and COPI, respectively [289, 
290]. Interestingly, Nef contains an acidic cluster, EEEE65, which in conjunction with 
residues W113 and Y120 facilitates binding to PACS-1 and PACS-2 [122, 123, 252]. Given 
that PACS-1 forms ternary complexes with AP-1 and cargo proteins [289], and that PACS-
1 binds to Nef and AP-1 [123, 289], PACS-1 may facilitate the formation of multi-protein 
complexes that include Nef, AP-1 and cargo molecules [291]. Indeed, the PACS proteins 
have been implicated in the ability of Nef to downregulate cell surface MHC-I, with 
mutation of the PACS-1/2 binding acidic cluster (EEEE64) or overexpression of dominant 
negative forms of PACS-1/2, inhibiting Nef-mediated MHC-I downregulation [122, 252]. 
Finally, the interaction between the PACS proteins and Nef may be important for mediating 
additional Nef functions, as mutation of the Nef EEEE65 acidic cluster also inhibits the 
ability of Nef to downregulate cell surface MHC-II [119], CD28 [280], and a variety of 
chemokine receptors [105]. 
1.6.1.4 Vesicular trafficking sorting signals: ubiquitin 
In addition to mediating recruitment of the membrane trafficking machinery through 
specific protein motifs, Nef can alter the localization of target proteins through pathways 
that are regulated by post-translational modifications. One key protein modification is the 
covalent addition of 8 kDa ubiquitin peptides in a process known as ubiquitination. 
Ubiquitination is classically thought of as functioning to mark proteins destined for 
degradation in the cytosolic proteasome, however ubiquitination also plays a role during 
membrane trafficking (reviewed in [292]). Specifically, ubiquitination functions as a signal 
for endocytosis from the cell surface by interacting with vesicular adaptor proteins. 
Moreover, endocytosed ubiquitinated proteins present in early endosomes are detected by 
components of the endosomal sorting complexes required for transport (ESCRT) 
machinery and are subsequently sorted into intraluminal vesicles that are degraded in the 
lysosome. HIV-1 Nef can hijack ubiquitin-dependent pathways in order to downregulate 
various cell surface receptors. Specifically, Nef hijacks the ESCRT associated protein 
ALIX, which binds to ubiquitinated cargo [293], by binding directly to ALIX to link un-
ubiquitinated CD4 to the ESCRT machinery [294]. This interaction mediates CD4’s sorting 
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into intraluminal vesicles and subsequent lysosomal degradation [294, 295]. Nef also 
mediates the accelerated trafficking of ubiquitinated SERINC5 to lysosomes where this 
restriction factor is degraded [169]. Additionally, Nef induces ubiquitination of the 
chemokine receptor CXCR4 to promote its downregulation from the cell surface [148]. 
Nef also enhances the ubiquitination and degradation of Giα2 which functions in signaling 
downstream of chemokine receptors [296]. Finally, the Nef protein itself can be 
ubiquitinated at K144 and mutation of this residue inhibits the ability of Nef to downregulate 
both CD4 and MHC-I [297, 298]. However, it is unknown if the ubiquitination of Nef is 
required for CD4 and MHC-I downregulation.  
1.6.1.5 Kinases: SFKs and PAK2 
Membrane trafficking pathways and proteins may be altered by signaling molecules, such 
as intracellular kinases. Nef may therefore modulate trafficking though its ability to bind 
to specific kinases, namely members of the Src family kinases (SFKs) and PAK2. 
Specifically, Nef binds to and mediates activation of the tyrosine kinases Hck, Lyn, and c-
Src, members of the SFKs [299]. The details of this interaction have been elucidated using 
mutational analyses, crystal structures, and solution NMR structures. These studies 
indicate that the RT loop of the SH3 domain in SFKs interacts with the Nef type II 
polyproline helix, specifically the P69xRPxxPxRP78 encoding region [256-260]. Similar 
SH3: polyproline helix interaction interfaces are commonly used by host cellular proteins 
[300]. Moreover, the Nef PxxP75 motif is critical for this interaction, as a Nef AxxA75 
mutant is unable to activate SFKs [299]. The Nef: SFK interaction has been implicated in 
the formation of a multi-kinase signaling complex which activates a phosphoinositide 3-
kinase (PI3K)-signaling pathway that induces the endocytosis of cell surface MHC-I [121, 
122, 301]. Therefore, mutation of the Nef PxxP75 motif or inhibition of Nef: SFK binding 
using small molecule inhibitors can block Nef-mediated downregulation of cell surface 
MHC-I [121, 301]. Interestingly, inhibition of the Nef: SFK interaction has also been 
shown to negatively affect the ability of Nef to increase virion infectivity and alter cellular 
activation [302, 303]. In addition, mutation of the Nef PxxP75 motif can inhibit Nef-
mediated downregulation of MHC-II [119, 304], NK cell activating receptors [109, 305], 
and chemokine receptors [105, 149-151]. While these effects may be due to the inability 
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of Nef to bind SFKs, the Nef PxxP75 motif is also implicated in facilitating the binding of 
Nef to the serine-threonine kinase PAK2 [306, 307].  
When Nef-associated serine-threonine kinase activity was first observed in T cells, the 
identity of the Nef-associated kinase was unknown. Thus, this complex was initially termed 
the Nef-associated kinase (NAK; [307, 308]). It was later recognized that the Nef-
associated kinase is PAK2 [309-311]. Unlike the Nef-binding SFKs, PAK2 lacks a SH3 
domain to interact with the Nef PxxP75 motif. Rather, mutational analysis and protein 
modeling suggests that PAK2 interacts with a hydrophobic patch on Nef containing H89 
and F191 [261, 262]. Thus, the requirement of the Nef PxxP75 motif for PAK2 binding has 
been suggested to be due to PAK2 forming a complex with Nef concomitantly with other 
associated proteins, including the SH3-domain containing protein Vav, which may act to 
stabilize the interaction between Nef and PAK2 [312]. The association of Nef with PAK2 
may facilitate PAK2 activation in cells [311]. The Nef: PAK2 interaction is primarily 
associated with the ability of Nef to alter T cell activation [187, 188, 194, 313], modulate 
T cell survival [207], and to mediate the secretion of extracellular vesicles [314]. Overall, 
Nef-mediated interactions with cellular kinases, including SFKs and PAK2, are key to 
many alterations in the cellular environment facilitated by Nef. 
1.6.2 Nef oligomerization  
In order for Nef to mediate its functions, including activating cellular kinases, protein 
dimerization may be required. Indeed, Nef dimers and trimers were observed in vitro [263, 
315]. Based on crystal structures and mutational analyses, a dimer interface was proposed 
which consists of a hydrophobic patch made up of Nef residues I109, L112, Y115 and F121 
flanked by electrostatic interactions between R105 on one monomer and D123 on the other 
monomer [257, 263]. Studies suggest that in cells Nef can oligomerize and that Nef 
dimerization requires the Nef I109/L112/Y115/F121 hydrophobic patch [316-318]. Moreover, 
the significance of this dimerization interface was supported by findings that mutation of 
D123 or the hydrophobic patch inhibits various Nef functions, including CD4 
downregulation, MHC-I downregulation and enhancement of virion infectivity [316, 319]. 
However, more recent work suggests that the Nef dimer interface may be altered when Nef 
interacts with various binding partners [260, 320], and the importance of Nef D123 for 
39 
 
dimerization has been questioned [247, 260, 321]. Nonetheless, it is believed that Nef’s 
ability to dimerize is critical for its function and the creation of small molecule inhibitors 
to block Nef’s effects via targeting dimerization have been proposed [318, 322]. 
1.6.3 Vpu oligomerization 
The HIV-1 Vpu protein, like Nef, is membrane associated given that it contains a 
transmembrane domain. Specifically, Vpu is a type I integral membrane protein with a 
single alpha helical transmembrane domain [268]. Interestingly, Vpu oligomerizes and is 
classified as a class IA viroporin, similar to the unrelated influenza A’s matrix 2 protein 
[323]. Computer modeling and NMR spectroscopy suggest Vpu forms pentameric 
oligomers [268, 324-326], thereby forming a pore within membranes which can mediate 
selective transport of cations [327, 328]. The functional significance of ion channel 
formation by Vpu remains enigmatic, though pore formation has been correlated with the 
ability of Vpu to downregulate CD4 and enhance virion release [328, 329]. In contrast, it 
has been suggested that the active form of Vpu for CD4 downregulation is monomeric, as 
mutation of Vpu residue W22 increases Vpu oligomerization and decreases the ability of 
Vpu to downregulate CD4, without inhibiting Vpu: CD4 interactions [330]. Moreover, a 
Vpu transmembrane domain mutation (S23A) which inhibits Vpu ion channel activity did 
not inhibit the ability of Vpu to counteract BST-2 [331]. Finally, the effects of Vpu ion 
channel formation may be restricted to specific subcellular locations given that live cell 
imaging indicates that Vpu does not oligomerize in the ER [326]. 
1.6.4 Vpu: host cell protein interactions 
1.6.4.1 Target protein binding 
In addition to mediating oligomerization, the transmembrane domain of Vpu is implicated 
in forming key interactions with host cellular proteins that Vpu targets for downregulation. 
Indeed, Vpu counteracts BST-2 by binding to BST-2 via an interaction interface that is 
mediated by the transmembrane domains of these proteins. This interface has been mapped 
using mutational analysis and NMR spectroscopy to Vpu residues A10, A14, A18 and W22, 
mutation of which inhibit Vpu: BST-2 interactions and the ability of Vpu to antagonize 
BST-2 [264, 265]. Moreover, structural modeling of Vpu suggests that the transmembrane 
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domain forms a helix with A10, A14, A18 and W22 located on same face of the helix [264, 
325]. This model implies that these residues could constitute an interaction interface. The 
transmembrane domain of Vpu has also been implicated in Vpu’s ability to downregulate 
cell surface CD4. Specifically, while a number of studies suggest that Vpu and CD4 
interact via their cytoplasmic domains [332-336], mutation of transmembrane domain 
residues or replacement of the Vpu transmembrane domain with that of other proteins have 
been shown to inhibit the ability of Vpu to degrade or bind CD4 [330, 337-339]. 
Additionally, combinations of mutations within the Vpu transmembrane domain residues 
A19, A14, A18 and W22 or scrambling of the Vpu transmembrane domain sequence inhibit 
the ability Vpu to downregulate NK cell activating receptors [108, 145, 305] and the 
chemokine receptor CCR7 [154]. These findings demonstrate that the Vpu transmembrane 
domain is critical for Vpu to mediate its function, likely through facilitating binding to 
target proteins.  
1.6.4.2 Vesicular adaptor proteins: AP-1 and AP-2 
The interactions between Vpu and host cell proteins enable Vpu to alter the subcellular 
localization of target proteins by linking them to cellular machinery, similar to the 
functions of Nef. Recently, it was demonstrated that Vpu can hijack membrane trafficking 
adaptor proteins. Specifically, the cytoplasmic tail of Vpu contains a dileucine-like motif 
(ExxxLV64; Figure 1.4), similar to the conventional adaptor protein-binding dileucine 
motif ([D/E]xxxL[L/I/V]). Using chromatography this motif in Vpu was shown to mediate 
a direct interaction with AP-1 and AP-2 [340]. Moreover, the formation of a fusion protein 
containing the cytoplasmic tails of BST-2 and Vpu exhibited enhanced AP-1 binding, 
compared to BST-2 or Vpu alone [340]. The latter BST-2: Vpu fusion was successfully co-
crystalized with AP-1 [340]. This structure indicated that Vpu forms a ternary complex 
with BST-2 and AP-1 whereby an atypical tyrosine binding motif, YxYxxØ (where Ø, 
where x is any amino acid and Ø is any amino acid with a bulky hydrophobic amino acid), 
in BST-2 binds to AP-1 μ. This structure also demonstrated that the Vpu dileucine-like 
motif binds to the AP-1 γ and σ subunits, while Vpu residues RL45 interact with AP-1 at 
the γ-σ interface [340]. The formation of a Vpu: BST-2: AP-1 complex may link BST-2 to 
the endocytic trafficking network to facilitate Vpu-mediated exclusion of BST-2 from viral 
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assembly sites and BST-2 lysosomal degradation. This possibility is supported by mutation 
of the Vpu dileucine-like (ExxxLV64) or RL45 motifs, which inhibits both Vpu-mediated 
decreases in cell surface BST-2 and increases in virion release [340-342]. Moreover, AP-
2 may form a ternary complex with Vpu and BST-2 similar to AP-1, as AP-2 was co-
immunoprecipitated with Vpu in BST-2 expressing HEK293T cells in a manner dependent 
on the Vpu ExxxLV64 motif [266]. Interestingly, the recruitment of AP-1 or AP-2 to BST-
2 to form a ternary complex may be regulated by phosphorylation of Vpu, specifically at 
serine residues S52/56 [266], which are phosphorylated by casein kinase II [343].  
1.6.4.3 LC3-associated phagocytosis mediators: LC3C 
In addition to mediating interactions with host cellular adaptor proteins, the Vpu ExxxLV64 
motif mediates an interaction with the protein LC3C [344]. LC3C is a member of the Atg8 
family of ubiquitin-like proteins that are conjugated to phospholipids. This conjugation 
leads to membrane association of cargo and facilitates selective transport of LC3 
conjugated membranes to either autophagosomes or a non-canonical phagocytic pathway 
termed LC3-associated phagocytosis (LAP) [345]. Interestingly, depletion of autophagy or 
LAP proteins revealed that proteins specifically facilitating LAP are required for Vpu to 
enhance virion release in a BST-2 dependent manner [344]. Therefore, formation of a Vpu: 
LC3C complex may contribute to the downregulation of BST-2 by connecting BST-2 to 
LAP machinery [344].  
1.6.4.4 Ubiquitin ligase machinery: β-TrCP 
Vpu mediates some of its effects by hijacking the cellular ubiquitin ligase machinery. 
Specifically, Vpu links target host cell proteins CD4 and BST-2 to β-transducin-repeat 
containing protein (β-TrCP) [162, 267, 346], a component of the Skp Cullin F-box 
containing (SCF) E3 ubiquitin ligase complex. Beta-TrCP functions as an adaptor molecule 
that binds phosphorylated cargo to connect it to the ubiquitin conjugating machinery [347]. 
Vpu usurps this machinery through its casein kinase phosphorylated serine residues which 
are part of the DSGNES56 motif in NL4.3 Vpu (Figure 1.4). This sequence partially 
matches the canonical β-TrCP recognition motif, DpSGøxpS, where x is any amino acid, ø 
is a hydrophobic residue, and the serine residues are phosphorylated [347]. Binding of Vpu 
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to β-TrCP facilitates formation of a ternary complex between Vpu, β-TrCP, and CD4 or 
BST-2 [162, 267, 346]. In the case of CD4, the formation of Vpu: CD4: β-TrCP complexes 
in the ER allows for β-TrCP to recruit additional components of the SCF E3 ubiquitin 
ligase machinery which mediates polyubiquitination of the CD4 cytoplasmic tail [139, 267, 
348]. Subsequently, components of the cellular ER associated degradation (ERAD) 
pathway mediate the translocation of ubiquitinated CD4 from the ER to the cytoplasm 
where CD4 is degraded by the proteasome [140, 337, 348]. Key to this process is the initial 
Vpu: β-TrCP interaction, as mutation of the DSGNES56 motif serine residues to non-
phosphorylatable residues inhibits β-TrCP binding to Vpu and Vpu-mediated CD4 
degradation [267, 335, 349, 350].  
In contrast to CD4 downregulation, Vpu binds to BST-2 on endosomes or at the trans-
Golgi network [161, 351]. Formation of Vpu: BST-2: β-TrCP ternary complexes can 
subsequently mediate lysosomal degradation of BST-2 [161, 351]. Specifically, binding of 
β-TrCP to Vpu that is bound to BST-2 may facilitate recruitment of E3 ubiquitin ligases 
which enhance the ubiquitination of BST-2 [351]. The ubiquitination of BST-2 serves as a 
signal to sort BST-2 into degradative lysosomes through detection by components of the 
ESCRT machinery. Namely, this activity is regulated by the ESCRT-0 protein hepatocyte 
growth factor-regulated tyrosine kinase substrate (HRS) which binds ubiquitinated cargo 
and links them to ESCRT machinery that mediates trafficking to lysosomes [292]. Indeed, 
HRS co-immunoprecipitated with BST-2 and Vpu while siRNA knock-down of HRS 
inhibited the ability of Vpu to downregulate cell surface and total BST-2 protein levels 
[352]. Moreover, inhibition of endosomal acidification or the use of lysosomal inhibitors 
reduced Vpu-mediated BST-2 downregulation [161, 163, 353]. Furthermore, siRNA- or 
shRNA-mediated knock-downs implicated β-TrCP in Vpu-mediated decreases of cell 
surface and total BST-2 protein levels [161, 353, 354]. However, mutation of the β-TrCP 
binding site does not completely abolish the ability of Vpu to enhance virion release [161, 
351, 353]. Thus, β-TrCP binding may only constitute one element of the mechanism 
through which Vpu counteracts BST-2. 
In addition to mediating the downregulation of CD4 and BST-2, the binding of β-TrCP to 
Vpu may have additional effects within infected cells. Specifically, the Vpu: β-TrCP 
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interaction may inhibit the ability of β-TrCP to fulfill its normal cellular functions. Briefly, 
when the NF-κB signaling pathway is initiated, the NF-κB inhibitor IκB is phosphorylated 
and subsequently bound by β-TrCP (reviewed in [355]). This interaction facilitates IκB 
ubiquitination and proteasomal degradation to allow for NF-κB to translocate into the 
nucleus and function as a transcription factor. However, binding of Vpu to β-TrCP may 
sequester β-TrCP away from this canonical target and prevent IκB degradation. This 
dissociation may contribute to Vpu’s ability to suppress NF-κB activation [197, 198, 356]. 
Similar to IκB, the pro-apoptotic protein p53 is also phosphorylated and subsequently 
degraded by β-TrCP [357]. Accordingly, expression of Vpu was shown to inhibit the 
degradation of p53 leading to increased p53-induced apoptosis [205]. Overall, Vpu 
mediates hijacking of the ubiquitin ligase machinery by connecting it to specific host 
proteins and may prevent β-TrCP from facilitating its normal functions. 
1.7 Thesis overview 
It is established that HIV-1 Nef and Vpu are essential for viral spread and contribute to 
AIDS pathogenesis. This is due to the ability of these viral proteins to alter and evade 
immune responses. Many specific functions of Nef and Vpu have been described that 
contribute to creating an optimal host cell environment for HIV. This is facilitated by the 
hijacking of host cell membrane trafficking machinery to alter the sub-cellular localization 
of target proteins. However, our understanding of how HIV-1 Nef and Vpu create the 
optimal host cell environment is not yet complete.  
Our general hypothesis is that these undefined pathways are mediated by Nef and Vpu 
commandeering host cell proteins that are implicated in membrane trafficking events. The 
work within this thesis involves investigating the mechanisms by which HIV-1 Nef and 
Vpu alter the host cellular environment, which may facilitate evasion of the immune system 
and support viral spread. Specifically, we examine the mechanisms by which HIV-1 Nef 
and Vpu reduce cell surface levels of the co-stimulatory molecule CD28 (Chapter 2) and 
the mechanism by which Nef reduces cell surface levels of MHC-I (Chapter 3). 
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1.7.1 Chapter 2 
Previous studies illustrated that the HIV-1 Nef protein can decrease cell surface levels of 
the T cell co-stimulatory molecule CD28 [118, 181]. However, these studies did not define 
the mechanistic details of CD28 downregulation during an HIV-1 infection. Therefore, our 
objectives were to: 
• Determine the subcellular fate of CD28 upon HIV-1 infection 
• Describe the HIV-1 viral proteins and their host cell binding motifs implicated in 
CD28 downregulation 
• Examine the functional consequences of CD28 downregulation 
In undertaking our investigation into the mechanism by which HIV-1 Nef reduces 
endogenous levels of cell surface CD28 on CD4+ T cells, we also observed downregulation 
of cell surface CD28 mediated by HIV-1 Vpu. Therefore, we examined the mechanism of 
CD28 downregulation mediated by both HIV-1 Nef and Vpu. We found that both Nef and 
Vpu decrease total CD28 protein levels and facilitate transport of CD28 to LAMP-1 
positive lysosomal compartments. Moreover, we identified viral protein motifs that were 
essential for this function, thereby demonstrating that specific membrane trafficking 
proteins known to interact with these motifs may be important for downregulating CD28. 
Finally, we postulate that the downregulation of CD28 is playing a role in the broad 
mechanisms through which Nef and Vpu modulate T cell activation.  
1.7.2 Chapter 3  
It is known that HIV-1 Nef reduces cell surface levels of MHC-I through its ability to 
facilitate trafficking of MHC-I to an intracellular compartment wherein this receptor is 
sequestered. A number of Nef-interacting host cell membrane trafficking proteins have 
been implicated in MHC-I downregulation, however given the sheer complexity of moving 
cargo within the cell, there are undoubtedly many additional host cell proteins that take 
part in this process. We hypothesized that the sorting nexin proteins SNX9 and SNX18 
were potential trafficking mediators that could facilitate this Nef function. The rationale 
for this being that SNX18 was previously shown to form a complex with Nef that localizes 
to AP-1 positive compartments, subcellular locales through which MHC-I traffics during 
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Nef-mediated downregulation [358]. Moreover, both SNX18 and SNX9 interact with Nef-
binding proteins, namely AP-1 and AP-2, respectively. Our objectives in this study were 
to: 
• Determine if Nef directly binds SNX18 and SNX9, and map this interaction 
• Determine if the Nef: SNX18 complex plays a role during MHC-I downregulation 
In this study, we showed that SNX18, but not SNX9, is a Nef-binding protein. We mapped 
this interaction to the SH3 domain of SNX18 and the Nef PxxP75 motif. Moreover, we 
demonstrated that reducing SNX18 protein levels reduces the ability of Nef to 
downregulate cell surface levels of SNX18. Overall, we have identified a novel Nef: host 
protein interaction which mediates MHC-I downregulation, a Nef function that is key to 
HIV-1 pathogenesis [359, 360]. 
1.7.3 Significance 
The work presented in this thesis details mechanisms through which the HIV-1 viral 
proteins Nef and Vpu subvert host cellular machinery to alter the sub-cellular localization 
of the immune cell receptors CD28 and MHC-I. The ability of viruses, like HIV-1, to hijack 
host cell machinery is key to their ability to replicate, as viruses cannot produce progeny 
virions without the host cell. Therefore, viruses have evolved ingenious ways to usurp host 
cellular pathways. Understanding how viruses take control of cellular pathways and the 
cellular machinery not only informs us about how viruses mediate their effects, but also 
about normal cellular function. 
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Chapter 2  
2 The downregulation of CD28 by HIV-1 Nef and Vpu 
2.1 Introduction 
Adaptive immune responses are primarily driven by B and T lymphocytes, which facilitate 
humoral and cell-mediated immunity (reviewed in [1]). Although a simplification, thymus 
derived lymphocytes, or T cells, can be classified as CD8+ CTLs or CD4+ T helper cells, 
and these cells play key roles during anti-viral responses. Naïve T cells require signaling 
from APCs to become competent effector cells. According to the two-signal model of T 
cell activation, APCs provide two signals to enable these cells to become productive 
effector cells. The first signal is established during MHC-restricted binding of the TCR: 
antigen complex, while signal 2 consists of co-stimulatory signaling (reviewed in [2, 3]). 
A lack of co-stimulatory signaling results in cells becoming unresponsive or anergic. Key 
co-stimulatory signaling is provided by binding of CD28, a transmembrane receptor 
expressed on the surface of T cells, to B7.1/B7.2 on the surface of APCs. Indeed, CD28 
receptor ligation initiates downstream signaling, which in conjunction with TCR signaling, 
results in cell activation and proliferation essential for mounting an immune response [4, 
5].  
The importance of the TCR and co-stimulatory signaling to the development of an effective 
immune response makes them prime targets of intracellular pathogens. Indeed, many 
viruses have evolved the capabilities to intricately modulate these T cell activation cues to 
optimize their replication and persistence. For instance, lymphotropic viruses, including 
HIV-1, HTLV, and Epstein-Barr Virus inhibit T cell activation by downregulating 
components of the TCR and the TCR-associated kinases essential for TCR signaling [6-
11]. Moreover, viruses inhibit signaling downstream of co-stimulatory receptors, or alter 
the levels of cell surface co-stimulatory or inhibitory molecules [12-15]. Ultimately, virus-
induced changes in T cell activation can result in immune evasion, enhanced viral 
replication, and increased viral persistence. The importance of viral alterations to immune 
cell activation are evidenced by the specific HIV-1 proteins that play key roles in T cell 
activation. 
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HIV-1 encodes four accessory proteins that lack any known enzymatic or structural 
functions: Vif, Vpr, Nef and Vpu (reviewed in [16-18]). Collectively, these viral proteins 
play critical roles in increasing infectivity, persistence and pathogenesis. While Nef and 
Vpu are arguably the most extensively studied accessory proteins, their roles in T cell 
activation are not fully understood. The ability of Nef and Vpu to downregulate various 
host cell receptors is a key function mediating their effects. Indeed, both Nef and Vpu 
downregulated multiple receptors in a screen to identify cell surface proteins that are 
altered by these viral proteins [19]. Specifically, Nef and Vpu facilitate degradation or 
intracellular sequestration of host receptors, including restriction factors and immune cell 
receptors, to thwart their cell surface expression and ultimately, their function [16]. By 
hijacking membrane trafficking proteins, such as the adaptor proteins AP-1 or AP-2, Nef 
and Vpu connect multiple cellular receptors to additional cellular trafficking machinery 
which alters the receptors’ subcellular localization. For example, Nef hijacks AP-1 to 
facilitate the endocytosis and sequestration of MHC-I molecules [17, 20-22], limiting 
recognition of infected cells by the immune system [23]. In parallel, the ability of Nef to 
hijack AP-2 results in the endocytosis and degradation of CD4, which limits superinfection 
and ADCC [24-31]. Similarly, Vpu hijacks BST-2 trafficking by associating with adaptor 
proteins to facilitate its sequestration and degradation [32-36]. Vpu also enables the 
degradation of CD4 by targeting newly synthesized CD4 to the ERAD pathway [37]. 
Interestingly, Nef expression leads to endocytosis of CD28 from the cell surface, in a 
manner dependent on both AP-1 and AP-2 [38, 39]. However, the fate of CD28 after Nef-
mediated endocytosis remains poorly understood and the effects of Vpu on CD28 are 
unexplored. 
In this chapter, we report that Nef and Vpu decrease cell surface and total cellular CD28 
levels in infected CD4+ T cells. Moreover, these decreases in total CD28 are blocked by 
inhibiting the cellular degradation machinery, consistent with Nef or Vpu facilitating 
trafficking of CD28 to an acidic lysosomal compartment. Additionally, a mutant Nef 
protein associated with impaired binding to the vacuolar ATPase was compromised in its 
ability to reduce cell surface and total CD28 levels, while a non-phosphorylatable Vpu 
protein unable to recruit protein degradation machinery was impaired in its ability to reduce 
cell surface and total CD28 levels. Moreover, we sought to determine if knock-downs of 
75 
 
specific host cell trafficking machinery impaired the observed downregulation of CD28. 
Finally, we found that the ability of Vpu to downregulate CD28 is not limited to the lab 
adapted HIV-1 strain NL4.3 Vpu, and infection of cells with viruses encoding Nef or Vpu 
have differential effects on activation upon stimulation of CD3 and CD28. 
2.2 Results 
2.2.1 The HIV-1 accessory proteins Nef and Vpu downregulate cell surface and total 
CD28 protein levels 
To investigate the effects of the HIV-1 accessory proteins Nef and Vpu on endogenous 
CD28 levels, CD4+ Sup-T1 T cells were infected with Gag-Pol truncated, vesicular 
stomatitis virus envelope glycoprotein (VSV-G) pseudotyped and eGFP expressing HIV-
1 NL4.3 viruses encoding both Nef and Vpu (NL4.3), Vpu alone (dNef), Nef alone (dVpu), 
or neither accessory protein (dVpu dNef). Infected Sup-T1 cells were analyzed by flow 
cytometry after staining for cell surface CD28 (Figure 2.1). Upon gating on live (Zombie 
RedTM-), infected (GFP+) single cells (Figure 2.2), significantly greater cell surface levels 
of CD28 were present on cells infected with viruses lacking Nef (dNef), Vpu (dVpu) or 
both Nef and Vpu (dVpu dNef), compared to cells infected with virus encoding both Nef 
and Vpu (NL4.3; Figure 2.1A, B, C). Accordingly, Western blot analysis confirmed the 
presence or absence of Nef and Vpu in infected Sup-T1 cells (Figure 2.1D). Moreover, we 
examined the ability of Nef and Vpu expressed from replication competent NL4.3 to 
downregulate cell surface CD28 in infected CD4+ T cells purified from peripheral blood 
mononuclear cells (PBMCs) (Figure 2.1E, F; Figure 2.3). In line with our observations in 
Sup-T1 cells, in the absence of Nef (dNef), Vpu (dVpu), or both Nef and Vpu (dVpu dNef) 
significantly greater cell surface levels of CD28 were present when compared to cells 
infected with NL4.3 (Figure 2.1E), indicating that Nef and Vpu independently 
downregulate cell surface CD28 in both primary CD4+ T cells and the immortal CD4+ T 
cell line, Sup-T1 cells. 
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Figure 2.1 HIV-1 Nef and Vpu downregulate cell surface CD28 protein levels 
CD4+ Sup-T1 and primary CD4+ T cells were infected with VSV-G pseudotyped or 
replication competent NL4.3. Viruses encoded Nef and Vpu (NL4.3, red), lacked Nef (dNef, 
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blue) or Vpu (dVpu, orange), or lacked both Nef and Vpu (dVpu dNef, green). Infected cells 
were stained for CD28 and analyzed by flow cytometry. Live infected Sup-T1 cells were 
analyzed by gating on Zombie RedTM- and GFP+ cells and infected primary CD4+ T cells 
were analyzed by gating on p24+ cells. (A) Representative dot plots illustrating cell surface 
CD28 (APC) and infection (GFP+) of live (Zombie RedTM-) Sup-T1 cells. (B) 
Representative histograms illustrating cell surface levels of CD28 or the appropriate isotype 
control on Sup-T1 cells after gating on live (Zombie RedTM-) and infected (GFP+) cells. 
CD28 (APC) geometric mean fluorescence intensities (MFI) are indicated. (C) Summary of 
the relative mean (+/-SE) cell surface CD28 levels on infected (GFP+) Sup-T1 cells based 
on MFIs (n=17). (D) Western blot illustrating expression of Nef and Vpu in infected Sup-
T1 cells. (E) Representative histograms illustrating cell surface levels of CD28 or the 
appropriate isotype control on uninfected (UI) or infected (p24+) CD4+ PBMCs. MFIs are 
indicated. (F) Summary of the relative mean (+/-SE) cell surface CD28 levels on infected 
CD4+ T cells based on MFIs obtained from infection of CD4+ T cells from two healthy 
donors (n ≥3). (UI: uninfected; SE: standard error; Mr: molecular weight; GAPDH: 
glyceraldehyde 3-phosphate dehydrogenase; GFP: green fluorescent protein; SE: standard 
error; *p≤ 0.05; **p≤ 0.01; ****p≤ 0.0001). 
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Figure 2.2 Gating of live infected Sup-T1 cells infected with Gag-Pol truncated 
VSV-G pseudotyped NL4.3 
To examine live infected cells, dead cells were excluded by gating on Zombie RedTM- 
cells, doublets were excluded and subsequently infected (GFP+) cells were gated on. In 
a representative experiment, 80.3% of cells were live (Zombie RedTM-) and 82.1% of live 
single cells were infected (GFP+). Gates were set based on FMO (fluorescence minus 
one) controls stained for all fluorophores except that which is being gated on. 
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Figure 2.3 Analysis of primary CD4+ T cells infected with replication competent 
virus 
Primary CD4+ T cells were purified and infected with replication competent NL4.3 
viruses and stained for cell surface CD28 and intracellular p24. (A) To examine the cell 
surface CD28 levels on infected cells, single cells were gated on followed by gating on 
the p24 (PE) and CD28 (APC) high populations. In a representative experiment, 5.22% 
of cells were p24 high. (B) Representative dot plots illustrating p24 (PE) and CD28 
(APC) on cells that were either uninfected and unstained or stained with the appropriate 
APC isotype control or infected and stained with the appropriate PE isotype control or 
both anti-CD28 (APC) and anti-p24 (PE). 
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Given that HIV-1 Nef and Vpu are known to decrease cell surface levels of various 
receptors by mediating their degradation, we next sought to determine if these viral proteins 
alter total CD28 protein levels. To examine total CD28 protein levels and due to the 
unavailability of an antibody capable of detecting endogenous CD28 on Western blots, we 
engineered an expression vector to facilitate overexpression of CD28 in cells. This vector 
was designed to optimize protein expression by fusing the CD8 α signal peptide to the 
CD28 protein coding sequence [40], as has been done previously to overexpress other cell 
receptors [41, 42]. Moreover, this vector contains an epitope (FLAG) tag to enable 
detection (Figure 2.4). We subsequently examined the effects of Nef on total CD28-FLAG 
protein levels, as Nef had the largest effect on cell surface CD28, as measured by flow 
cytometry (Figure 2.1C). Thus, HeLa cells were co-transfected with expression vectors 
encoding CD28-FLAG and Nef-eGFP or eGFP alone and total protein was examined by 
Western blot. A decrease in CD28-FLAG levels in the presence of Nef was observed 
(Figure 2.5). To further investigate Nef-mediated decreases in total CD28 protein levels in 
T cells, CD4+ Sup-T1 cells were transduced with VSV-G pseudotyped HIV-1 NL4.3 
engineered to encode epitope tagged CD28 and Nef (F2A CD28-FLAG Nef) or no Nef 
(F2A CD28-FLAG dNef; Figure 2.6). Forty-eight hours post transduction cells were lysed 
and total cellular CD28-FLAG was visualized by Western blot (Figure 2.7). As in 
transfected HeLa cells, decreases in CD28-FLAG in the presence of Nef were observed. 
Notably, Nef-mediated decreases in CD28-FLAG were observed inconsistently, which we 
hypothesize may be due to the overexpression of CD28-FLAG above level of endogenous 
CD28 protein, thus limiting our ability to detect viral protein mediated decreases.  
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Figure 2.4 Schematic of CD28-FLAG construct utilized to overexpress CD28 in 
cells 
The CD8α signal peptide (blue) was cloned in frame with the coding sequence for the 
CD28 protein (residues 19-220 of CD28 protein), including the CD28 extracellular 
domain (orange; residues 153-179 of CD28 protein), transmembrane domain (red; 
residues 153-179 of CD28 protein) and cytoplasmic tail (green; residues 180-220 of 
CD28 protein) and was epitope (purple; DYKDDDDK) tagged on the C-terminus. 
Numbers denote residues in the CD28-FLAG construct. 
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Figure 2.5 Decreased CD28-FLAG protein levels are detected in the presence of 
Nef in HeLa cells 
HeLa cells were transfected with plasmids encoding CD28-FLAG and Nef-eGFP or 
eGFP. Forty-eight hours post transfection, cells were lysed and lysate analyzed for the 
presence of CD28-FLAG (top), Nef-eGFP or eGFP (middle) and a loading control (actin, 
bottom) via Western blot. Indicated are relative intensities of the band corresponding to 
CD28-FLAG as determined using LI-COR Image Studio software (top). (eGFP: 
enhanced green fluorescent protein; Mr: molecular weight; NT: non-transfected) 
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Figure 2.6 HIV-1 lentiviral vector utilized to express epitope tagged CD28 in the 
presence or absence of Nef 
Illustration of a linear map of the lentiviral vector utilized to overexpress epitope tagged 
CD28 in T cells. The vector was modified from previously described lentiviral vectors 
produced from modification of the HIV-1 laboratory strain NL4.3 [43]. The HIV-1 gag 
and pol genes are truncated to encode the foot-and-mouth disease virus 2A peptide (F2A) 
and the CD8α signal peptide fused to a FLAG-tagged CD28-encoding gene. The 
remaining pUC vector backbone is not shown. 
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Figure 2.7 CD28-FLAG protein levels are reduced in the presence of Nef in CD4+ 
Sup-T1 T cells 
Sup-T1 T cells were transduced with a VSV-G pseudotyped lentivirus encoding CD28-
FLAG and Nef (F2A CD28-FLAG Nef) or CD28-FLAG and no Nef (F2A CD28-FLAG 
dNef). Forty-eight hours post transduction cells were lysed and proteins were analyzed 
by Western blot. Shown is CD28-FLAG (top), Nef (middle) and actin (bottom). (Mr: 
molecular weight) 
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Due to the inconsistent nature of our results obtained when using overexpressed epitope 
tagged CD28, we next sought to examine the effects of Nef and Vpu on endogenous CD28 
total protein levels within CD4+ T cells, a more biologically relevant system. Briefly, Sup-
T1 cells or whole peripheral blood mononuclear cells (PBMCs) were infected with VSV-
G pseudotyped HIV-1 NL4.3 viruses, as in Figure 2.1. Infected cells were stained for total 
CD28 levels by permeabilizing the cells prior to staining for CD28 and cells were 
subsequently analyzed by flow cytometry. Levels of CD28 were analyzed in Sup-T1 cells 
after gating on single live (Zombie NIRTM-) infected (GFP+) cells (Figure 2.2), while 
PBMCs were gated on CD4+ and infected (GFP+) cells. As with cell surface CD28, total 
CD28 levels were significantly higher in cells infected with viruses lacking Nef (dNef) or 
Vpu (dVpu), relative to cells infected with viruses encoding both viral proteins (NL4.3), in 
both Sup-T1 and primary CD4+ cells (Figure 2.8). Moreover, the highest total CD28 levels 
were observed in Sup-T1 cells infected with virus lacking functional nef and vpu genes 
(dVpu dNef; Figure 2.8C).   
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Figure 2.8 HIV-1 Nef and Vpu downregulate total CD28 protein levels 
CD4+ Sup-T1 cells or peripheral blood mononuclear cells were infected with VSV-G 
pseudotyped NL4.3. Viruses encoded Nef and Vpu (NL4.3, red), lacked Nef (dNef, 
blue), lacked Vpu (dVpu, orange) or lacked both Nef and Vpu (dNef dVpu, green). 
Forty-eight hours post-infection, cells were permeabilized, stained for CD28 and 
analyzed by flow cytometry. (A) Representative dot plots illustrating total CD28 (APC) 
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and infection (GFP) levels of live (Zombie RedTM-) Sup-T1 cells. (B) Representative 
histograms illustrating total levels of CD28 (APC) after gating on live (Zombie RedTM-) 
infected (GFP+) cells. Geometric mean fluorescence intensities (MFI) are indicated. (C) 
Summary of mean (+/-SE) relative total CD28 based on MFI (n=12). (D) Representative 
dot plots illustrating purified CD4+ T cells infection (GFP) and total CD28 (APC) levels. 
(E) Summary of mean (+/-SE) total CD28 levels on infected (GFP+) CD4+ T cells (n=5). 
Data were obtained from infection of cells obtained from two healthy donors. (UI: 
uninfected; SE: standard error; *p≤ 0.05; **p≤ 0.01; ***p≤ 0.001; ****p≤ 0.0001; GFP: 
green fluorescent protein).  
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To alternatively confirm that the HIV-1 accessory proteins Nef and Vpu alter endogenous 
CD28, we infected Sup-T1 cells with VSV-G pseudotyped NL4.3 viruses encoding or 
lacking the viral proteins and examined CD28 localization using widefield microscopy 
(Figure 2.9). Specifically, due to the observed decreases in total CD28 protein levels 
(Figure 2.5; Figure 2.7; Figure 2.8), we stained cells for endogenous CD28 and lysosomal-
associated membrane protein 1 (LAMP-1), a marker of the degradative lysosomal 
compartment. Interestingly, we observed that in the presence of Nef and Vpu, CD28 
localized away from the cell surface (NL4.3; Figure 2.9A), inconsistent with the plasma 
membrane localization observed in uninfected cells (UI; Figure 2.9A). Moreover, upon 
elimination of the viral proteins we observed a rescue in CD28’s localization to the cell 
surface (dVpu dNef; Figure 2.9A). Upon quantification of CD28: LAMP-1 co-localization, 
we found that in the presence of both viral proteins (NL4.3) the co-localization of CD28 
with LAMP-1 was significantly greater than in the absence of either (dNef, dVpu) or both 
(dVpu dNef) viral proteins (Figure 2.9B). This microscopy analysis confirms that Nef and 
Vpu downregulate endogenous CD28 and suggests this downregulation is mediated by 
transport of CD28 to the degradative lysosome.  
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Figure 2.9 The subcellular localization of CD28 is altered in the presence of Nef or 
Vpu 
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CD4+ Sup-T1 cells were infected with VSV-G pseudotyped NL4.3 viruses encoding or 
lacking Nef and/or Vpu. Infected cells were stained for CD28 and the lysosomal marker 
LAMP-1 and visualized by widefield microscopy. (A) Shown are representative infected 
(GFP+) cells (left) and a graphical representation of CD28 (blue) and LAMP-1 (red) 
fluorescence intensity relative to the maximum along the illustrated line (right). The scale 
bar indicates 10 m and the vertical lines labelled PM indicate where the illustrated line 
meets the plasma membrane (PM). Insets in the merged panel illustrate the GFP channel. 
(B) The percentage overlap between CD28 and LAMP-1 is calculated based on the mean 
(+/- SD) Manders’ overlap coefficients from at least 30 cells and 3 independent 
experiments. (UI: uninfected; LAMP-1: Lysosomal-associated membrane protein 1; SD: 
standard deviation; ****p≤ 0.0001). 
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2.2.2 Nef and Vpu-mediated effects on CD28 are dependent on the cellular 
degradation machinery 
Cellular protein levels can be reduced via degradation by acidic hydrolases within acidified 
endosomal compartments [44]. Since we observed the co-localization of CD28 and LAMP-
1 in infected cells (Figure 2.9), we sought to determine if Nef- and Vpu-mediated 
reductions in total CD28 could be blocked by inhibition of endosomal acidification. To test 
this, we treated infected Sup-T1 cells with the base ammonium chloride to increase intra-
vesicular pH [45]. We specifically measured total CD28 within Sup-T1 cells infected with 
pseudotyped NL4.3 and treated with ammonium chloride prior to staining. Interestingly, 
upon ammonium chloride treatment, total CD28 detected by flow cytometry increased 
relative to untreated cells (Figure 2.10). Moreover, the fold increase, or recovery, of total 
CD28 protein levels upon ammonium chloride treatment was significantly lower when 
cells were infected with viruses lacking either (dNef, dVpu) or both Nef and Vpu (dVpu 
dNef), compared to Nef- and Vpu-encoding virus (NL4.3; Figure 2.10A). As a control, we 
measured total CD4 within infected cells treated or not with ammonium chloride. Similar 
to CD28, the recovery of CD4 levels upon ammonium chloride treatment was significantly 
less in cells infected with virus lacking one or both of the accessory proteins (dNef, dVpu, 
dVpu dNef; Figure 2.11). Therefore, in the presence of the viral accessory proteins Nef and 
Vpu, a decrease in total CD28 occurs and this effect is most likely mitigated by inhibition 
of endosomal acidification.  
To further confirm these findings, we used widefield microscopy to visualize CD28 within 
Sup-T1 cells infected with VSV-G pseudotyped NL4.3. Specifically, we examined the 
subcellular localization of CD28 within infected cells treated with the general endosome 
acidification inhibitor ammonium chloride or treated with Bafilomycin A1 or 
Concanamycin A, specific inhibitors of the endosome acidifying proton pump, the vacuolar 
ATPase [46, 47]. We observed that upon treatment with ammonium chloride, Bafilomycin 
A1 or Concanamycin A, the distribution of CD28 within VSV-G pseudotyped NL4.3 
infected cells was altered relative to vehicle (DMSO) treated cells (Figure 2.10). Indeed, 
inhibitor treatment resulted in the increased localization of CD28 to the cell surface when 
compared to cells treated with vehicle. Moreover, quantification of the co-localization of 
CD28 and LAMP-1 in inhibitor treated cells indicated that upon inhibitor treatment CD28 
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co-localizes significantly less with the lysosomal marker LAMP-1 (Figure 2.10C). These 
results suggest that the ability of Nef and Vpu to downregulate CD28 is dependent on 
lysosomal acidification. 
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Figure 2.10 Inhibition of the degradation machinery increases CD28 protein levels 
in infected cells 
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CD4+ Sup-T1 cells were infected with VSV-G pseudotyped NL4.3 encoding or lacking 
Nef and/or Vpu. Infected cells were analyzed 48 hours post-infection after treatment for 
24 hours with 40 mM ammonium chloride or treatment for five hours with 100 nM 
Bafilomycin A1 or 100 nM Concanamycin. Cells were stained for CD28 and the 
lysosomal marker LAMP-1 and analyzed by widefield microscopy or stained for CD28 
and analyzed by flow cytometry. (A) Representative histograms illustrating total CD28 
levels of infected cells treated with complete RPMI with (blue) or without (red) 40 mM 
ammonium chloride. Geometric mean fluorescence intensities (MFIs) are indicated. MFI 
of infected cells were determined after gating on live (Zombie RedTM-), infected (GFP+) 
cells and the relative fold increase (+/-SE) in total CD28 upon ammonium chloride (n≥5) 
treatment is illustrated (right). (B) Representative infected (GFP+) Sup-T1 cells 
subjected to treatment with vehicle (DMSO), ammonium chloride (NH4Cl), 
Concanamycin A (ConA) or Bafilomycin A1 (BafA) and visualized by widefield 
microscopy (left). The scale bar indicates 10 m and insets in merged panel illustrate 
GFP channel. A graphical representation of CD28 and LAMP-1 fluorescence intensity 
relative to max along the illustrated line is shown (right). The vertical lines labelled PM 
indicate where the illustrated line meets the plasma membrane (PM). (C) The percentage 
of overlap between CD28 and LAMP-1 is based on the mean (+/-SD) Manders’ overlap 
coefficient measured on at least 30 cells from 3 independent experiments (UI: 
uninfected; SD: standard deviation; LAMP-1: Lysosomal-associated membrane protein; 
****p≤ 0.0001). 
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Figure 2.11 Ammonium chloride treatment increases total CD4 levels in infected 
cells 
CD4+ Sup-T1 cells were infected with Gag-Pol truncated VSV-G pseudotyped NL4.3 
encoding or lacking Nef and/or Vpu. Infected cells were treated with 40 mM ammonium 
chloride for twenty-four hours prior to staining for CD4 and analyzed by flow cytometry. 
(A) Representative histograms illustrating CD4 (APC) levels on live infected cells. Mean 
geometric fluorescence intensities (MFIs) are indicated. (B) MFIs of infected cells were 
determined after gating on live, infected (Zombie RedTM- and GFP+) cells and the relative 
fold increase (+/-SE) in total CD4 (n≥5) upon ammonium chloride treatment is 
illustrated. (SE: standard error; ****p≤ 0.0001). 
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2.2.3 Motifs ascribed to specific Nef: host cell protein interactions are critical for 
Nef-mediated CD28 downregulation 
To further elucidate the mechanisms used by Nef to downregulate CD28, we sought to 
determine if this function is dependent on motifs within Nef that have been previously 
implicated in interacting with membrane trafficking regulators that act to downregulate 
other cell surface receptors. Accordingly, Sup-T1 cells were infected with isogenic Gag-
Pol truncated VSV-G pseudotyped NL4.3 viruses that only differed at the following Nef 
motifs: the myristoylation site (G2; [48]), the methionine residue critical for Nef: AP-1: 
MHC-I complex formation (M20; [21]), the dileucine motif implicated in adaptor protein-
complex formation (LL165; [49]) and the diacidic motif implicated in vacuolar ATPase 
binding (DD175; [50]). Specifically, Sup-T1 cells were infected with pseudotyped NL4.3 
encoding a non-functional Vpu protein and the various Nef mutants. Subsequently, live 
and infected single cells were analyzed (Figure 2.2). In addition, cells were infected with 
pseudotyped NL4.3 encoding a functional Vpu protein and the various Nef mutants (Figure 
2.12; Figure 2.13). As expected, cells infected with virus encoding Nef G2A [48], which 
disrupts most known Nef functions, exhibited significantly higher cell surface levels of 
CD28 compared to cells infected with virus encoding wild-type Nef (Figure 2.13; Figure 
2.14A, B). Interestingly, cells infected with viruses encoding the LL165AA and DD175GA 
Nef mutations also showed significantly higher cell surface levels of CD28, suggesting that 
the LL165 and DD175 motifs are critical for cell surface CD28 downregulation (Figure 
2.13A; Figure 2.14A, B). Conversely, mutation of M20 (M20A), a residue essential for the 
downregulation of MHC-I via the interaction with AP-1 [21, 51], did not affect CD28 cell 
surface downregulation (Figure 2.13A; Figure 2.14A, B). Importantly, the dileucine 
(LL165AA) and diacidic (DD175GA) motif mutations did not inhibit other Nef functions, as 
these mutated Nef proteins retained the ability to downregulate cell surface MHC-I (Figure 
2.13C), demonstrating that the dileucine and diacidic motifs function in downregulating 
CD28.  
In parallel, Sup-T1 cells were infected with the isogenic Gag-Pol truncated VSV-G 
pseudotyped NL4.3 viruses that only differed at various Nef motifs and total CD28 levels 
were measured by flow cytometry. The observed decrease in total CD28 in the presence of 
Nef (Figure 2.14C) was abolished by mutation of the myristolation site (G2A) and the 
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diacidic motif (DD175GA), as cells infected with viruses encoding these mutated Nef 
proteins exhibited significantly higher total levels of CD28 compared to those infected with 
virus encoding wild-type Nef (Figure 2.13; Figure 2.14C). However, unlike cell surface 
CD28, the total CD28 levels did not differ significantly between cells infected with virus 
encoding wild-type Nef versus Nef LL165AA in cells infected with viruses also encoding 
Vpu (Figure 2.13B). Contrastingly, in cells infected with virus lacking Vpu and encoding 
the Nef LL165AA mutation, we observed significantly greater levels of cell surface CD28 
(Figure 2.14C). Finally, expression of the mutated Nef proteins was confirmed by Western 
blot (Figure 2.14). Taken together, these findings implicate the Nef diacidic motif (DD175) 
in the downregulation of total and cell surface CD28. 
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Figure 2.12 Gating of Sup-T1 cells infected with VSV-G pseudotyped NL4.3 
encoding various Nef mutants 
To examine the population of interest, cells were gated on, followed by gating on 
infected (GFP+) cells. In a representative experiment 97.9% of cells were infected 
(GFP+). 
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Figure 2.13 Nef: host protein interaction motifs are critical for Nef-mediated 
CD28 downregulation in the presence of Vpu 
Infected CD4+ Sup-T1 cells were stained for CD28 or MHC-I and analyzed by flow 
cytometry. Cells infected with VSV-G pseudotyped wild-type NL4.3 (NL4.3, red) or 
NL4.3 lacking Nef (dNef, blue) were used as controls. (A) Mean (+/- SE) relative cell 
surface CD28 of cells infected with NL4.3 encoding various mutations in the nef gene 
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(n ≥5). (B) Mean (+/-SE) relative cell surface MHC-I on cells infected with NL4.3 
encoding various nef mutations (n≥4). (C) Relative mean (+/- SE) total CD28 within live 
cells infected with NL4.3 encoding various nef mutations (n≥6). (SE: standard error; 
*p≤ 0.05; **p≤ 0.01; ****p≤ 0.0001) 
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Figure 2.14 Nef: host cell protein interaction motifs are critical for Nef-mediated 
CD28 downregulation 
Infected CD4+ Sup-T1 cells were stained for CD28 and analyzed by flow cytometry. 
Cells infected with VSV-G pseudotyped NL4.3 lacking Vpu (dVpu, orange) or Vpu and 
Nef (dVpu dNef, green) were used as controls. (A) Representative dot plots illustrating 
CD28 (APC) and infection (GFP) in live (Zombie RedTM-) cells. (B) Mean (+/-SE) 
relative cell surface CD28 MFIs of cells infected with NL4.3 lacking Vpu and encoding 
the indicated mutations in nef (n ≥4). (C) Relative mean (+/-SE) total CD28 within live 
cells infected with NL4.3 encoding various Nef mutations (n≥5). (D) Western blot 
illustrating expression of the mutated Nef proteins. (Mr: molecular weight; UI: 
uninfected; SE: standard error; *p≤ 0.05; ***p≤ 0.001; ****p≤ 0.0001) 
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2.2.4 Motifs in Vpu implicated in interactions with specific host cellular proteins are 
critical for CD28 downregulation  
Next, we sought to gain insight into the mechanism used by Vpu to downregulate CD28 
by examining the ability of mutant Vpu proteins to modulate cell surface and total CD28 
levels. Mutated motifs within the NL4.3 vpu gene which have been previously implicated 
in the ability of Vpu to downregulate CD4 [52-54] or the restriction factor BST-2 [55-57] 
were inserted into a NL4.3 viral backbone encoding eGFP, but lacking a functional nef 
gene (pNL4.3 dG/P eGFP dNef). Sup-T1 cells were infected with these VSV-G 
pseudotyped isogenic NL4.3 viruses, which only differ in the specific vpu gene mutations. 
Relative to cells infected with virus encoding wild-type Vpu (dNef), significantly greater 
levels of cell surface CD28 were present on cells infected with viruses encoding Vpu 
mutations at the adaptor protein interaction interface (LV64AA Vpu dNef) and serine 
residues (S52/56N Vpu dNef) which are phosphorylated by casein kinase II to facilitate 
recruitment of E3 ubiquitin ligase complex components (Figure 2.15; [37]). In contrast, 
relative to cells infected with virus encoding wild-type Vpu (dNef), cell surface CD28 
levels were not significantly different on cells infected with virus encoding a mutation 
within a Vpu transmembrane domain residue implicated in downregulation of CD4 and 
BST-2 (W22L Vpu dNef [53, 56]; Figure 2.15A, B). The functionality of the mutant Vpu 
proteins was tested by examining the effects of the mutations on Vpu-mediated CD4 
downregulation in Sup-T1 cells (Figure 2.16). Indeed, upon infection with viruses 
encoding the W22L, S52/56N or LV64AA mutations, significantly greater cell surface levels 
of CD4 were present relative to cells infected with virus encoding wild-type Vpu (dNef; 
Figure 2.16A), suggesting that the W22 motif is critical for CD4, but not cell surface CD28 
downregulation.  
In parallel, viruses encoding mutated Vpu proteins were also tested for their effects on the 
downregulation of total CD28. Total CD28 levels were not significantly different when 
comparing cells infected with virus encoding wild-type Vpu or the W22L or LV64AA 
mutations (Figure 2.15C). In contrast, there was significantly greater total CD28 in the 
absence of Vpu (dVpu dNef) and in the presence of Vpu encoding the S52/56N mutation 
(S52/56N dNef) relative to virus encoding wild-type Vpu (dNef; Figure 2.15C). As an 
additional control, we demonstrated that cells infected with virus encoding the W22L, 
103 
 
S52/56N or LV64AA mutations exhibited significantly greater total levels of CD4 relative to 
cells infected with virus encoding wild-type Vpu (Figure 2.16B). Expression of all mutated 
Vpu proteins was confirmed by Western blot (Figure 2.15D). As with our findings for cell 
surface CD28 downregulation, this suggests that the molecular determinants of CD28 
downregulation by Vpu are distinct from those utilized to downregulate CD4.  
  
104 
 
 
105 
 
Figure 2.15 Motifs in Vpu are critical for downregulation of CD28 
Infected CD4+ Sup-T1 cells were stained for CD28 and analyzed by flow cytometry. 
Mean geometric fluorescence intensities (MFI) of cells were determined after gating on 
live and infected (Zombie RedTM- and GFP+) cells. Cells infected with VSV-G 
pseudotyped NL4.3 lacking Nef (dNef, blue) and both Nef and Vpu (dNef dVpu, green) 
were used as controls. (A) Representative histograms illustrating cell surface CD28 on 
live (Zombie RedTM-) infected (GFP+) cells. MFIs are indicated. (B) Mean (+/-SE) 
relative cell surface CD28 on cells infected with viruses encoding mutations in vpu (n 
≥9). (C) Relative mean (+/-SE) total CD28 within cells infected with viruses encoding 
the indicated vpu mutations (n≥7). (D) Western blot illustrating expression of mutated 
Vpu proteins. (Mr: molecular weight; UI: uninfected; SE: standard error; *p≤ 0.05; 
**p≤ 0.01; ****p≤ 0.0001) 
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Figure 2.16 Specific motifs in Vpu are critical for downregulation of CD4 
Infected CD4+ Sup-T1 cells were stained for CD4 and analyzed by flow cytometry. Mean 
geometric fluorescence intensities of cells (MFI) were determined after gating on live 
and infected (Zombie RedTM- and GFP+) cells. Cells infected with VSV-G pseudotyped 
NL4.3 lacking Nef (dNef, blue) and both Nef and Vpu (dNef dVpu, green) were used as 
controls. (A) Mean (+/-SE) relative cell surface CD4 on cells infected with NL4.3 
encoding various mutations in vpu (n≥4). (B) Relative mean (+/- SE) total CD4 within 
cells infected with NL4.3 encoding various Vpu mutations (n≥5). (SE: standard error; 
*p≤ 0.05; **p≤ 0.01; ***p≤ 0.001; ****p≤ 0.0001) 
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2.2.5 Implicating host cell proteins in Nef- and Vpu-mediated CD28 downregulation 
We next sought to utilize the information gained through our mutational analysis to test for 
the requirements of putative host cell proteins in Nef- or Vpu-mediated downregulation of 
CD28. Specifically, the Nef LL165 and DD175 motifs, which were critical for CD28 
downregulation (Figure 2.13; Figure 2.14), and the Vpu LV64 motif, which was critical for 
cell surface CD28 downregulation (Figure 2.15), have been implicated in binding to the 
membrane trafficking adaptor protein AP-2 [24, 50, 57]. Thus, we sought to test for the 
requirement of AP-2 in CD28 downregulation. To test this, CD4+ Sup-T1 T cells were 
infected with lentiviral vectors encoding eGFP and shRNAs targeting the AP-2 α and μ 
subunits. The next day, these cells were infected with VSV-G pseudotyped NL4.3 encoding 
mStrawberry and Nef, Vpu, or Nef and Vpu. Forty-eight hours later cell surface CD28 was 
measured by flow cytometry. Live (Zombie NIRTM-) cells transduced with both the shRNA 
encoding viruses (eGFP+) and viral protein encoding viruses (mStrawberry+) were 
analyzed for cell surface CD28 levels by gating on double positive cells (eGFP+ 
mStrawberry+), and the relative downregulation mediated by Nef or Vpu was determined. 
Compared to cells transduced with virus encoding a non-specific (NS) shRNA, no 
significant effect of AP-2 α and μ knock-down on Nef or Vpu mediated CD28 
downregulation was observed (Figure 2.17A). Knock-down of the AP-2 subunits was 
confirmed using Western blotting (Figure 2.17 B, C). These findings suggest that Nef- and 
Vpu-mediated decreases in cell surface levels of CD28 may be AP-2 independent, or 
alternatively may demonstrate that cells can compensate for the loss of the AP-2 α and μ 
subunits.  
  
108 
 
 
Figure 2.17 Downregulation of cell surface CD28 by Nef and Vpu in the presence 
of shRNA targeting AP-2 
Sup-T1 T cells were infected with lentiviruses encoding eGFP and non-specific (NS) or 
AP-2 α and μ subunit targeting shRNA. Twenty-four hours post transduction cells were 
infected with VSV-G pseudotyped NL4.3 encoding mStrawberry and encoding or 
lacking Nef and Vpu. Forty-eight hours later, cells were stained for cell surface CD28 
and analyzed by flow cytometry. Cell surface CD28 levels on live (Zombie NIRTM-), 
dual infected (eGFP+ mStrawberry+) cells was determined. (A) Mean (+/-SD) relative 
levels of CD28 downregulation mediated by the various viral proteins in the presence or 
absence of Nef and/or Vpu (n=8). Downregulation was calculated by comparing cell 
surface levels of CD28 on cells expressing vs. lacking the viral protein of interest, and 
downregulation in the presence of the AP-2 α- and μ-targeting shRNAs was normalized 
to downregulation in the presence of non-specific (NS) control shRNA (set to 1). (B) 
Western blot illustrating AP-2 μ protein levels in cells transduced with virus encoding 
the knock-down (KD) shRNA or non-specific shRNA (NS). (C) Western blot illustrating 
AP-2 α protein levels in cells transduced with virus encoding the knock-down (KD) 
shRNA or non-specific shRNA (NS). (SD: standard deviation; AP-2: adaptor protein 2; 
NS: non-specific; KD: knock-down; GFP: green fluorescent protein; GAPDH: 
glyceraldehyde 3-phosphate dehydrogenase) 
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In order to further confirm that knock-down of AP-2 does not affect Nef-mediated CD28 
downregulation, we tested for the requirement of the membrane trafficking regulator 
sorting nexin 9 (SNX9), which functions in membrane trafficking by binding to AP-2 [58]. 
Moreover, in uninfected cells CD28 is removed from the cell surface in a SNX9 dependent 
manner [59]. To test for the requirement of SNX9 in Nef-mediated cell surface CD28 
downregulation, CD4+ Sup-T1 cells were transduced with VSV-G pseudotyped NL4.3 
which was modified to express a previously described non-functional dominant negative 
SNX9 protein lacking the PX and BAR domains [58], as well as Nef-eGFP or a non-
functional mutant Nef G2A-eGFP. In parallel, cells were infected with viruses encoding 
wild-type SNX9 and Nef-eGFP or Nef G2A-eGFP. These vectors also lacked a functional 
vpu gene to ensure only Nef-mediated CD28 downregulation could occur. Forty-eight 
hours post transduction, cells were analyzed for cell surface CD28 levels using flow 
cytometry. The downregulation of CD28 in live, transduced (Zombie RedTM- and GFP+) 
cells was calculated based on mean fluorescence intensity of cells expressing Nef-eGFP 
versus Nef G2A-eGFP. Subsequently, cell surface CD28 downregulation was compared 
between cells transduced with virus encoding wild-type SNX9 (F2A SNX9 (WT)) or 
dominant negative SNX9 (F2A SNX9 (DN); Figure 2.18A). Expression of the SNX9 and 
Nef proteins of interest within transduced cells was confirmed by Western blotting (Figure 
2.18B). No difference in Nef-mediated downregulation of cell surface CD28 was seen 
between cells expressing wild-type versus dominant negative SNX9 (Figure 2.18A), 
indicating that SNX9 may be dispensable for cell surface downregulation of CD28 by Nef. 
Alternatively, cells may compensate for the disruption in SNX9-mediated trafficking by 
utilizing alternate trafficking pathways. 
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Figure 2.18 Nef-mediated cell surface downregulation of CD28 in the presence of 
overexpressed wild-type or dominant negative non-functional SNX9 
Sup-T1 T cells were infected with VSV-G pseudotyped lentiviruses encoding wild-type 
or dominant negative SNX9 and Nef-eGFP or a non-functional Nef mutant (Nef G2A-
eGFP). Forty-eight hours later, cells were stained for cell surface CD28 and analyzed by 
flow cytometry. (A) Mean (+/-SD) relative levels of CD28 downregulation mediated by 
Nef in live (Zombie RedTM-) and infected (eGFP+) cells. (n=8) (B) Western blot 
illustrating expression of wild type or dominant negative SNX9-FLAG and Nef-eGFP 
or Nef G2A-eGFP within transduced cells. (SD: standard deviation; SNX9: sorting nexin 
9; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; eGFP: enhanced green 
fluorescent protein; WT: wild-type; DN: dominant negative; UI: uninfected) 
  
111 
 
In addition to testing the requirement of SNX9 for the downregulation of cell surface 
CD28, we also sought to determine if SNX9 is required for Nef-mediated decreases in total 
CD28 protein levels. To test this, HeLa cell lines stably expressing SNX9-targeting or non-
specific shRNA were generated. These cells were subsequently transfected with expression 
vectors encoding epitope tagged CD28 and Nef, and total protein was examined using 
Western blotting (Figure 2.19). Decreased CD28-FLAG was observed in cells expressing 
Nef and a non-specific shRNA, while this Nef-mediated decrease in CD28-FLAG was 
absent in cells expressing shRNA targeting SNX9 (Figure 2.19), indicating SNX9 may be 
required for Nef-mediated reductions in total CD28 protein levels. To test this in T cells, 
CD4+ Sup-T1 cells were infected with VSV-G pseudotyped lentiviruses encoding SNX9-
targeting or non-specific shRNA. The next day, infected cells were transduced with a 
modified NL4.3 virus, as in Figure 2.7, that encodes CD28-FLAG and Nef (F2A CD28-
FLAG Nef) or no Nef (F2A CD28-FLAG dNef; Figure 2.6). Forty-eight hours post 
transduction, cells were lysed and total CD28-FLAG was visualized by Western blot 
(Figure 2.20). In cells transduced with virus expressing a non-specific shRNA (NS), there 
was a reduction in CD28-FLAG detected in cells expressing Nef, compared to those 
lacking Nef. However, in cells transduced with lentivirus encoding a SNX9-targeting 
shRNA there was no difference in CD28-FLAG levels in the presence or absence of Nef 
(Figure 2.20). Overall, these findings suggest that the AP-2-binding membrane trafficking 
regulator SNX9 may be required for the ability of Nef to decrease total CD28 protein levels. 
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Figure 2.19 HeLa cells with decreased SNX9 expression exhibit reductions in Nef-
mediated decreases in total CD28-FLAG 
HeLa cell lines were established that stably express shRNA targeting SNX9 (clone D1) 
or non-specific shRNA (clone NS1). These cells were transfected with vectors encoding 
CD28-FLAG and Nef-eGFP or eGFP alone. Forty-eight hours post transfection cells 
were lysed and proteins analyzed by Western blot. (A) Western blot illustrating CD28-
FLAG and Nef-eGFP or eGFP expression in cells expressing SNX9-targeting (anti-
SNX9; left) or non-specific (right) shRNA. (B) Western blot illustrating SNX9 protein 
levels in the stable cell lines utilized. Clone D1 was transduced with a virus encoding 
SNX9-targeting shRNA, clone NS1 was transduced with virus encoding a non-specific 
shRNA. (eGFP: enhanced green fluorescent protein; Mr: molecular weight; SNX9: 
sorting nexin 9) 
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Figure 2.20 SNX9-targeting shRNA reduces Nef-mediated decreases in total CD28 
in Sup-T1 cells 
CD4+ Sup-T1 T cells were transduced with lentiviruses encoding shRNA that targets 
SNX9 or non-specific shRNA. The next day, cells were transduced with lentiviruses 
encoding CD28-FLAG and Nef (F2A CD28-FLAG Nef) or no Nef (F2A CD28-FLAG 
dNef). Forty-eight hours post infection cells were lysed and analyzed by Western blot. 
Shown are Western blots illustrating CD28-FLAG (top) protein levels in cells transduced 
with viruses encoding SNX9-targeting (left) or non-specific-targeting (right) shRNAs 
and Nef (middle) and actin (bottom) protein levels in these cells. (Mr: molecular weight) 
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2.2.6 Patient-derived Vpu proteins mediate CD28 downregulation 
Our findings suggest that HIV-1 NL4.3 can downregulate CD28 by both Nef and Vpu. 
However, as HIV-1 is genetically diverse, functions observed in the laboratory strain 
NL4.3 may not necessarily play a prominent role in the epidemic at large. We therefore 
wanted to determine if Vpu-mediated CD28 downregulation is a conserved function. Thus, 
we tested the ability of multiple group M Vpu proteins to downregulate cell surface and 
total CD28. To test this, the NL4.3 vpu gene from a gag-pol truncated NL4.3 virus lacking 
Nef (NL4.3 dG/P eGFP dNef) was replaced with vpu genes from a HIV-1 subtype B 
reference strain (B.US.86.JRFL), a subtype C reference strain (C.BR.92.92BR025; [60]), 
or a gene encoding a subtype C consensus protein (CC). Sup-T1 cells were infected with 
these VSV-G pseudotyped isogenic viruses which differed only in the encoded Vpu 
proteins, and cell surface and total CD28 levels were measured by flow cytometry. Cells 
infected with virus encoding a subtype C consensus protein or a subtype B reference strain 
(B.US.86.JRFL) Vpu protein did not significantly differ in cell surface levels of CD28 
relative to cells infected with virus encoding NL4.3 Vpu (Figure 2.21A, B), suggesting that 
these additional Vpu proteins were capable of downregulating cell surface CD28. In 
contrast, cells infected with virus encoding a subtype C reference strain 
(C.BR.92.92BR025) vpu gene had significantly greater cell surface levels of CD28, as with 
virus lacking a functional vpu gene (dVpu dNef; Figure 2.21A, B). Moreover, staining for 
total cellular CD28 revealed that cells infected with virus encoding the B.US.86.JRFL and 
consensuses C vpu genes did not differ in total cellular CD28 levels relative to cells infected 
with virus encoding NL4.3 vpu, while the C.BR.92.92BR025 Vpu protein did not 
downregulate total CD28 (Figure 2.21C). To confirm that these findings were not unique 
to the Sup-T1 cell line, PBMCs were infected with the same pseudotyped NL4.3 viruses 
(Figure 2.21A) and cell surface CD28 levels on infected (GFP+) CD4+ cells was measured 
(Figure 2.1E, F, G; Figure 2.22). A similar trend to that observed in Sup-T1 cells was seen 
whereby the levels of CD28 were greater on cells infected with virus lacking the vpu gene 
than in cells infected with virus encoding the B.US.86.JRFL vpu gene. However, unlike in 
Sup-T1 cells, significantly more cell surface CD28 is present on cells infected with virus 
encoding CC Vpu than NL4.3 Vpu. Moreover, expression of these proteins in a 
heterologous system revealed equivalent protein levels for all Vpus except for Vpu from 
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C.BR.92.92BR025, which is weakly expressed (Figure 2.21D). Overall, this suggests that 
Vpu-mediated cell surface and total CD28 downregulation is not limited to the laboratory 
adapted HIV-1 strain NL4.3. 
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Figure 2.21 Non-NL4.3 Vpu proteins downregulate cell surface CD28 
CD4+ Sup-T1 and peripheral blood mononuclear cells (PBMCs) were infected with 
VSV-G pseudotyped NL4.3 viruses lacking Nef and encoding wild-type Vpu (dNef, 
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blue), no Vpu (dNef dVpu, green) or three non-NL4.3 Vpu proteins (grey). Cells were 
analyzed by flow cytometry and mean geometric fluorescence intensities (MFI) of 
infected (GFP+) cells were determined. (A) Representative histograms illustrating cell 
surface CD28 on live infected Sup-T1 cells. MFIs are indicated. (B) Mean (+/-SE) 
relative cell surface CD28 on Sup-T1 cells infected with NL4.3 lacking a functional Nef 
protein (dNef), but encoding various Vpu proteins (n=5). (C) Mean (+/-SE) relative total 
cellular CD28 of Sup-T1 cells infected with NL4.3 encoding various Vpu proteins (n≥8). 
(D) Western blot illustrating expression of eGFP-tagged versions of the analyzed Vpu 
proteins from transfected HEK293T cells. (E) Representative dot plots illustrating GFP 
and cell surface CD28 (APC) on CD4+ cells. (F) Representative histograms illustrating 
cell surface CD28 on either uninfected (isotype control, uninfected) or CD4+ infected 
(GFP+) cells. MFIs are indicated. (G) Mean (+/-SE) relative cell surface CD28 on CD4+ 
cells infected with viruses encoding various vpu genes (n=8). Data were obtained from 
infection of PBMCs from two healthy donors. (NT: non-transfected; Mr: molecular 
weight; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; GFP: green fluorescent 
protein; SE: standard error; UI: uninfected; *p≤ 0.05; **p≤0.01; ****p≤ 0.0001). 
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Figure 2.22 Gating of CD4+ peripheral blood mononuclear cells infected with 
VSV-G pseudotyped NL4.3 
To examine the population of interest, lymphocytes were gated on, followed by gating 
on CD4+ (APC-Cy7) and infected (GFP+) positive cells. In a representative experiment 
35.9% of single lymphocytes were CD4+ and 1.3% of these were infected (GFP+). Gates 
were set based on isotype stained (APC-Cy7) and uninfected controls. 
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2.2.7 Nef and Vpu differentially alter responsiveness to CD28-mediated stimulation 
Given that HIV-1 decreases cell surface levels of CD28 (Figure 2.1), a key immune cell 
stimulatory receptor, we postulated that decreased cell surface levels of CD28 on infected 
cells leads to a decreased ability of cells to become activated by CD28/CD3 stimulation. 
Thus, we wished to test what effects Nef and Vpu may have on activation in cells 
stimulated by CD28/CD3. We therefore infected primary CD4+ T cells with VSV-G 
pseudotyped NL4.3 encoding both Nef and Vpu (NL4.3), Nef alone (dVpu), Vpu alone 
(dNef) or lacking both Nef and Vpu (dVpu dNef). Infected cells were stimulated with 
soluble anti-CD28 and plate bound anti-CD3, and activation was determined by measuring 
intracytoplasmic production of IL-2, an event that occurs downstream from CD28 
activation (Figure 2.23; [61]). Upon infection with virus encoding Vpu alone (dNef), the 
percentage of infected cells that produced IL-2 after stimulation was significantly lower 
than in cells infected with virus encoding Nef and Vpu (NL4.3; Figure 2.23B), suggesting 
that the presence of Nef leads to increased activation, consistent with Nef’s previously 
reported role in T-cell activation upon anti-CD3 and anti-CD28 treatment of Jurkat cells 
[62]. In contrast, in primary cells infected with a virus lacking Vpu (dVpu), the proportion 
of IL-2 positive infected cells were significantly increased, suggesting that Vpu decreases 
the anti-CD3/CD28 dependent cell activation. Overall, this suggests that the Nef and Vpu, 
which influence cell surface and total CD28 levels, differentially regulate the 
responsiveness to CD28 stimulation.  
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Figure 2.23 Infected cell response to CD28-stimulation changes in the absence of 
Nef or Vpu 
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Purified CD4+ T cells were infected with VSV-G pseudotyped NL4.3 encoding Nef and 
Vpu (NL4.3, red), lacking Nef (dNef, blue) or Vpu (dVpu, orange), or lacking both Nef 
and Vpu (dVpu dNef, green). Twenty-four hours post-infection cells were activated with 
anti-CD3/anti-CD28 for 24 hours. Cells were then incubated with Brefeldin A for 12 
hours and stained for intracellular IL-2 prior to analysis by flow cytometry. (A) 
Representative dot plots illustrating intracellular IL-2 (APC) and infection (eGFP) 
levels. Quadrants were selected based on the IL-2 isotype and uninfected controls. The 
percentage of infected cells that are IL-2 positive is indicated (red). The percentage of 
cells making up the uninfected and IL-2 negative population (Q4) are as follows: 
uninfected unstimulated: 99.8%, isotype control: 99.7%, uninfected stimulated: 92.8%, 
NL4.3: 91.3, dNef: 95.5%, dVpu: 90.1, dVpu dNef: 89.3%. (B) Mean (+/-SE) percentage 
of infected cells that are IL-2 positive (n≥6). The means were obtained by analysis of 
infected cells from two healthy donors. (SE: standard error; *p≤ 0.05) 
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2.3 Discussion 
In this chapter, we describe the ability of both HIV-1 Nef and Vpu to decrease cell surface 
and total levels of CD28 in CD4+ T cells. Specifically, we have shown cell surface CD28 
downregulation with VSV-G pseudotyped NL4.3 in Sup-T1 cells and primary cells, as well 
as downregulation in primary CD4+ T cells infected with replication competent NL4.3 
(Figure 2.1; Figure 2.21). These results are consistent with observations made in cell lines 
transiently transfected with Nef and/or Vpu expression vectors. Downregulation of 
endogenous CD28 was previously illustrated in Jurkat cells transiently expressing Nef [39]. 
Moreover, Haller et al. completed a large screen for receptors downregulated by Nef and 
Vpu through transient expression of the viral proteins in A3.01 T lymphocytes and 
observed downregulation of CD28 by both HIV-1 Nef and Vpu [19]. Interestingly, the 
latter study demonstrated varying degrees of downregulation by HIV-1 Nef and Vpu, as 
well as SIVmac239 Nef, with respect to the multiple tested receptors [19]. Accordingly, we 
observed that the effects of Nef and Vpu on CD28 are subtler than the effects of Nef and 
Vpu on other receptors, namely MHC-I and CD4 (Figure 2.13; Figure 2.16), but 
nevertheless in the presence of Nef and Vpu this receptor traffics to a degradative 
lysosomal compartment and decreased total CD28 protein levels are observed (Figure 2.8; 
Figure 2.9; Figure 2.10). Moreover, it has been shown that there are varying degrees of 
CD28 downregulation by various Nef proteins, with HIV-2 and certain SIV derived Nef 
proteins exhibiting more efficient downregulation than HIV-1 Nef proteins [19, 63]. 
However, this does not limit the potential physiological relevance of CD28 downregulation 
by HIV-1 and our current findings demonstrate mechanistic details of Nef and Vpu-
mediated CD28 downregulation.  
Our results demonstrate that slight increases in cell surface CD28 levels can be observed 
in cells infected with viruses lacking Nef and Vpu (dVpu dNef) in comparison to 
uninfected cells (Figure 2.1B, E). This suggests that HIV-1 proteins other than Nef and 
Vpu may also be contributing to changes in cell surface CD28 levels upon infection. The 
latter effects may be due to events independent of membrane trafficking and could be the 
consequence of changes at the level of CD28 transcription. Notably, CD28 expression 
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levels may be affected at the transcriptional level via the HIV-1 tat protein, as it interacts 
with the Sp1 transcription factor which positively affects CD28 transcription [64, 65]. 
Given that Nef and Vpu collaborate to mediate the downregulation and degradation of 
cellular receptors, specifically CD4 [27, 66-68], we hypothesized that the observed 
decreases in total CD28 levels in the presence of Nef and Vpu were due to CD28 
degradation. This is supported by our observation that CD28 co-localizes with the 
lysosome marker LAMP-1 in the presence of the viral proteins (Figure 2.9). Moreover, we 
found that we could limit Nef- and Vpu-mediated decreases in total CD28 and CD4 protein 
levels upon treatment with ammonium chloride (Figure 2.10; Figure 2.11). The effects of 
ammonium chloride on CD4 downregulation are of interest given the previously reported 
Vpu-dependent proteasomal degradation of CD4 [69]. In our experiments, ammonium 
chloride may be playing a non-specific role by impacting cellular physiology by affecting 
general cell acidification. Importantly, we have used the specific endosomal acidification 
inhibitors Bafilomycin A1 and Concanamycin A to provide a more unambiguous 
mechanistic explanation of Nef- and Vpu-dependent effects on CD28 (Figure 2.10), 
thereby bypassing the more general effects of using ammonium chloride. The specific 
inhibition of the vacuolar ATPase with these molecules limits the co-localization of CD28 
with LAMP-1 in Nef and Vpu-expressing cells (Figure 2.10).  
We also report how CD28 depletion involves the distinct ability of Nef and Vpu to interact 
with host cellular proteins. Indeed, cell surface CD28 downregulation was inhibited by 
mutation of Nef LL165 and DD175, while maintaining the ability to downregulate MHC-I 
(Figure 2.13; Figure 2.14). The findings that Nef LL165 and DD175 are critical for cell 
surface CD28 downregulation is in accordance with previously published reports [39, 70], 
and suggests that the Nef LL165 and DD175 motif binding proteins AP-2 [49] and the 
vacuolar ATPase [50] may be critical for cell surface downregulation by Nef. Interestingly, 
mutation of the G2, LL165 and DD175 motifs abolished Nef-dependent decreases in total 
levels of cellular CD28 in the absence of Vpu (Figure 2.14), while mutation of the LL165 
motif did not significantly alter total CD28 levels in the presence of Vpu (Figure 2.13). 
This may be due to Vpu’s ability to compensate for specific Nef mutations. Our observed 
increases in total cellular CD28 when the ability of Nef to interact with the vacuolar 
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ATPase is inhibited further supports the idea that Nef mediates degradation of CD28 
(DD175GA; Fig. 5C). The Nef DD175 motif is also critical for Nef-mediated lysosomal 
degradation of the co-inhibitory receptor CTLA-4 [71], which interestingly, competes with 
CD28 for binding the same receptors, B7.1/B7.2 [72]. Overall, this suggests that as with 
cell surface downregulation, the downregulation of total CD28 levels is dependent on 
specific Nef: host cell protein interaction motifs.  
We have also provided mechanistic details on how Vpu modulates CD28 expression and 
localization within HIV-1 infected cells. Intriguingly, the mutations exhibited different 
effects on CD28 and CD4 downregulation (Figure 2.15; Figure 2.16), indicating that CD28 
downregulation by Vpu may have evolved independently. Specifically, mutation of the 
Vpu W22, S52/56 and LV64 motifs inhibited the ability of Vpu to downregulate cell surface 
CD4 (Figure 2.16), in agreement with previous reports [52-54]. In contrast, mutation of the 
highly conserved W22 did not inhibit cell surface downregulation of CD28 (Figure 2.15A, 
B), suggesting that this residue is dispensable for CD28 downregulation despite being 
implicated in the downregulation of CD4 and BST-2 [53, 56, 73, 74].  
Similarly to CD4 downregulation, mutation of Vpu S52/S56 and LV64 inhibited cell surface 
downregulation of CD28 (Figure 2.15A, B). Interestingly, these Vpu motifs play distinct 
roles with AP-1 and AP-2, in addition to contributing to mechanisms that promote the 
degradation of cellular proteins. Indeed, the non-phosphorylatable mutants of Vpu (Vpu 
S52/56N) do not recruit AP-1 and AP-2 and subsequently fail to downregulate BST-2 [36], 
whereas Vpu LV64 promotes the degradation of BST-2 via phagocytosis [75]. Thus, the 
ability of Vpu to downregulate CD28 from the cell surface may require AP-1 or AP-2 
binding to the LV64 motif in a Vpu S52/S56 dependent manner to exclude CD28 from the 
cell surface post-endocytosis or prior to anterograde transport.  
Interestingly, only the S52/56N mutations in Vpu inhibited Vpu-mediated decreases in total 
CD28, whereas the W22, S52/56 and LV64 motifs were all necessary to decreasing total CD4 
(Figure 2.15C; Figure 2.16). The adaptor protein-binding motif in Vpu (LV64) was critical 
for cell surface downregulation, but dispensable for decreasing total CD28 (Figure 2.15B, 
C). This motif may be unnecessary for reducing total CD28 levels as additional host cell 
125 
 
binding factors, either known or currently unidentified, may compensate for mutation of 
the LV64 motif. Overall, the mechanism of Vpu-mediated CD28 cell surface 
downregulation is discrete from that which mediates total decreases in cellular CD28, and 
this mechanism is distinct from Vpu-mediated downregulation of total CD4. 
In addition to utilizing mutations in host cell binding motifs to shed light on the 
mechanisms of Nef- and Vpu-mediated CD28 downregulation, we employed shRNA 
knock-downs to potentially implicate specific host cellular proteins in CD28 
downregulation. Interestingly, despite the fact that mutation of the Nef and Vpu AP-2 
binding sites abolished the ability of these proteins to downregulate cell surface CD28 
(Figure 2.13; Figure 2.14; Figure 2.15), shRNA depletion of the AP-2 α and μ subunits in 
CD4+ Sup-T1 cells did not alter the ability of Nef or Vpu to downregulate surface CD28 
relative to cells expressing a non-specific control shRNA (Figure 2.17). The incomplete 
depletion of these AP-2 subunits may be insufficient to completely abolish the ability of 
AP-2 to mediate trafficking. Alternatively, the dileucine binding motifs in Nef and Vpu 
may be facilitating hijacking of AP-1, rather than AP-2, to downregulate CD28. The 
dispensability of AP-2 for cell surface CD28 downregulation is supported by our finding 
that a dominant negative SNX9 protein, which inhibits AP-2 dependent trafficking events 
[58], did not inhibit Nef-mediated cell surface CD28 downregulation (Figure 2.18). 
However, despite our findings that suggest AP-2 and SNX9 may be dispensable for cell 
surface CD28 downregulation, it is possible that upon AP-2 depletion or inhibition of 
SNX9 trafficking pathways additional membrane trafficking proteins compensate for these 
losses to facilitate CD28 downregulation. This is supported by the redundant functions 
observed for SNX9 and the related SNX18 protein [76, 77]. Moreover, shRNA-mediated 
knock-down of SNX9 inhibited Nef-mediated decreases in total protein levels of 
overexpressed epitope tagged CD28 in HeLa and Sup-T1 cells (Figure 2.19; Figure 2.20). 
This discrepancy between the effects of SNX9 on Nef-mediated cell surface and total 
protein downregulation may be due to differences that occur as a result of overexpressing 
CD28 versus examining endogenous CD28. Indeed, our observations made using over-
expressed CD28 were often much less reproducible than our findings with endogenous 
CD28. Alternatively, SNX9, and perhaps AP-2, may be dispensable for mediating 
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decreases in cell surface CD28, but are required for degradation of CD28, as CD28 
degradation may occur independently of cell surface downregulation. 
We demonstrated that the ability of Vpu to downregulate cell surface and total CD28 is not 
specific to the laboratory adapted NL4.3 strain Vpu protein. Specifically, a subtype C 
consensus Vpu protein and a subtype B reference strain (B.US.86.JRFL) protein 
downregulated cell surface and total CD28 in infected Sup-T1 cells (Figure 2.21). 
Contrastingly, the Vpu protein derived from a subtype C reference strain 
(C.BR.92.92BR025) did not downregulate CD28 (Figure 2.21), which may be attributable 
in part to decreased expression (Figure 2.21D). Interestingly, in a separate study we found 
that this subtype C reference strain encodes a non-functional Nef protein and has previously 
been shown to have lower fitness when compared to other well described subtype reference 
strains [78, 79]. Moreover, we found that in infected CD4+ PBMCs both the NL4.3 and 
B.US.86.JRFL derived Vpu proteins were capable of downregulating cell surface CD28 
(Figure 2.21E, F, G). However, unlike in Sup-T1 cells, PBMCs infected with virus 
encoding the consensus C Vpu protein did not exhibit downregulation (Figure 2.21G). The 
observed difference between Sup-T1 cells and CD4+ PBMCs may be due to intrinsic 
differences between Sup-T1 and primary cells, as well as potential differences in the 
expression pattern of the various Vpu proteins in different cell types. Interestingly, upon 
examination of the amino acid sequences of these various Vpu proteins, we observed that 
they exhibit conservation at the S52/56 motif we demonstrated to be critical for NL4.3 Vpu-
mediated CD28 downregulation (Figure 2.15; Figure 2.24). However, the B.JFRL, CC and 
C.BR92025 Vpu proteins all lack the LV64 motif found in the NL4.3 Vpu protein, which 
was critical for NL4.3 Vpu cell surface CD28 downregulation (Figure 2.15B; Figure 2.24). 
Therefore, perhaps non-NL4.3 Vpu proteins contain unique residues which influence 
CD28 downregulation ability. Nonetheless, the ability of distinct Vpu proteins to 
downregulate cell surface and total CD28 suggests that this function is conserved to some 
extent, despite high HIV-1 diversity [80]. 
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Figure 2.24 Protein sequence alignment of the Vpu proteins which were tested for 
their ability to downregulate CD28 
The protein sequences of the NL4.3, B.JFRL, CC and C.BR92025 Vpu proteins were 
aligned using Clustal Omega [81]. The residues in NL4.3 Vpu that were mutated and 
tested for their effects on CD28 downregulation are indicated. 
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HIV-1 has evolved multiple means of downregulating CD28, which are in part genetically 
separable from CD4 and MHC-I downregulation, implying that CD28 downregulation is 
critical during infection. Moreover, we hypothesize that the function of CD28 
downregulation is relevant during infection and that CD28 downregulation by Nef and Vpu 
may alter cell activation through CD28 receptor stimulation. Indeed, we observed that in 
primary CD4+ T cells infected with pseudotyped virus encoding Vpu alone (dNef), a 
significantly smaller proportion of infected cells secreted IL-2 upon CD3/CD28 
stimulation, relative to cells infected with virus encoding Nef and Vpu (NL4.3; Figure 
2.23B). In contrast, cells infected with virus lacking Vpu (dVpu) displayed an increase in 
cell activation (Figure 2.23), indicating that Nef alone increases CD28 stimulation 
responsiveness. 
The observed differences in cell activation in the presence or absence of Nef and Vpu may 
be partially attributable to other reported functions of these viral proteins. Namely, Nef 
alters the subcellular localization of the T cell receptor and immunological synapse 
associated kinase Lck, leading to a physical separation of the T cell receptor from the 
immunological synapse [6, 82]. Nef also binds and activates the serine/threonine kinase 
PAK2, which induces T cell activation [62]. Nef thus alters the activation status of cells, 
perhaps inducing the correct balance between activating and inhibitory signaling, thereby 
enabling optimal viral replication without inducing anergy or activation induced cell death 
[83]. However, when compared to Nef, little is known regarding how Vpu alters T cell 
activation. Nonetheless, Vpu may interfere with T cell activation and IL-2 production 
through its ability to inhibit NF-κB [84]. Ultimately, the evolution of CD28 downregulation 
may be one component of the multitude of alterations within infected cells that act to attain 
optimal levels of cell activation. 
The role or function of CD28 downregulation in vivo remains elusive, however we 
speculate it may play a role in cell activation. CD28 is critical for T cell activation, 
providing co-stimulatory signaling necessary for activation upon binding to CD80/CD86 
[4, 5] and in the absence of CD28, T cell receptor ligation can lead to an unresponsive, 
anergic state [85]. The importance of CD28 in vivo has been demonstrated through the use 
of anti-CD28 therapies to induce immunosuppression following transplantation, in patients 
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with autoimmune diseases (reviewed in [86]) and during cancer immunotherapies via 
CD28 activation [87]. In addition, reductions in IL-2 levels, as observed in the presence of 
Vpu (Figure 2.23), may lead to impairments in T cell survival, proliferation and function 
(reviewed in [88]). Interestingly, decreases in IL-2 levels are observed in HIV infected 
individuals [89, 90], and clinical trials have examined the benefit of administering 
recombinant IL-2 in combination with anti-retroviral therapy [91]. IL-2 has also been 
associated with reactivation of latently infected cells [92, 93]. Therefore, it is conceivable 
that CD28 downregulation alters responsiveness and activation of infected T cells. 
Alterations in the activation status of infected cells, which may in part be achieved through 
CD28 downregulation, could have effects in vivo during HIV-1 infection. Upon HIV-1 
infection, a transcriptionally silent latent reservoir of cells is formed, which currently 
present the largest obstacle for achieving a HIV-1 cure [94]. A decrease in cell activation 
as a result of alterations in cell surface CD28 levels may allow an infected cell to enter a 
transcriptionally silent, latent state. Indeed, CD28 activation is capable of inducing HIV-1 
transcription and replication, even in the absence of TCR activation [95]. Moreover, viral 
microRNA-mediated silencing of genes that contribute to cellular activation, which may 
include CD28 [96], have been suggested to be important for the development of latency 
[97]. Furthermore, CD28 activation is utilized to reactivate latent cells, as mTOR, a kinase 
activated downstream of CD28 signaling [98], was identified as a critical controller of 
HIV-1 latency [99]. 
Overall, we have demonstrated that the HIV-1 Nef and Vpu accessory proteins 
downregulate CD28 from the cell surface and at the cellular level. This effect is observed 
with more than just the laboratory adapted NL4.3 strain, indicating this function is 
conserved. We propose that the decreases in total cellular CD28 may be potentiated by 
lysosomal degradation of CD28. Moreover, our analysis of Nef and Vpu mutants suggest 
that the Nef: vacuolar ATPase interaction and phosphorylation of Vpu S52/56 are both 
critical for downregulation of cell surface and total protein levels of this key co-stimulatory 
molecule. Finally, the presence or absence of Nef and Vpu modulates the ability of cells to 
respond to CD28-mediated stimulation. 
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2.4 Materials and Methods 
2.4.1 DNA constructs 
2.4.1.1 Expression vectors 
To facilitate efficient overexpression of epitope tagged CD28, the human CD28 gene was 
amplified out of the MegaMan Human Transcriptome Library (Agilent Technologies, 
Santa Clara, CA) and subsequently amplified with a forward primer containing the CD8α 
signal peptide and a reverse primer encoding the FLAG epitope tag. The CD8α signal 
peptide-CD28-FLAG encoding DNA was subsequently sub-cloned into the peGFP-N1 
expression vector (Clontech, Mountain View, CA) in which eGFP was removed by 
restriction digestion. For expression of Nef-eGFP and eGFP, the NL4.3 nef gene was 
subcloned into the peGFP-N1 expression vector or this vector was left unmodified. To test 
the expression of the non-NL4.3 Vpu proteins the Vpu encoding fragments were PCR 
amplified and sub-cloned into the peGFP-N1 expression vector (Clontech). 
2.4.1.2 Lentiviral vectors 
Viral infection plasmids used for VSV-G pseudotyped lentivirus production were 
engineered from the previously described pNL4.3 dG/P eGFP or pNL4.3 dG/P eGFP dNef 
backbones [100, 101]. To make viral constructs lacking Vpu, HIV-1NL4-3 vpu/nef/UD 
Deletion Mutant (p230-11; NIH-AIDS reagents catalog number 2535) was digested with 
EcoRI and BamHI and the fragment encoding the vpu gene was sub-cloned into pNL4.3 
dG/P eGFP or pNL4.3 dG/P eGFP dNef. NL4.3 based lentiviral vectors encoding 
mStrawberry, CD28-FLAG and SNX9 were produced through insertion into a previously 
described vector encoding truncated gag and pol genes and the foot and mouth disease 2A 
(F2A) site [43]. Specifically, to make a viral vector for overexpression of CD28-FLAG, 
CD8α-CD28-FLAG from the aforementioned expression vector was PCR amplified and 
sub-cloned into the F2A-containing lentiviral vectors of interest. For the expression of 
wild-type or dominant negative SNX9, the full SNX9 gene or only residues 2 through 182, 
respectively, were PCR amplified from a SNX9/pGEX-KG vector obtained from R. 
Prekeris (University of Colorado, Aurora, CO) with a forward primer encoding the FLAG 
epitope.  
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Mutations in the NL4.3 nef gene were produced by site directed mutagenesis within a pN1 
expression vector encoding NL4.3 Nef. Mutagenesis primers were created with the Agilent 
Technologies QuickChange Primer Design program (Agilent Technologies). The nef genes 
containing mutations were subsequently PCR amplified with primers encoding XmaI and 
NotI cut sites, and were inserted into a previously described vector encoding XmaI and 
NotI cut sites flanking the nef gene [43]. Mutations in the NL4.3 vpu gene were produced 
by site directed mutagenesis in a pN1 Vpu-FLAG expression vector. Vpu genes encoding 
mutations were subsequently PCR amplified and inserted into pRECnfl HIV-1 
dVpu/URA3 (obtained from Eric Arts, University of Western Ontario), using a previously 
described yeast recombination system [102]. The vpu-encoding fragment was then sub-
cloned into a NL4.3 backbone lacking a functional nef gene (pNL4.3 dG/P eGFP dNef) 
using the EcoRI and BamHI restriction sites. Vpu genes derived from a subtype C reference 
strain (C.BR.92.92BR025), subtype B reference strain (B.US.86.JRFL) or a consensus C 
protein synthesized using Invitrogen GeneArt Synthesis (Thermo Fisher Scientific, 
Mississauga, ON) were inserted into the pRECnfl HIV-1 dVpu/URA3 vector followed by 
sub-cloning into pNL4.3 dG/P eGFP dNef, as described above.  
Viral infection plasmids utilized to make replication competent NL4.3 were engineered 
from the previously described pNL4.3 vector [101]. A Nef deficient plasmid (pNL4.3 
dNef) was obtained from Gary Thomas (University of Pittsburgh) and Vpu (dVpu) and Nef 
and Vpu (dVpu dNef) deficient plasmids were produced by subcloning the vpu encoding 
portion of HIV-1NL4-3 vpu/nef/UD Deletion Mutant into pNL4.3 or pNL4.3 dNef, as 
described above.  
2.4.1.3 shRNA encoding vectors 
The shRNA encoding lentiviral vectors encoding a non-specific (catalog number 
TR30021) or SNX9 (catalog number TL307006D) targeting shRNA were obtained from 
OriGene (OriGene Technologies, Inc., Rockville, MD). The lentiviral vectors encoding 
AP-2 targeting shRNAs were produced as previously described [83]. 
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2.4.2 Cell culture 
HEK293T (American Type Culture Collection (ATCC)), HeLa (ATCC) and U87 CD4+ 
CXCR4+ (National Institutes of Health-AIDS Research and Reference Reagent program; 
catalog number 4036) cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 4 mM L-glutamine, 4500 mg/L glucose and sodium pyruvate 
(HyClone, Logan, UT) and supplemented with 1% Penicillin-Streptomycin (Hyclone) and 
10% fetal bovine serum (FBS; Wisent, St-Bruno, QC). Sup-T1 cells were maintained in 
Roswell Park Memorial Institute media (RPMI) 1640 media with L-glutamine 
supplemented with 100 g/ml penicillin-streptomycin, 1% sodium pyruvate, 1% non-
essential amino acids, 2 mM L-glutamine (Hyclone) and 10% FBS. All cell lines were 
grown at 37°C in the presence of 5% CO2 and sub-cultured in accordance with supplier’s 
recommendations.  
Primary peripheral blood mononuclear cells were isolated from four healthy donors by 
density centrifugation using Histopaque (Sigma-Aldrich, Oakville, ON) and 
cryopreserved. Upon revival, cells were maintained in RPMI with L-glutamine 
supplemented with 100 μg/ml penicillin-streptomycin, 1% sodium pyruvate, 1% non-
essential amino acids, 2 mM L-glutamine (Hyclone) and 10% FBS at 37°C and 5% CO2 in 
the presence or absence of IL-2 and phytohemagglutinin (PHA) stimulation, as indicated. 
CD4+ T cells were purified from PBMCs using the MojoSortTM human CD4 T cell isolation 
kit (BioLegend, San Diego, CA) and Magnetic-activated cell sorting cell separation 
columns (Miltenyi Biotec, Auburn, CA), according to the manufacturer’s protocol. 
For ammonium chloride treatment, cells were pelleted and culture medium was replaced 
with complete RPMI containing or lacking 40 mM ammonium chloride (Sigma-Aldrich) 
in phosphate buffered saline (PBS) twenty-four hours prior to analysis. For vacuolar 
ATPase inhibitor treatment, cells were pelleted and culture medium was replaced with 
complete RPMI containing vehicle, 100 nM Concanamycin A (Santa Cruz Biotechnology, 
Dallas, TX) or 100 nM Bafilomycin A1 (Sigma-Aldrich) in DMSO 5 hours prior to 
analysis. 
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HeLa cells stably expressing shRNA with a non-specific target or targeting SNX9 were 
produced by transduction with shRNA-encoding lentiviral vectors. Briefly, HeLa cells 
were transduced with VSV-G pseudotyped lentivirus produced as described below with 
pGFP-C-shLenti plasmid encoding a scrambled shRNA (TR30021, Origene) or a SNX9 
targeting shRNA (TL307006D, Origene). Transduced cells were selected for using 0.8 
ug/mL puromycin and clones were selected. Cells were subsequently maintained in 
DMEM containing 0.4 ug/mL puromycin. 
2.4.3 Transfections and Infections 
2.4.3.1 Transfections 
To examining CD28 expression levels in HeLa cells in the presence or absence of Nef, 
HeLa cells were transfected with the appropriate plasmids using PolyJet (FroggaBio, North 
York, ON), as per the manufacturer’s protocol. 
2.4.3.2 Lentivirus production 
For VSV-G pseudotyped lentivirus production, HEK293T cells were triply transfected 
with the lentiviral vector of interest, the VSV-G envelope-encoding pMD2.G plasmid 
(Addgene; catalog number 12259) and pCMV-DR8.2 (Addgene; catalog number 12263) 
using PolyJet (FroggaBio) as per the manufacturer’s protocol. Forty-eight hours post 
transfection, lentivirus was harvested via cell culture supernatant clarification by spinning 
at 1500 x g, followed by 20 m filtration. For production of NL4.3 provirus, viral vectors 
were transfected into HEK293T cells using PolyJet. Forty-eight hours post-transfection, 
cell supernatant was applied to U87 CD4+ CXCR4+ cells to propagate the virus. Cell 
supernatant was harvested four to six days post infection as described above. Viruses were 
stored in 20% FBS at -80C.  
2.4.3.3 Lentivirus transduction 
For infection of Sup-T1 cells with VSV-G pseudotyped NL4.3 viruses to examine effects 
on endogenous CD28, 8 x 105 Sup-T1 cells were pelleted and re-suspended in the 
appropriate volume of pseudovirus in 20% FBS, 8 g/mL polybrene and brought to one 
mL with 10% complete RPMI. Forty-eight hours post infection, cells were analyzed via 
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flow cytometry, microscopy or Western blotting. For infection of peripheral blood 
mononuclear cells with VSV-G pseudotyped viruses, cells were cultured for three days in 
10 ng/mL IL-2 (PeproTech, Rocky Hill, NJ) and 5 μg/mL PHA (Sigma-Aldrich). Cells 
were then pelleted and re-suspended in the appropriate volume of pseudovirus containing 
8 g/mL polybrene. Cells were subsequently spinoculated for four hours at 2880 x g at 
room temperature, re-suspended in fresh RPMI and incubated for two days prior to 
analysis. For infection of primary CD4+ T cells with replication competent NL4.3 viruses, 
cells were cultured for three days in 10 ng/mL IL-2 and 5 g/mL PHA-L. CD4+ T cells 
were then purified as described above and re-suspended in the appropriate volume of virus 
in 20% FBS and 8 g/mL polybrene. Subsequently, cells were spinoculated for four hours 
at 2880 x g at room temperature, re-suspended in fresh complete RPMI containing 5 ng/mL 
IL-2 and 5 g/mL PHA-L. Two days post-infection, cells were pelleted and re-suspended 
in fresh media containing PHA and IL-2 and four days post-infection cells were fixed and 
stained. For infection of purified CD4+ T cells with VSV-G pseudotyped virus, cells were 
cultured for three days in 10 ng/mL IL-2 and 5 g/mL PHA-L. CD4+ T cells were then 
purified as described above and re-suspended in the appropriate volume of virus in 20% 
FBS and 8 g/mL polybrene. Subsequently, cells were spinoculated for four hours at 2880 
x g at room temperature, re-suspended in fresh complete 10% RPMI and analyzed forty-
eight hours post-infection. 
For examination of the effects of AP-2 μ or α knock-down on endogenous CD28 
downregulation, 1 x 106 Sup-T1 cells were suspended in 8 g/mL polybrene and virus 
preparations in 20% FBS produced as described above from pGFP-C-shLenti vectors 
encoding different shRNAs. Cells were then spinoculated for four hours at 2880 x g at 
room temperature and re-suspended in fresh RPMI. The next day, cells were pelleted and 
re-suspended in 10% RPMI (mock infection) or pNL4.3 dG/P F2A-mStrawberry Nef/dNef 
pseudovirions in 20% FBS and 8 g/mL polybrene. Forty-eight hours later, cells were 
analyzed via flow cytometry or Western blotting. For examination of the effects of SNX9 
knock-down on CD28-FLAG, cells were infected as above with pGFP-C-shLenti vectors 
encoding NS or SNX9 targeting shRNAs, infected the next day with viruses encoding 
CD28-FLAG and Nef or no Nef, and forty-eight hours later analyzed by Western blot.  
135 
 
2.4.4 Flow cytometry analysis of cell surface receptors  
Cells were analyzed using a BD Biosciences FACSCanto SORP (BD Biosciences, San 
Jose, CA). Data analysis was performed using FlowJo software (version 9.6.4, FlowJo 
LLC, Ashland, OR).  
2.4.4.1 Sup-T1 cells 
For cell surface staining of Sup-T1 cells, forty-eight hours post infection, cells were washed 
twice with PBS, followed by staining for 20 minutes at room temperature with 1:6000 
Zombie RedTM (BioLegend) or 1:6000 Zombie NIRTM (BioLegend) in PBS, where 
appropriate. Cells were then washed in FACS buffer (1% FBS, 50 mM 
ethylenediaminetetraacetic acid (EDTA) in PBS) and fixed in 1% paraformaldehyde (PFA) 
for 20 minutes at room temperature. Cells were subsequently washed twice with FACS 
buffer and stained with the appropriate antibodies by rocking for 40 minutes at room 
temperature. Cells were then washed twice with FACS buffer and re-suspended in PBS. 
For staining of CD28 and CD4, 1:25 APC-conjugated mouse-anti-CD28 (clone CD28.2, 
BioLegend) and 1:25 APC-conjugated mouse-anti-CD4 (clone OKT4, BioLegend) were 
utilized, respectively. For cell surface MHC-I staining, cells were stained with W6/32 (anti-
MHC-I, pan-selective for HLA-A, B and C, provided by D. Johnson, Oregon Health and 
Science University), washed twice with FACS buffer, incubated with an APC-conjugated 
species specific secondary antibody, followed by washing with FACS buffer and re-
suspending in PBS. For analysis of total CD28 or CD4 levels, cells were prepared as above, 
but were permeabilized and blocked prior to staining. Specifically, after fixation, cells were 
permeabilized by incubation with 0.5% saponin for 15 minutes at room temperature. Cells 
were then washed with 1% FBS, 0.1% saponin, 5 mM EDTA and blocked for thirty 
minutes with blocking buffer (10% FBS, 0.1% saponin, 5 mM EDTA in PBS). Cells were 
incubated with primary antibody diluted in blocking buffer followed by washing with 1% 
FBS, 0.1% saponin, 5 mM EDTA and re-suspending in PBS.  
2.4.4.2 Primary cells 
For cell surface staining of peripheral blood mononuclear cells infected with VSV-G 
pseudotyped NL4.3 encoding eGFP, cells were fixed in 2% PFA for 20 minutes at room 
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temperature, followed by washing twice with cell staining buffer (BioLegend). Cells were 
then incubated for 40 minutes at room temperature with the appropriate fluorescently 
labeled primary antibodies (1:50 APC-Cy7 conjugated anti-CD4 (clone OKT4, 
BioLegend), 1:25 APC conjugated anti-CD28 (clone CD28.2, BioLegend)). Cells were 
then washed twice with cell staining buffer and re-suspended in PBS prior to analysis.  
For analysis of total CD28 in primary CD4+ T cells infected with VSV-G pseudotyped 
NL4.3 provirus, cells were washed twice with cell staining buffer (BioLegend) and fixed 
and permeabilized in BD Cytofix/Cytoperm solution (BD Biosciences). Cells were 
subsequently washed twice with Perm/Wash buffer (BD Biosciences) and stained for 30 
minutes at 4°C for CD28 level analysis (1:25 APC conjugated anti-CD28 (clone CD28.2, 
BioLegend)). Cells were then washed, re-suspended in PBS and analyzed.  
For analysis of cell surface CD28 on primary CD4+ T cells infected with replication 
competent NL4.3 provirus, cells were washed twice with cell staining buffer (BioLegend) 
and incubated for 30 minutes at 4°C with fluorophore conjugated primary antibodies 
against the appropriate cell surface antigen (1:25 APC conjugated anti-CD28 (clone 
CD28.2, BioLegend)). Cells were then washed twice with cell staining buffer and then 
fixed and permeabilized in BD Cytofix/Cytoperm solution (BD Biosciences, San Jose, 
CA). Cells were subsequently washed twice with Perm/Wash buffer (BD Biosciences) and 
stained for 30 minutes at 4°C for p24 level analysis (1:50 anti-p24; clone KC57, Beckman 
Coulter). Cells were then washed, re-suspended in PBS and analyzed. The following 
isotype control antibodies were used in lieu of primary antibody as required: APC-Cy7 
conjugated mouse IgG2b, κ isotype (clone MOPC-21, BioLegend), APC mouse IgG1 κ 
isotype control (clone MOPC-21, BioLegend), PE mouse IgG1κ (clone: MOPC-21, 
BioLegend).  
2.4.5 Protein analysis 
Infected Sup-T1 cells and HeLa or HEK293T cells transfected as described above were 
lysed forty-eight hours post transduction or transfection for protein expression analysis. 
Briefly, cells were pelleted and lysed by rocking in lysis buffer (0.5 M HEPES, 1.25 M 
NaCl, 1 M MgCl2, 0.25M EDTA, 0.1% Triton X-100 and 1X complete Protease Inhibitor 
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Tablets (Roche, Indianapolis, IN)) for one hour at 4C. The supernatant was then clarified 
by spinning at 16100 x g for 30 minutes at 4C, mixed with SDS-PAGE sample buffer 
(0.312 M Tris pH 6.8, 2.6 M 2-Mercaptoethanol, 50% glycerol, 10% SDS) and boiled at 
95C for 10 minutes. Samples were run on 12 or 14% SDS-PAGE gels followed by 
transferring to nitrocellulose. Membranes were blocked with 5% milk in TBST (50 mM 
Tris, 150 mM NaCl, 0.1% Tween 20) for one hour at room temperature, followed by 
incubation overnight at 4C with the appropriate primary antibody in 5% milk in TBST. 
The following primary antibodies were used: 1:1000 rabbit anti-Nef polyclonal antibody 
(NIH-AIDS Research and Reference Reagent program, catalog number 2949), 1:2000 
rabbit anti-GFP polyclonal antibody (Clontech), 1:5000 rabbit anti-Vpu polyclonal 
antibody (NIH-AIDS Research and Reference Reagent program, catalog number 969), 
1:2000 mouse anti-Actin monoclonal antibody (Thermo Fisher Scientific, 1:1000 rabbit 
anti-GAPDH polyclonal antibody (Thermo Fisher Scientific), 1:500 rabbit anti-AP2 μ (BD 
Biosciences), 1:1000 rabbit anti-AP-2 α (Sigma-Aldrich), 1:800 rabbit anti-SNX9 (Sigma-
Aldrich), 1:1000 rat anti-DYKDDDK (BioLegend). The next day, membranes were 
washed three times with TBST and incubated for two hours at room temperature with the 
appropriate species specific HRP-conjugated secondary antibodies (1:2000, Thermo Fisher 
Scientific) in 5% milk in TBST. Blots were subsequently washed and developed using ECL 
substrates (Millipore, Etobicoke, ON) and a C-DiGit chemiluminescence Western blot 
scanner (LI-COR Biosciences, Lincoln, NE). Relative intensities of protein bands were 
determined using LI-COR Image Studio software. 
2.4.6 Microscopy 
For microscopy experiments, cells were infected and treated with inhibitors as described 
above. Cells were then adhered to poly-L-lysine (Sigma-Aldrich) coated coverslips and 
fixed in 2% PFA for 10 minutes at room temperature. Cells were subsequently washed 
twice with PBS and permeabilized with methanol for 20 minutes. Cells were then washed 
twice with PBS and blocked in 2% bovine serum albumin (BSA) in PBS for 1 hour at room 
temperature. Cells were subsequently stained for two hours with mouse anti-CD28 
(Thermo Fisher Scientific) and rabbit anti-LAMP-1 (Developmental Studies Hybridoma 
Bank, University of Iowa) diluted at 1:200 in 0.2% BSA in PBS, washed twice with 0.2% 
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BSA in PBS and incubated for one and a half hours with the appropriate fluorophore 
conjugated secondary antibodies (Alexa-Fluor-647 conjugated anti-mouse and Cy3-
conjugated anti-rabbit; Jackson ImmunoResearch, West Grove, PA) at 1:400 in 0.2% BSA 
in PBS. Finally, cells were washed twice with PBS and mounted on coverslips with DAPI 
Fluoromount-G (SouthernBiotech, Birmingham, AL). Cells were imaged on a Leica 
DMI6000 B at 63X or 100X magnification using the FITC, Cy3, Cy5 and DAPI filter 
settings and imaged with a Hamamatsu Photometrics Delta Evolve camera. Images were 
subsequently deconvolved using the Advanced Fluorescence Deconvolution application 
(Lecia, Wetzlar, Germany) on the Leica Application Suite software. Co-localization 
analysis was conducted using Mander’s Coefficient from the ImageJ plugin JACoP, as 
described previously [103]. 
2.4.7 Cell activation analysis 
To examine activation in infected cells, cryopreserved PBMCs were revived and rested for 
6 hours in complete RPMI media (without PHA/IL-2) at 37º C and 5% CO2. CD4
+ T cells 
were then purified as described above and spinoculated with the appropriate VSV-G 
pseudotyped NL4.3 virus encoding both Nef and Vpu (NL4.3 dG/P eGFP), encoding Vpu 
alone (NL4.3 dG/P eGFP dNef), encoding Nef alone (NL4.3 dG/P eGFP dNef), or lacking 
both Nef and Vpu (NL4.3 dG/P eGFP dVpu dNef). After spinoculation, cells were 
incubated in complete 10% RPMI for 24 hours prior to incubating with anti-CD3 (10 
μg/ml, clone OKT3, BioLegend) immobilized on a plate and soluble anti-CD28 (5μg/ml, 
clone CD28.2, BioLegend). After 24 hours of activation, cells were treated with Brefeldin 
A (1:1000 dilution, BD Biosciences) for 12 hours before proceeding for intracellular IL-2 
staining. 
For intracellular staining of IL-2, infected CD4+ T cells were fixed using Cytofix/Cytoperm 
solution (BD Biosciences) for 20 minutes at 4ºC, washed twice with Perm/Wash buffer 
(BD Biosciences) and stained for intracellular IL-2 with an APC-conjugated anti-IL-2 
antibody (clone MQ1-17H12, BD Biosciences), or the appropriate isotype control (APC 
Rat IgG2a, κ isotype control, clone R35-95, BD Biosciences), for 1 hour at 4ºC (1:20 
dilution in Perm/Wash buffer). Cells were then washed twice using Perm/Wash buffer prior 
to analysis by flow cytometry. In order to determine the percentage of the infected cells 
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that were IL-2 positive, the percentage of GFP+ IL-2+ cells (Q2, Figure 2.23) was divided 
by the total percentage of infected cells (sum of GFP+ IL-2+ (Q2, Fig. 8) and GFP
+ IL-2- 
(Q3, Figure 2.23)
 and multiplied by 100.  
2.4.8 Data and Statistical analysis 
2.4.8.1 Flow cytometry data analysis 
For analyses of flow cytometry data obtained for Sup-T1 cells infected with VSV-G 
pseudotyped NL4.3 encoding Vpu and various Nef mutations, relative levels of receptors 
were determined by normalizing geometric mean fluorescence intensity after gating on 
infected (GFP+) cells. For all other analysis of cell surface receptors on Sup-T1 cells 
infected with a single VSV-G pseudotyped virus, relative levels of receptors were 
determined by normalizing geometric mean fluorescence intensity after gating on single, 
live (Zombie RedTM-), infected (GFP+) cells. Relative levels of CD28 on primary CD4+ T 
cells infected with replication competent NL4.3 were determined by normalizing 
geometric mean fluorescence intensity after gating on single, p24 high and CD28+ cells. 
Relative levels of CD28 on VSV-G pseudotyped NL4.3 infected PBMCs, were determined 
by normalizing geometric mean fluorescence intensity after gating on CD4+ and infected 
(GFP+) lymphocytes. For all cell surface or total receptor analysis by flow cytometry, the 
geometric mean fluorescence intensity of the control in each experiment (left-most sample 
on each graph) was set to 1 and the other sample MFIs were calculated relative to the 
control having an MFI of 1.  
To calculate the relative increase in intracellular staining upon ammonium chloride 
treatment, the geometric mean fluorescence intensity of the live and infected cells treated 
with ammonium chloride was divided by the geometric mean fluorescence intensity of cells 
that were untreated. This ratio was then normalized such that the fold increase in MFI for 
cells infected with NL4.3 was equal to one.  
For analysis of cell surface levels of CD28 on Sup-T1 cells infected with VSV-G 
pseudotyped viruses encoding shRNAs and eGFP and mStrawberry and Nef and/or Vpu, 
geometric mean fluorescence intensity of CD28 was determined after gating on single, live 
(Zombie NIRTM-), doubly infected (mStrawberry+ GFP+) cells. The relative Nef or Vpu-
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mediated downregulation of cell surface CD28 in the presence of the shRNA vectors was 
then determined based on the MFI of cells infected with virus encoding versus lacking the 
accessory protein of interest. The downregulation of CD28 was then normalized to the 
downregulation mediated by the same viral protein in the presence of the non-specific 
shRNA. 
To analyze the effects of overexpression of wild-type SNX9 or dominant negative SNX9, 
levels of CD28 downregulation were calculated by determining geometric mean 
fluorescence intensity after gating on single, live (Zombie RedTM-), infected (GFP+) cells 
and normalizing the levels on cells expressing Nef-eGFP to those expressing Nef G2A-
eGFP. Downregulation levels were then compared between cells transduced with virus 
encoding wild-type SNX9 or dominant negative SNX9. 
2.4.8.2 Statistical analyses 
All statistics for analysis of receptor levels were conducted using a one-way analysis of 
variance with Bonferroni’s multiple comparison test. For analysis of CD28: LAMP-1 co-
localization, the mean Manders’ overlap coefficients were compared using a one-way 
analysis of variance with Bonferroni’s multiple comparison test to compare wild-type 
infected cells to cells infected with viruses encoding or lacking Nef and/or Vpu (Fig. 3) or 
wild-type infected cells treated with vehicle to cells treated with various inhibitors (Fig. 4). 
Alternatively, for analysis of the percentage of IL-2 positive infected cells, a paired two-
tailed t-test was used. All statistical tests were completed using Graph Pad Prism (Graph 
Pad Software Inc., La Jolla, CA). 
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Chapter 3  
3 Defining the role of the novel interaction between HIV-1 
Nef and the membrane trafficking protein SNX18 
3.1 Introduction 
In order for viruses to persist within their hosts, they must evade host anti-viral immune 
responses. This is particularly critical for viruses that cause chronic infections, such as 
HIV-1, which fails to be eliminated by the immune response upon establishment of 
infection. Key to the ability of HIV-1 to evade the immune response are the actions of the 
accessory protein Nef. Nef mediates multiple functions to facilitate the evasion of both 
innate and adaptive immune responses (reviewed in [1]). A central mechanism by which 
Nef enables evasion of immune responses is via the reduction of cell surface levels of 
MHC-I molecules [2]. Briefly, cell surface MHC-I molecules present antigens to the 
adaptive immune cells CD8+ cytotoxic T cells, which secrete cytotoxic enzymes to induce 
the death of cells presenting viral antigens on MHC-I molecules [3]. Therefore, as a result 
of the Nef-dependent reduction of cell surface MHC-I molecules, cells infected with HIV-
1 encoding a functional nef gene are less effectively killed by CD8+ cytotoxic T cells [4]. 
Moreover, increased downregulation of MHC-I by Nef correlates with faster disease 
progression and higher viral loads in rhesus macaques infected with the related simian 
immunodeficiency virus [5-8].  
Nef mediates its functions, including decreasing surface MHC-I molecules, by interacting 
with host cell proteins and subverting their functions. Specifically, many Nef-dependent 
functions require Nef to alter the subcellular localization of various host cell proteins by 
hijacking host proteins implicated in cellular membrane trafficking. A well characterized 
example of this is the hijacking of the membrane trafficking adaptor proteins AP-1 and 
AP-2. Indeed, Nef binds to both AP-1 and AP-2 to connect host cell cargo to the trafficking 
machinery, whereby these Nef: adaptor protein: cargo complexes mediate the transport of 
cellular cargo to specific subcellular locations [9-12]. However, in order for cargo to be 
trafficked to different locations within the cell a multitude of host cellular machinery are 
necessary, as vesicular trafficking is complex and generally requires many factors [13], 
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leading to the possibility that Nef recruits one or more additional factors to facilitate cargo 
trafficking.  
An additional protein that may facilitate Nef-dependent cargo trafficking is SNX18, which 
was shown to form a complex with Nef in infected HeLa cells [14]. SNX18 is a member 
of a subgroup of sorting nexin proteins that contain an SH3 domain, which also includes 
the proteins SNX9 and SNX33 (SNX30) [15]. Together, these sorting nexin proteins 
facilitate membrane trafficking by mediating the formation of tubulated membranes [15, 
16], which may ultimately form vesicles. In addition, SNX9, SNX18 and SNX33 have been 
reported to interact with and recruit additional membrane trafficking proteins, thereby 
making these key regulators of membrane trafficking events. Notably, the SH3 domains of 
SNX18, SNX9 and SNX33 interact with the GTPase dynamin-II [15, 17, 18], which 
mediates the scission of membranes to form vesicles during membrane trafficking [19]. 
Interestingly, SNX9 and SNX18 also interact with the Nef-binding vesicular adaptor 
proteins. Specifically, SNX9 immunoprecipitated with AP-2 and SNX18 with AP-1 from 
K562 and HeLa cells, respectively [15, 20]. Moreover, endogenous SNX18 co-localizes 
with the Nef and AP-1 binding protein PACS-1 in HeLa cells [15]. Given that the classical 
trafficking organelles, clathrin coated vesicles, contain upwards of 200 discrete proteins 
which can contribute to their trafficking within cells [21], the relatively small number of 
host cell proteins currently characterized as essential for Nef-mediated trafficking of host 
cell cargo are undoubtedly not sufficient to facilitate membrane trafficking. Therefore, we 
hypothesize that additional host cell factors are required during Nef-mediated trafficking 
events and have focused on SNX18 and SNX9 as potential candidates. 
Herein, we investigate the SNX18: Nef interaction further by mapping the protein domains 
implicated in this complex using in vitro protein binding assays. We demonstrate that Nef 
interacts directly with SNX18, but not the related protein SNX9, and map this interaction 
to the SH3 domain of SNX18 and the PxxP75 motif of Nef. Moreover, we investigate the 
role of the Nef: SNX18 interaction in cells, specifically by examining the requirement for 
this interaction for Nef-mediated MHC-I downregulation. Our findings suggest that 
SNX18 may be important for Nef to mediate decreases in cell surface MHC-I in T cells.  
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3.2 Results 
3.2.1 SNX18 and Nef interact in vitro through a SNX18 SH3 domain: Nef PxxP motif 
interaction 
We first sought to map the interaction between Nef and members of the sorting nexin 
family of proteins, in addition to determining if this interaction is direct. Interestingly, the 
HIV-1 Nef protein contains a motif (PxxP75) implicated in direct interactions with SH3-
domain containing proteins [22-25], and these same SH3 domains are present in the sorting 
nexin proteins SNX18 and SNX9. We first tested if Nef and SNX18 or SNX9 interact 
directly. To monitor this, in vitro capture assays were performed using bacterially produced 
and subsequently purified proteins. Specifically, purified His6-Nef (SF2) was incubated 
with glutathione conjugated beads and increasing concentrations of GST-tagged SNX18 
and SNX9 or GST alone. In the presence of GST-SNX18, His6-Nef was detected via 
Western blot in the pulled-down proteins, unlike in the presence of SNX9 (Figure 3.1A). 
Relative to our control, GST, significantly greater SNX18, but not SNX9, pulled down 
Nef, and there was greater His6-Nef detected when an increased amount of SNX18 bait 
protein was utilized (Figure 3.1B). Overall, this suggests that SNX18 interacts with Nef in 
vitro, thus demonstrating a direct interaction, while the related protein SNX9 does not 
interact with Nef.  
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Figure 3.1 GST-SNX18, but not GST-SNX9, pulls down His6-Nef 
Various GST-tagged proteins and His6-Nef protein were bacterially produced and 
subsequently purified. His6-Nef was then pulled down by sepharose beads bound with 
the indicated amounts of GST, GST-SNX18 or GST-SNX9 and detected by Western 
blot. (A) Anti-His6 Western blot of 5% of input (top); Anti-His6 Western blot of protein 
remaining associated with glutathione sepharose after washing with 500 mM sodium 
chloride (middle); Ponceau S stain of membrane from pulled down proteins (bottom). 
(B) Mean (+/-SD) band intensity of relative His6-Nef pulled down by GST, GST-SNX18 
or GST-SNX9. Mean His6-Nef binding was compared using a one-way Anova and the 
Bonferroni’s multiple comparisons test was utilized to compare binding to GST. Assays 
were performed in quadruplicate. (SD: standard deviation; * p≤ 0.05; **** p≤ 0.0001; 
WB: Western blot) 
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Next, we mapped the SNX18: Nef interaction interface. To determine if the SH3 domain 
of SNX18 mediates the Nef: SNX18 interaction, as it does with the SFK interaction with 
Nef [26], a GST-tagged variant of the SH3 domain of SNX18 was bacterially produced 
and subsequently purified, along with a GST-tagged version of SNX18 that is devoid of its 
SH3 domain (SH3; Figure 3.2A). Upon performing in vitro pull-down assays, we 
observed that His6-Nef was indeed pulled down by the SH3 domain of SNX18, but not by 
the SH3 protein (Figure 3.2B, C). This result suggests that the SH3 domain is necessary 
and sufficient for interacting with Nef in vitro. Moreover, to further test the specificity of 
the SNX18 SH3 domain in mediating a direct interaction with Nef, we designed a GST-
tagged chimeric protein in which the SH3 domain of the SNX18 protein was replaced with 
the SH3 domain of SNX9 (Figure 3.2A), which fails to bind Nef in vitro (Figure 3.1), and 
tested for its ability to pull down His6-Nef. Interestingly, the SNX9 SH3/SNX18 chimera 
failed to pull down His6-Nef in an in vitro binding assay, in a similar manner to the GST 
protein negative control (Figure 3.2D, E), confirming the specificity and importance of the 
SNX18 SH3 domain for binding to Nef in vitro.  
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Figure 3.2 The direct Nef: SNX18 interaction is dependent on the SH3 domain 
GST-tagged bait proteins and His6-Nef were bacterially produced and subsequently 
purified. His6-Nef was then pulled-down by glutathione-sepharose beads coated with the 
indicated GST-tagged proteins and detected by Western blot. (A) Schematics indicating 
the GST-tagged constructs utilized as bait proteins. (B) His6-Nef was captured by 
glutathione sepharose bound GST, GST-tagged SH3 domain of SNX18 or GST-tagged 
ΔSH3 (SNX18 lacking the SH3 domain) and detected by Western blotting. Anti-His6 
Western blot of 5% of input (top); Anti-His6 Western blot of protein remaining 
associated with glutathione sepharose after washing with 500 mM sodium chloride 
(middle); Ponceau S stain of membrane from pulled down proteins (bottom). (C) Mean 
band intensity of relative His6-Nef pulled down by GST, GST-SH3 or GST-ΔSH3. 
Assays were performed multiple times (n=7) and the results are presented as the mean 
(+/-SD). Mean His6-Nef binding was compared using a one-way Anova and the 
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Bonferroni’s multiple comparisons test was utilized to compare binding in all conditions 
versus GST. (E) Anti-His6 Western blot of 5% of input (top); Anti-His6 Western blot of 
protein remaining associated with glutathione sepharose after washing with 500 mM 
sodium chloride (bottom). (F) Mean band intensity of relative His6-Nef pulled down by 
GST, GST-SNX18, GST-SNX9 or a GST-SH3 domain chimera comprised of the SH3 
domain of SNX9 fused to the entire SNX18 protein except for the SH3 domain. Assays 
were performed in triplicate and results are presented as the mean (+/-SD). Mean His6-
Nef binding was compared using a one-way Anova and the Bonferroni’s multiple 
comparisons test was utilized to compare binding in all conditions versus GST. (SD: 
standard deviation; * p≤ 0.05; ** p≤ 0.01; *** p≤ 0.001; **** p≤ 0.0001; WB: Western 
blot) 
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It has been previously demonstrated that Nef interactions that are dependent on SH3 
domains are mediated by the Nef PxxP75 motif [23, 26], which has defined roles in AIDS 
pathogenesis and immune evasion [26-30]. To test for the requirement of the Nef PxxP75 
motif for interacting with the SNX18 SH3 domain and thereby establishing a Nef motif 
implicated in the Nef: SNX18 interaction, we repeated our in vitro protein pull-down assay 
using purified His6-Nef or His6-Nef AxxA75, a Nef mutant that fails to bind SFKs ([26]; 
Figure 3.3). We observed that significantly less His6-Nef AxxA75 was pulled down by the 
GST-tagged SNX18 SH3 domain when compared to wild-type His6-Nef (Figure 3.3A, B). 
Overall, this data demonstrates that SNX18 and Nef interact directly in vitro, unlike the 
related SNX9 protein which fails to bind Nef. Moreover, mapping of this interaction 
revealed its dependence on the SH3 domain of SNX18 and the Nef PxxP75 motif. 
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Figure 3.3 In vitro protein capture of His6-Nef and a Nef mutant, His6-Nef AxxA75, 
by the SH3 domain of SNX18 
Bacterially produced and subsequently purified GST-tagged SH3 domain of SNX18 was 
bound to sepharose beads and tested for its ability to pull down wild-type or AxxA75 
mutant His6-tagged Nef. (A) His6-Nef or His6-Nef AxxA75 was captured by glutathione-
sepharose bound GST or GST tagged SH3 domain of SNX18 and detected by Western 
blotting. Top: Anti-His6 Western blot of 5% of input; bottom: Anti-His6 Western blot of 
protein remaining associated with glutathione sepharose after washing with 500 mM 
sodium chloride. (B) Mean (+/-SD) band intensity of hexa-histidine tagged protein 
pulled down by GST-tagged SNX18 SH3 domain, relative to protein pulled down by 
GST. Assays were performed in triplicate and the relative mean band intensities were 
compared using a Student’s t-test.  (SD: standard deviation; **= p≤ 0.01; WB: Western 
blot) 
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3.2.2 SNX18 and Nef interact in cells 
We next sought to define the molecular determinants implicated in the Nef: SNX18 
interaction in cells. Our group previously described the detection of a close association 
between SNX18 and Nef within cells using the technique of Bimolecular Fluorescence 
Complementation (BiFC) [14], which reconstitutes a split fluorophore to demonstrate a 
protein-protein interaction. Therefore, with the molecular details of the Nef: SNX18 
interaction interface acquired in vitro (Figure 3.3), we wished to validate the previously 
observed Nef: SNX18 BiFC signal. To test this, we expressed vectors encoding wild-type 
or the PxxP75 mutant Nef (NL4.3) protein fused to a C-terminal fragment of the Venus 
fluorophore (Nef-VC or Nef AxxA75-VC) and SNX18 fused to a N-terminal fragment of 
Venus (SNX18-VN) in HeLa cells and examined the reconstitution of the fluorophore using 
wide field microscopy (Figure 3.4). We observed that the mean fluorescence intensity of 
the Nef: SNX18 BiFC signal was significantly reduced with the mutant Nef (Nef AxxA75-
VC), compared to wild type Nef (Figure 3.4B). Moreover, expression of the Nef-VC and 
Nef AxxA75-VC proteins was confirmed by Western blotting (Figure 3.4C). These findings 
suggest that the Nef: SNX18 interaction occurs within cells and is mediated at least in part 
by the Nef PxxP75 motif.  
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Figure 3.4 Mutation of the Nef PxxP75 motif reduces SNX18: Nef BiFC intensity 
HeLa cells were co-transfected with vectors encoding SNX18-VN-FLAG and either Nef-
VC or Nef AxxA75-VC. Twenty-four hours post transfection, cells were incubated in the 
dark for 1 hour to mature the fluorophore, followed by fixation in 4% PFA and 
subsequent visualization by wide field microscopy. (A) Representative images of 
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transfected cells illustrating Nef: SNX18 BiFC signal (left), anti-FLAG staining (middle) 
and merge (right). (B) Mean (+/-SD) fluorescence intensity of non-transfected (NT), 
SNX18-VN-FLAG and Nef-VC transfected, or SNX18-VN-FLAG and Nef AxxA75-VC 
transfected cells (n=30). The mean fluorescence intensities were compared using a one-
way ANOVA followed by Tukey’s multiple comparisons test. (C) Western blots 
demonstrating expression of Nef-VC and Nef AxxA75-VC.  (*** p≤ 0.001; NT: non-
transfected; Mr: molecular weight) 
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3.2.3 SNX18 is required for Nef-dependent reductions in cell surface MHC-I  
We next sought to identify if the Nef: SNX18 interaction is required for Nef-mediated 
decreases in cell surface MHC-I, a key mechanism utilized by HIV-1 to evade immune 
surveillance. Indeed, it has been previously demonstrated that the Nef PxxP75 motif which 
mediates SNX18 binding also binds SFKs to trigger an intracellular signaling cascade 
which downregulates cell surface MHC-I [30, 31]. To test this, CD4+ Sup-T1 T cells were 
transduced with lentiviral vectors encoding both GFP and shRNA sequences targeting 
SNX18 or an irrelevant non-specific shRNA. In addition, these same Sup-T1 cells were 
transduced with a modified HIV-1 NL4.3 vector encoding the fluorescent protein 
mStrawberry in addition to encoding (Nef) or lacking Nef (dNef). Cell surface MHC-I 
levels on dual infected (GFP+ mStrawberry+) cells were quantified by flow cytometry 
(Figure 3.5A). We observed a small, but significant, increase in the amount of cell surface 
MHC-I in the presence of Nef in cells infected with virus decreasing SNX18 expression, 
compared to cells expressing the non-specific shRNA (Figure 3.5B, C), suggesting that 
Nef-mediated decreases in cell surface MHC-I are dependent on SNX18 expression. 
Moreover, efficient knock-down of SNX18 in Sup-T1 cells was confirmed using Western 
blot analyses of infected cells (Figure 3.5D). Indeed, we observed a significant decrease in 
cellular SNX18 levels in cells transduced with SNX18 targeting shRNAs, compared to 
non-specific shRNA (Figure 3.5E). Overall, these findings suggest that the presence of 
SNX18 is important for the ability of Nef to decrease cell surface MHC-I levels. 
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Figure 3.5 Knock-down of SNX18 reduces Nef-mediated MHC-I downregulation 
CD4+ Sup-T1 T cells were infected with viruses encoding both GFP and non-specific or 
SNX18 targeting shRNAs in addition to a virus encoding mStrawberry and encoding or 
lacking Nef. Infected cells were stained for cell surface MHC-I (HLA-A, B, C) and 
analyzed by flow cytometry. (A) Illustration of gating strategy. Dual infected (GFP+ 
mStrawberry+) cells were gated on and cell surface MHC-I was quantified on dual 
infected cells. (B) Representative histograms illustrating cell surface MHC-I levels on 
dual infected cells infected with non-specific (NS) shRNA or SNX18 targeting (anti-
SNX18) shRNA and with virus encoding (Nef; blue) or lacking (dNef; orange) Nef. (red: 
isotype stained cells) (C) Relative mean (+/-SD) cell surface MHC-I in cells infected 
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with virus encoding Nef and a non-specific (NS) or SNX18 (anti-SNX18) targeting 
shRNA. (n=16) Relative means were compared using a paired Student’s t-test. (D) 
Western blot illustrating endogenous levels of SNX18 in uninfected Sup-T1 cells (UI) 
or cells infected with viruses encoding a non-specific (NS) or SNX18 (anti-SNX18) 
targeting shRNA. (E) Quantification of relative mean (+/-SD) SNX18 levels in 
uninfected Sup-T1 cells (UI) or cells infected with viruses encoding a non-specific (NS) 
or SNX18 (anti-SNX18) targeting shRNA detected by Western blots (n=8). Mean 
SNX18 levels were compared using a one-way Anova and Dunnett’s multiple 
comparisons test. (GFP: green fluorescent protein; MHC-I: major histocompatibility 
complex type I; Mr: molecular weight; * p≤ 0.05; ** p≤ 0.01; SD: standard deviation; 
UI: uninfected; SNX18: sorting nexin 18) 
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3.2.4 SNX18 is unlikely to be required for Nef-mediated secretion in extracellular 
vesicles 
In order to decrease cell surface levels of MHC-I, Nef facilitates the endocytosis and 
intracellular sequestration of cell surface MHC-I [32]. However, it has also been reported 
that Nef can facilitate the secretion of extracellular vesicles containing MHC-I via 
exocytosis [33, 34]. To perform this function, Nef activates host cell signaling proteins to 
form the Nef-associated kinase complex [35], which facilitates the complex’s interaction 
with the scaffold protein Paxillin [34]. Interestingly, Paxillin has been previously shown to 
interact with the SNX18-binding metalloproteinases ADAM-10 and ADAM-17 to promote 
the inclusion of Nef, ADAM-17 and ADAM-10 into extracellular vesicles [34, 36]. 
Therefore, we hypothesized that SNX18 may contribute to Nef-mediated decreases in cell 
surface MHC-I by facilitating the secretion of extracellular vesicles. Thus, we examined if 
the SNX18: Nef BiFC complex localizes to the late endosome or mutivesicular body 
(MVB) compartment, which contains vesicles that can serve as precursors for extracellular 
vesicles [37]. Specifically, to label the MVB compartment we utilized an antibody that 
recognizes the tetraspanin protein CD63. We observed that the Nef: SNX18 BiFC signal 
co-localized with CD63 in HeLa cells (Figure 3.6). Interestingly, the SNX18: Nef BiFC 
signal co-localized with CD63 to a greater extent than GPF-tagged SNX18 or the related 
protein SNX9, which does not bind Nef (Figure 3.1), in the absence of Nef (Figure 3.6). 
Therefore, given that neither SNX9 or SNX18 localize to CD63 positive compartments in 
the absence of Nef, this suggests that at least in the case of SNX18, this membrane 
trafficking protein is being diverted to MVBs in the presence of Nef.  
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Figure 3.6 The SNX18: Nef BiFC complex co-localizes with CD63 
HeLa cells were transfected with vectors encoding eGFP, SNX9-eGFP, SNX18-eGFP or 
SNX18-VN and Nef-VC. Twenty-four hours post transfection, cells were incubated in the 
dark to mature the fluorophore, stained for endogenous CD63 and visualized using wide 
field microscopy. (A) Representative images of transfected cells. Puncta where SNX18: 
Nef BiFC and CD63 overlap are denoted by arrows. Scale bar = 10 μm. (B) Mean (+/-SD) 
Pearson correlation coefficient between signal in the FITC (eGFP/BiFC) and Cy3 (CD63) 
channels (n≥7). Means were compared using one way ANOVA followed by Tukey’s 
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multiple comparisons test. (*** p≤ 0.001; eGFP: enhanced green fluorescent protein; SD: 
standard deviation) 
167 
 
Next, we wanted to determine if SNX18 is required for Nef-mediated secretion of 
extracellular vesicles. To investigate this, stable HEK293T cell lines expressing shRNA 
targeting SNX18 (293TαSNX18) or a non-specific target control (293TNS) were produced. 
These cells were then transfected with the pNL4.3 dG/P eGFP lentiviral vector. The 
extracellular vesicles from this transfected cell culture supernatant were purified and 
probed for their content (Figure 3.7). Specifically, the cell lysate and purified extracellular 
vesicles were probed for the viral proteins Nef and Vpu, which were previously shown to 
be secreted into extracellular vesicles, and specific markers for intracellular proteins 
(Calnexin, Actin) and extracellular vesicles (TSG-101). In addition, we probed for the 
metalloprotease ADAM-17, which has been previous implicated in the sorting of Nef into 
extracellular vesicles [34]. Through five independent experiments, a significant difference 
in the amount of Nef secreted from 293TαSNX18 or 293TNS cells was not observed (Figure 
3.7B). However, upon Western blotting for Nef in the extracellular vesicle preparations, 
an additional protein band was consistently observed. Moreover, Nef exhibited an altered 
migration pattern, as was seen in the extracellular fraction for the HIV-1 protein Vpu and 
for ADAM-17.  
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Figure 3.7 Extracellular vesicles purified from Nef-expressing SNX18 knock-down 
cells 
HEK293T cells stably expressing non-targeting (NS) or SNX18 targeting (anti-SNX18) 
shRNAs were transfected with a vector encoding all HIV-1 viral accessory proteins 
(NL4.3 dG/P eGFP). Forty-eight hours post transfection, extracellular vesicles in cell 
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culture supernatants were purified using a commercial purification reagent (exoquick) 
and the associated proteins analyzed by Western blotting. (A) Representative Western 
blots illustrating cellular and extracellular vesicle proteins. (B) Mean relative 
extracellular Nef (+/-SD) from five independent experiments. Mean relative extracellular 
Nef was not significantly different, as determined using a Student’s t-test. (Mr: molecular 
weight, SD: standard deviation) 
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3.3 Discussion 
In the present work, we identify and investigate the underlying mechanism of a novel Nef: 
host protein interaction, the interaction between Nef and SNX18. Using in vitro protein 
capture assays, we have shown that Nef binds directly to SNX18 (Figure 3.1). This 
interaction was dependent on the SH3 domain of SNX18 and was specific to SNX18, as 
the SH3 domain from a related family member, SNX9, could not mediate binding to Nef 
(Figure 3.2). Moreover, the Nef: SNX18 interaction was reduced upon mutation of the Nef 
PxxP75 motif both in vitro and in mammalian cells (Figure 3.3; Figure 3.4). Notably, while 
mutation of the Nef PxxP75 motif inhibited complex formation with full length SNX18 
within cells (Figure 3.4), the examination of the effects of this Nef mutation on binding in 
vitro was limited to the interaction with the SH3 domain of SNX18 (Figure 3.3). Therefore, 
future experiments to examine Nef AxxA75 binding to full length SNX18 protein in vitro 
may be of value.  The finding that this interaction required the SH3 domain of SNX18 and 
the PxxP75 motif of Nef is consistent with the previously defined role of SH3 domains in 
binding to the Nef polyproline motif [26], an interaction critical for the immunoevasive 
effects of Nef [30]. Indeed, the Nef PxxP75 motif is critical for interacting with the SH3 
domains of multiple SFKs to mediate the downregulation of cell surface MHC-I [30, 31]. 
Thus, the use of the Nef PxxP75 motif to hijack two different host proteins, SFKs and 
SNX18, by recognizing a common SH3 domain, exemplifies the amazing ability of viral 
proteins to efficiently mediate their functions by expanding their repertoire of binding 
partners. Moreover, given that proteins containing SH3 domains classically interact with 
other proteins via polyproline rich interaction interfaces [38], this is a prime example of 
viruses evolving the ability to mimic host cellular interactions while maintaining a degree 
of binding specificity, as SH3 domain binding was specific to SNX18 (Figure 3.2). Given 
that the affinity of previously identified Nef polyproline helix: SH3 domain interactions 
have been shown to be goverened by a specific region of the SH3 domain, known as the 
RT-loop [24, 39], future studies to investigate the residues within the SNX18 RT-loop that 
faciliate Nef binding may be of interest. The specificity of Nef: host protein interactions 
that required the Nef polyproline motif may also be mediated by differences in subcellular 
localization. Specifically, upon the localization of Nef to the TGN, wherein SFKs are 
enriched, Nef can interact with and activate a signaling cascade that initiates MHC-I 
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downregulation [30]. Concomitantly, Nef may interact with SNX18 at peripheral endocytic 
compartments. This multi-functionality of a viral protein interaction motif is not unlike that 
seen with host cellular proteins, including SNX18, whereby, in uninfected cells the SH3 
domain of SNX18 is implicated in binding to the polyproline rich domains of the proteins 
N-WASP and dynamin-II [15, 40].  
In order to investigate the functional consequence of Nef: SNX18 interactions in cells, we 
utilized shRNA to silence SNX18 expression in T cells. We observed a reduction in Nef’s 
ability to downregulate cell surface MHC-I in the absence of SNX18 (Figure 3.5). Notably, 
the effect of our SNX18 knock-down on MHC-I downregulation was small. These studies 
may be limited by the functional redundancy between SNX18 and the related protein SNX9 
[40, 41], whereby SNX9 may compensate for the knock-down of SNX18 despite the lack 
of a direct Nef: SNX9 interaction. Specifically, a recent study illustrated that knock-down 
of both SNX18 and SNX9 was required to inhibit the proper trafficking of the 
metalloproteinase ADAM9, an effect not observed upon knock-down of the proteins 
independently [41]. Thus, future studies examining MHC-I downregulation upon reduction 
of both SNX18 and SNX9 may be of value. Additionally, the knock-down of SNX18 
observed via Western blot was variable and limited (Figure 3.5E), with some experiments 
exhibiting reductions in uninfected (UI) cell SNX18 protein levels relative to cells 
transduced with lentiviral vectors encoding non-specific (NS) shRNA. These observed 
decreases in SNX18 protein levels within uninfected cells may be a result of global changes 
in cells resulting from lentiviral vector infection. These experiments could be improved 
through creation of SNX18 knock-out cell lines utilizing CRISPR/Cas9 technology [42]. 
The observed inhibition of Nef-mediated MHC-I downregulation upon knock-down of 
SNX18 is not likely due to SNX18 facilitating Nef-mediated extracellular vesicle release, 
as SNX18 was dispensable for Nef-induced extracellular vesicle release in HEK293T cells 
(Figure 3.7B). However, we did note molecular weight shifts in multiple proteins when 
comparing migration patterns in the cellular fraction vis-a-vis the extracellular fraction 
(Figure 3.7A), as has been seen previously observed with Nef in extracellular vesicle 
preparations [43, 44]. These differences in Nef, Vpu and ADAM-17 migration patterns 
may reflect post-translation modifications which act as signals to mediate the incorporation 
172 
 
of these proteins into intraluminal vesicles destined to be secreted from the cell [45]. 
However, we have not examined the physical properties or biogenesis pathway of our 
extracellular vesicle preparations, thus we cannot conclude that we are examining 
extracellular vesicles derived from the secretion of intraluminal vesicles. 
As an alternative to mediating decreases in cell surface MHC-I through secretion of 
extracellular vesicles, the Nef: SNX18 interaction may be facilitating the endocytosis of 
MHC-I which is transiting from the cell surface to the TGN for intracellular sequestration, 
a virus induced activity which limits antigen presentation [32, 46, 47]. It has been 
previously established that to downregulate MHC-I, Nef and AP-1 form a ternary complex 
with the cytoplasmic tail of MHC-I [11, 12]. Additionally, it is proposed that PACS-1, 
which can bind both Nef and AP-1 and co-localizes with SNX18 [15, 32, 48, 49], facilitates 
this interaction and mediates proper trafficking of the Nef: AP-1: MHC-I ternary complex 
[32, 47]. Since SNX18 binds AP-1 and Nef, via the SH3 domain and low complexity 
domain, respectively ([15]; Figure 3.2), it is plausible that SNX18 may be recruited to and 
interact with the Nef: AP-1: MHC-I ternary complex. Notably, due to the ability of SNX18 
to dimerize [15, 40], it is conceivable that despite the potential for competition between 
Nef and other polyproline rich proteins for SH3 domain binding, a single SNX18 dimer 
could bind to both Nef and an additional interaction partner simultaneously (Figure 3.8).  
There are numerous mechanisms by which Nef-bound SNX18 could facilitate the 
endocytic trafficking of MHC-I. Firstly, SNX18 contains a BAR domain, which can 
dimerize with other BAR domains into crescent shaped structures which forms a concave 
“bent” surface capable of interacting with membranes, thereby contributing to overall 
membrane bending [50]. Membrane bending is a hallmark state of lipid bilayers that 
facilitates the scission of membranes, thereby ensuring the formation of small vesicles that 
bud from one membrane enclosed structure to transport cargo from one location to another 
[50]. Moreover, SNX18 can promote the scission of membranes by interacting with 
dynamin-II [15], which uses the energy from GTP hydrolysis to enable membrane scission 
[19]. Furthermore, SNX18 interacts with N-WASP [40], the recruitment of which may 
facilitate changes in actin dynamics to promote vesicular trafficking [51]. Ultimately, we 
propose that the interaction between Nef and SNX18 may be facilitating the vesicular 
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trafficking of MHC-I during Nef-mediated sequestration of MHC-I away from the cells 
surface.  
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Figure 3.8 Proposed model for the role of SNX18 in Nef-mediated MHC-I 
trafficking 
SNX18 can dimerize via its BAR domain and interact with curved membranes. The 
SNX18 low-complexity domain interacts with AP-1, which also forms a ternary complex 
with Nef and the cytoplasmic tail of MHC-I. Moreover, the Nef PxxP75 motif interacts 
with the SH3 domain of SNX18. Nef and AP-1 also interact with PACS-1, which can 
co-localize with SNX18, to facilitate MHC-I trafficking. While one SNX18 monomer in 
a single heterodimer interacts with Nef, the other can interact with additional host 
cellular trafficking proteins through its SH3 domain, including dynamin-II or N-WASP, 
to further promote membrane trafficking. 
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In conclusion, our results identify a novel Nef: host protein interaction, specifically 
between Nef and SNX18, that may contribute to the ability of Nef to evade the immune 
system via MHC-I downregulation. This interaction is mediated by a highly conserved 
polyproline motif in Nef and therefore may be conserved across the diverse HIV-1 clades. 
The finding that additional Nef: host protein interactions may mediate immune evasion, 
highlights the complexity of the mechanism evolved by the HIV-1 virus to persist within 
the host and contribute to pathogenesis. 
3.4 Material and Methods 
3.4.1 DNA vectors  
Plasmids encoding GST-tagged SNX18 and SNX9 in pGEX-6P1 and pGEX-KG 
backbones, respectively, were kindly provided by R. Prekeris (University of Colorado, 
Aurora, CO). GST-SNX18 SH3 domain and GST-SNX18 ΔSH3 expression vectors were 
produced by PCR amplification of the SNX18 SH3 domain (residues: 1-61) or low 
complexity through BAR domains (residues: 62-624) with primers encoding EcoRI and 
NotI restriction sites, followed by insertion into pGEX-4T1. A vector encoding the GST-
tagged SNX9 SH3 domain- SNX18 chimeric protein was produced by insertion of a 
HindIII restriction site immediately downstream of the SH3 domain (residue 63) of SNX18 
using site directed mutagenesis with mutagenesis primers created with the Agilent 
Technologies QuikChange Primer Design program (Agilent Technologies, Santa Clara, 
CA). The SNX18 SH3 domain was subsequently replaced with PCR amplified SNX9 SH3 
domain (residues: 1-61) using the inserted HindIII restriction site. The bacterial expression 
vector for production of His6-Nef encoded hexa-histidine tagged Nef from the HIV-1 SF2 
strain and was provide by T. Smithgall (University of Pittsburgh, Pittsburgh, PA). A His6-
Nef AxxA75 mutant was produced by site directed mutagenesis, as above. 
The SNX18 gene was sub-cloned into a peGFP-N1 backbone, in which the eGFP 
fluorophore was replaced with an N-terminal portion of Venus (VN 1-173) FLAG tagged 
on the N-terminus. The Nef-VC expression vector was previously described [46] and a Nef 
AxxA75-VC expression vector was produced using site directed mutagenesis, as described 
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above. The SNX18 and SNX9 genes were sub-cloned into peGFP-N1 to produce SNX18-
eGFP and SNX9-eGFP expression vectors.  
Viral infection plasmids were engineered via insertion of the mStrawberry encoding region 
of the previously described pNL4.3 F2A-mStrawberry vector into pNL4.3 dG/P eGFP or 
pNL4.3 dG/P eGFP dNef backbones [14, 52, 53]. Lentiviral vectors encoding shRNAs 
were obtained from OriGene (OriGene Technologies, Inc., Rockville, MD) and are 
described below.  
3.4.2 Bacterial protein expression and purification 
E. coli BL21(DE3) were transformed with expression vectors encoding GST or hexa-
histidine tagged proteins of interest and cultured in LB media containing the appropriate 
antibiotic to an optical density at 600 nanometers (OD600) between 0.5-0.7. GST tagged 
sorting nexin proteins or domains of interest were subsequently induced with 0.1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) (Thermo Fisher Scientific, Mississauga, 
ON) overnight at 30° C, while GST and His6-Nef were induced for four hours with 1.0 mM 
IPTG at 37° C and 1.5 mM IPTG at 30° C, respectively. Induced E. coli BL21 (DE3) 
transformed with GST-tagged protein expression vectors were pelleted at 3,840 x g, re-
suspended in lysis buffer [0.1 M sodium phosphate (pH 7.2), 1 M sodium chloride, 10 mM 
benzamidine, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol 
(DTT)], and lysed using a French press. The lysate was ultra-centrifuged at 256,630 x g to 
separate the soluble and insoluble lysate components. The supernatant was incubated with 
glutathione sepharose 4B (GE Healthcare, Baie-D’Urfé, QC), with rocking for one hour at 
4° C. The resin was then pelleted, the supernatant removed, and the resin washed to remove 
unbound or non-specifically bound proteins. Briefly, the resin was washed sequentially as 
follows: two washes with 12 resin volumes of wash buffer 1 [0.1 M sodium phosphate 
buffer (pH 7.2), 1 M sodium chloride, 0.5 mM EDTA, 1 mM DTT], three washes with 12 
resin volumes of wash buffer 2 [0.1 M sodium phosphate buffer (pH 7.2), 150 mM sodium 
chloride, 1 mM DTT], and two washes with one resin volume of elution buffer [50 mM 
Tris buffer (pH 8.0), 15 mM reduced glutathione]. The elution buffer washes were pooled 
and proteins were further purified using a size exclusion column and fast protein liquid 
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chromatography such that eluted proteins were in 20 mM Tris buffer (pH 8.0), 150 mM 
sodium chloride, 1 mM DTT, and 0.5 mM EDTA.   
The induced E. coli BL21 (DE3) transformed with His6-Nef expression vectors were 
pelleted at 3,840 x g, re-suspended in lysis buffer [50 mM sodium phosphate (pH 8.0), 200 
mM sodium chloride, 10 mM imidazole], lysed using a French press, and the lysate ultra-
centrifuged at 256,630 x g. The supernatant was then incubated with nickel-nitriloacetic 
acid (Ni2+-NTA) agarose (5 PRIME, Mississauga, ON) for one hour at 4°C with rocking. 
The elution of proteins bound to the Ni2+-NTA agarose resin was performed using buffer 
containing imidazole. Specifically, the resin was pelleted and washed sequentially as 
follows: two washes with 12 resin volumes of wash buffer 1 [50 mM sodium phosphate 
buffer (pH 8.0), 200 mM sodium chloride, 20 mM imidazole], three washes with 12 resin 
volumes of wash buffer 2 [50 mM sodium phosphate buffer (pH 8.0), 200 mM sodium 
chloride, 100 mM imidazole], and one wash with 6 resin volumes of wash buffer 3 [50 mM 
sodium phosphate buffer (pH 8.0), 200 mM sodium chloride, 250 mM imidazole]. The 
protein eluted in the 100 and 250 mM imidazole washes was concentrated using 10,000 Da 
cut-off centricon centrifugal filters (EMD Millipore, Billerica, MA) and stored at -80ºC. 
3.4.3 Protein capture assay 
In vitro captures of His6-Nef were performed using the various GST-tagged bait proteins. 
Variable amounts of bait protein (GST-tagged proteins), as quantified by Lowry assay, 
were incubated with rocking for 45 minutes at room temperature with glutathione 
sepharose in binding buffer [20 mM Tris (pH 8.0), 150 mM sodium chloride, 0.5 mM 
EDTA, 0.1% NP-40 alternative]. Subsequently, 8 µg His6-Nef was then combined with 
each bait protein, at which time a loading control sample was obtained. After incubating 
for one hour at room temperature with rocking the resin was pelleted at 1,200 x g and 
washed three times with 25 resin volumes of wash buffer [20 mM Tris (pH 8.0), 500 mM 
sodium chloride, 0.1 mM EDTA, 0.1% NP-40 alternative], and re-suspended in SDS-
PAGE sample buffer for Western blot analysis.    
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3.4.4 Cell culture 
HEK293T (ATCC) cells and HeLa cells (ATCC) were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 4 mM L-glutamine, 4500 mg/L glucose and sodium 
pyruvate (HyClone, Logan, UT) and supplemented with 1% Penicillin-Streptomycin 
(Hyclone) and 10% fetal bovine serum (FBS; Wisent, St-Bruno, QC). Sup-T1 cells were 
maintained in Roswell Park Memorial Institute media (RPMI) 1640 media with L-
glutamine supplemented with 100 g/ml penicillin-streptomycin, 1% sodium pyruvate, 1% 
non-essential amino acids, 2 mM L-glutamine (Hyclone) and 10% FBS. All cell lines were 
grown at 37°C in the presence of 5% CO2 and sub-cultured in accordance with supplier’s 
recommendations.  
HEK293T cells stably expressing shRNAs against a non-specific target or SNX18 were 
produced by transduction with shRNA-encoding lentiviral vectors. Briefly, HEK293T cells 
were transduced with VSV-G pseudotyped lentivirus produced as described below with 
pGFP-C-shLenti plasmid encoding a scrambled shRNA (TR30021, Origene) or a SNX18 
targeting shRNA (TL307432D, Origene). Transduced cells were selected for using 0.8 
ug/mL puromycin and clones were selected. Cells were subsequently maintained in 
DMEM containing 0.4 ug/mL puromycin. 
3.4.5 Transfections and virus production  
Transfection of HeLa cells for microscopy and Western blotting was performed using 
PolyJet (FroggaBio, North York, ON) as per the manufacturer’s protocol. For VSV-G 
pseudotyped lentivirus production, HEK293T cells were triply transfected with the NL4.3 
or shRNA encoding vector of interest, the VSV-G envelope-encoding pMD2.G plasmid 
(Addgene; catalog number 12259) and pCMV-DR8.2 (Addgene; catalog number 12263) 
using PolyJet (FroggaBio) as per the manufacturer’s protocol. Seventy-two hours post 
transfection, lentivirus was harvested via cell culture supernatant clarification by spinning 
at 1500 x g, followed by 20 m filtration. Viruses were stored in 20% FBS at -80C.  
3.4.6 Western blot analysis 
For Western blotting of whole cell lysates, cells were pelleted and lysed by rocking in lysis 
buffer [0.5 M HEPES, 1.25 M NaCl, 1 M MgCl2, 0.25M EDTA, 0.1% Triton X-100 and 
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1X complete Protease Inhibitor Tablets (Roche, Indianapolis, IN)] for one hour at 4C. The 
supernatant was then clarified by spinning at 16,100 x g for 30 minutes at 4C, combined 
with SDS-PAGE sample buffer (0.312 M Tris pH 6.8, 3.6 M 2-Mercaptoethanol, 50% 
glycerol, 10% SDS) and boiled at 95C for 10 minutes. 
All Western blots were completed by running samples on 10 or 12% SDS-PAGE gels, 
followed by transferring to a nitrocellulose membrane. Membranes were blocked with 5% 
milk in TBST (50 mM Tris, 150 mM NaCl, 0.1% Triton-X) for one hour at room 
temperature, followed by incubation overnight at 4C with the appropriate primary 
antibody in 5% milk in TBST. The next day membranes were washed three times with 
TBST and incubated for two hours at room temperature with the appropriate species 
specific HRP-conjugated secondary antibodies (1:2000, Thermo Fisher Scientific) in 5% 
milk in TBST. Blots were subsequently washed and developed using ECL substrates 
(Millipore, Etobicoke, ON) and a C-DiGit chemiluminescence Western blot scanner (LI-
COR Biosciences, Lincoln, NE). The following primary antibodies were utilized: 1:100 
THETM His antibody (GenScript, Piscataway, NJ), 1:1000 rabbit anti-Nef polyclonal 
antibody (NIH-AIDS Research and Reference Reagent program; catalog number 2949), 
1:5000 rabbit anti-Vpu polyclonal antibody (NIH-AIDS Research and Reference Reagent 
program; catalog number 969), 1:2000 mouse anti-Actin monoclonal antibody (Thermo 
Fisher Scientific), 1:2000 rabbit anti-Calnexin (abcam, Cambridge, MA; catalog number 
ab22595), 1:1000 rabbit anti-ADAM17 (abcam; catalog number ab2051), 1:1000 mouse 
anti-TSG-101 (abcam; catalog number ab83), 1:1000 rabbit anti-SNX18 (Sigma-Aldrich, 
Oakville Ontario;  catalog number HPA037800). 
3.4.7 Microscopy 
For microscopy experiments, cells were plated on cover slips and transfected with the 
expression vectors of interest using PolyJet, as described above. Twenty-four hours post 
transfection cells were incubated at room temperature for 2 hours to mature the fluorophore 
and fixed with 4% paraformaldehyde. Cells were subsequently washed twice with PBS and 
permeabilized and blocked in 2% bovine serum albumin (BSA) and 0.1% Triton-X in PBS 
for 2 hour at room temperature. Cells were subsequently stained for two hours with anti-
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DYKDDDK (BioLegend, San Diego, CA) or anti-CD63 (Developmental Studies 
Hybridoma Bank, The University of Iowa) diluted down to in 2% BSA in PBS, washed 
twice with 0.2% BSA in PBS and incubated for one and a half hours with the appropriate 
fluorophore conjugated secondary antibodies (Alexa-Fluor-647 conjugated anti-mouse or 
anti-Rat; Jackson ImmunoResearch, West Grove, PA) in 0.2% BSA in PBS. Finally, cells 
were washed twice with PBS and mounted on coverslips with DAPI Fluoromount-G 
(SouthernBiotech, Birmingham, AL). Cells were imaged on a Leica DMI6000 B at 63X 
or 100X magnification using the FITC, Cy5 and DAPI filter settings and imaged with a 
Hamamatsu Photometrics Delta Evolve camera. Images were subsequently de-
convolved using the Advanced Fluorescence Deconvolution application on the Leica 
Application Suite software (Lecia, Wetzlar, Germany). The mean fluorescence intensity 
of the fluorescence signal was determined using image J [54] and co-localization 
analysis was conducted using Pearson correlation coefficient between signal in the FITC 
(eGFP/BiFC) and Cy3 (CD63) channel using the ImageJ plugin JACoP, as described 
previously [55]. 
3.4.8 Extracellular vesicle purification 
HEK293T cells stably expressing a non-specific or SNX18 targeting shRNA were 
transfected with the pNL4.3 dG/P eGFP vector using PolyJet, as described above. Forty-
eight hours post transfection the cell culture medium was removed and processed to purify 
extracellular vesicles, while the cells were washed with 1 x PBS followed by lysis and 
preparation for Western blotting, as described above. To purify extracellular vesicles, 
culture supernatant was pelleted at 3000 x g for 15 minutes and the supernatant was run 
through a 2 m filter. Culture supernatant was then concentrated using a 10,000 Da cut-off 
PeirceTM protein concentrator (Thermo Fisher Scientific). The extracellular vesicles were 
then precipitated from concentrated supernatants using ExoQuick exosome precipitation 
solution (FroggaBio), as per the manufactures protocol. Briefly, the exosome precipitation 
solution was mixed with the culture supernatant and incubate at 4ºC overnight prior to 
pelleting extracellular vesicles and removing supernatant via subsequent spins at 1500 x g 
for 30 mins and 5 mins. Pelleted vesicles were then re-suspended in RIPA-Doc buffer 
(140 mM NaCl, 10 mM NaH2PO4, 1% NP-40, 0.05% SDS, 0.5% sodium deoxycholate) 
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and mixed with SDS-PAGE sample buffer (0.312 M Tris pH 6.8, 3.6 M 2-
Mercaptoethanol, 50% glycerol, 10% SDS) and boiled at 95C for 10 mins. 
3.4.9 Transient shRNA knock-down experiments 
For the dual infection of Sup-T1 cells with VSV-G pseudotyped viruses, 1 x 106 Sup-T1 
cells were suspended in 8 g/mL polybrene and virus preparations in 20% FBS produced 
as described above from pGFP-C-shLenti vectors encoding different shRNAs. Cells were 
then spinoculated for four hours at 2880 x g at room temperature and re-suspended in fresh 
RPMI. The next day, cells were pelleted and re-suspended in 10% RPMI (mock infection) 
or pNL4.3 dG/P F2A-mStrawberry Nef/dNef pseudovirions in 20% FBS and 8 g/mL 
polybrene. Forty-eight hours later, cells were analyzed via flow cytometry or Western 
blotting.  
3.4.10 Flow cytometry  
For cell surface staining of MHC-I on transduced Sup-T1 cells, cells were washed twice 
with PBS, followed by fixing in 1% paraformaldehyde for 20 minutes at room temperature. 
Cells were subsequently washed twice with FACS buffer (1% FBS, 50 mM 
ethylenediaminetetraacetic acid (EDTA) in PBS) and stained with the appropriate antibody 
by rocking for 40 minutes at room temperature. Cells were then washed twice with FACS 
buffer and re-suspended in PBS. For staining of MHC-I 1:25 APC-Cy7-conjugated mouse-
anti-HLA-A, B, C (clone W6/32, BioLegend) or an isotype control antibody (APC-Cy7 
conjugated mouse IgG2b, κ isotype, clone MOPC-21, BioLegend) was utilized. Cells were 
analyzed using a BD Biosciences FACSCanto SORP (BD Biosciences). Data analysis was 
performed using FlowJo software (version 9.6.4, FlowJo LLC, Ashland, OR).  
3.4.11 Data analysis 
3.4.11.1 In vitro protein capture assays 
For in vitro pull-down assays, Western blots were acquired using a C-DiGit 
chemiluminescent blot scanner (LI-COR) and band intensities were quantified using Image 
Studio (LI-COR). The band intensities were normalized to the highest intensity in each 
assay and the mean normalized intensities were analyzed by one-way analysis of variance 
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followed by Bonferroni’s multiple comparison test (Figures 3.1B, 3.2C, E) or a Student’s 
t-test (Figure 3.3B). 
3.4.11.2 Microscopy 
For analysis of Nef: SNX18 BiFC and CD63 overlap, the mean (+/-SD) Pearson correlation 
coefficient between signals in the FITC (eGFP/BiFC) and Cy3 (CD63) were determined 
using the ImageJ plugin JACoP, as described previously [55]. Means were compared 
using an Ordinary one-way analysis of variance followed by Tukey’s multiple 
comparison test. The mean fluorescence intensity of Nef-VC: SNX18-VN and Nef 
AxxA75-VC: SNX18-VN BiFC signal was compared using an unpaired Student’s t-test.  
3.4.11.3 Transient shRNA knock-down experiments 
For analyses of flow cytometry data obtained for dual infected Sup-T1 cells, double 
positive (GFP+ mStrawberry+) cells we gated on based on fluorescence minus one controls. 
The relative levels of MHC-I on double positive cells were determined by normalizing MFI 
levels on cells infected with virus encoding Nef to those infected with virus lacking Nef 
(dNef), where cell surface levels of MHC-I in cells infected with dNef virus was set to 100. 
The relative levels of MHC-I on cells infected with virus encoding Nef was then compared 
between cells infected with virus encoding a non-specific and SNX18-targeting shRNA 
using a paired t-test.  
To quantify the amount of SNX18 in Sup-T1 cells transduced with virus encoding a non-
specific and SNX18-targeting shRNA, SNX18 and actin band intensities obtained by 
Western blotting, as described above, were quantified using Image Studio (LI-COR). The 
intensity of the SNX18 protein bands were normalized to actin levels from the same sample 
and normalized to the SNX18 intensity in cells transduced with virus encoding a non-
specific shRNA. The mean relative SNX18 levels were then analyzed by one-way analysis 
of variance followed by Dunnett’s multiple comparison test. 
3.4.11.4 Extracellular vesicle purifications 
To quantify the amount of Nef in the extracellular vesicle purifications from transfected 
cells, the Western blot band intensities were quantified using Image Studio (LI-COR). The 
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intensity of Nef from the extracellular fraction was normalized to the intracellular levels of 
Nef. The relative levels of extracellular Nef in 293TαSNX18 knock-down cells was than 
normalized to those in 293TNS cells from the same experiment. Mean levels of extracellular 
Nef purified from 293TαSNX18 and 293TNS cell supernatants was then compared using a 
Student’s t-test. 
3.4.11.5 Statistical analysis 
All statistical tests were completed using Graph Pad Prism (Graph Pad Software Inc., La 
Jolla, CA). 
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Chapter 4  
4 General Discussion 
4.1 Thesis overview 
The work presented in this thesis aimed to provide novel insights into the mechanisms by 
which the HIV-1 accessory proteins Nef and Vpu alter the host cellular environment. We 
posited that the functions of Nef and Vpu are mediated through the ability of these viral 
proteins to hijack host cellular proteins, specifically those involved in the trafficking of 
cargo to different cellular locales. In Chapter 2, we observed Nef- and Vpu-mediated 
downregulation of the immune cell co-stimulatory molecule CD28 and also implicated host 
cell protein binding motifs located within the viral proteins in this process. In Chapter 3, 
we identified a novel host cell binding partner of Nef, the membrane trafficking regulator 
SNX18, which we propose is hijacked by Nef via a host cell protein binding motif to 
mediate dysregulation of the immune cell receptor MHC-I. 
4.1.1 Chapter 2: Findings, limitations and future work 
In Chapter 2, we set out to examine how the HIV-1 accessory proteins alter the co-
stimulatory molecule CD28. Prior studies suggested that Nef downregulates cell surface 
levels of CD28 [1, 2], however it was unknown how Nef was mediating this process. 
Moreover, the cell surface downregulation of CD28 by the accessory protein Vpu had only 
been previously documented in a large-scale screen of receptors that are modulated by Nef 
and Vpu [3]. Given that Nef and Vpu alter the subcellular localization of other cell surface 
receptors by hijacking cellular trafficking machinery, we hypothesized that this is how Nef 
and Vpu mediate their effects on CD28. Overall, the work in this chapter has given us an 
unprecedented view of the mechanism of Nef- and Vpu-mediated downregulation of 
endogenous CD28 in CD4+ T cells. Moreover, this is the first examination of Vpu-mediated 
CD28 downregulation. 
4.1.1.1  The subcellular fate of CD28 upon HIV-1 infection 
We observed that in infected cells HIV-1 Nef and Vpu mediate decreases in cell surface 
levels of CD28, as well as decreases in total CD28 protein levels (Figure 2.1; Figure 2.8). 
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These decreases in CD28 were accompanied by increased CD28 localization to lysosomal 
compartments (Figure 2.9). Moreover, our results support a mechanism whereby total 
CD28 protein levels are decreased by the viral proteins in an endosomal acidification-
dependent manner (Figure 2.10). Thus, we concluded that the mechanism by which Nef 
and Vpu decrease cell surface CD28 is mediated, at least in part, by decreasing total protein 
levels via mis-localizing CD28 to acidified degradative compartments. Similar 
mechanisms are utilized by Nef and Vpu to downregulate cell surface CD4 and BST-2, 
respectively [4-9]. 
4.1.1.2 Nef and Vpu motifs in CD28 downregulation 
We hypothesized that Nef and Vpu mediate their effects within the cell by hijacking 
cellular trafficking proteins. Therefore, we examined the consequences of introducing 
mutations in motifs that were previously implicated in mediating interactions between the 
viral proteins and host cellular proteins. We observed that mutations in specific virus: host 
protein interaction motifs inhibited downregulation of CD28 at both the cell surface and 
total protein levels, namely mutation of the Nef LL165 and DD175 motifs (Figure 2.13; 
Figure 2.14) and the Vpu S52/56 motif (Figure 2.15). Given that these motifs mediate 
interactions with host cell proteins to downregulate other cellular receptors [10-14], these 
findings support our hypothesis that CD28 downregulation is facilitated by Nef and Vpu 
hijacking host cellular trafficking proteins. To more directly test this hypothesis, we sought 
to knock-down or inhibit specific cellular trafficking proteins and examined the effects on 
CD28 downregulation. We did not observe any impairment in Nef-mediated cell surface 
CD28 downregulation upon knock-down of the membrane trafficking adaptor AP-2 α and 
μ subunits or overexpression of a dominant negative form of the membrane trafficking 
regulator SNX9 (Figure 2.17; Figure 2.18). As described in section 2.3, these experiments 
may be limited by the fact that host cellular trafficking proteins and pathways can be 
redundant or capable of compensating for the loss of specific trafficking proteins. Indeed, 
previous work suggests that upon knock-out of adaptor protein subunits, namely AP-1µ, 
cells may compensate for this loss by upregulating other membrane trafficking proteins 
[15]. Further studies would benefit from simultaneous knock-down or inhibition of 
multiple membrane trafficking proteins, though this may be technically difficult. 
190 
 
Moreover, the effects of knock-downs may be increasingly apparent if more efficient 
decreases in protein levels are obtained, which could be achieved through the use of gene 
editing technologies to knock-out genes of interest [16, 17]. Nonetheless, it would be useful 
to validate our AP-2 knock-downs or SNX9 dominant negative protein by determining if 
they impede the Nef-mediated downregulation of receptors believed to be downregulated 
in an AP-2-dependent manner. In addition to the trafficking mediators explored herein, the 
importance of the Nef LL165 and DD175 motifs and the Vpu S52/56 motif also suggest 
potential involvement of AP-1, LC3C and β-TrCP in Vpu-mediated downregulation [13, 
18, 19], and the v-ATPase in Nef-mediated CD28 downregulation [20, 21]. Thus, these 
host proteins represent strong candidates for further exploration. 
4.1.1.3 Conservation of Vpu-mediated CD28 downregulation 
In addition to exploring the mechanism of Nef- and Vpu-mediated CD28 downregulation, 
we sought to determine if the ability of Vpu to downregulate CD28 was a feature unique 
to the HIV-1 lab adapted strain NL4.3, or if Vpu proteins from other HIV-1 viruses can 
downregulate CD28. This is important as the HIV-1 epidemic is comprised of a large array 
of diverse viruses [22-24]. Thus, if Vpu-mediated CD28 downregulation is observed for 
multiple distinct viruses, our findings may be more applicable to the epidemic as a whole. 
We observed that the downregulation of CD28 in CD4+ Sup-T1 cells can be mediated by 
Vpu proteins derived from the HIV-1 strain B.JFRL and a consensus C Vpu protein (Figure 
2.21). However, our analysis was limited to a small number of Vpu proteins. Furthermore, 
we examined the ability of these Vpu proteins to downregulate CD28 in the context of a 
viral backbone derived from NL4.3. Therefore, it would be worthwhile for future studies 
to examine Vpu-mediated downregulation of CD28 by a variety of viruses using full length 
molecular clones. Additionally, the dileucine-like motif of NL4.3 Vpu was required for 
cell surface CD28 downregulation (Figure 2.15). However, this motif is absent in the 
B.JRFL Vpu protein which also mediated efficient CD28 downregulation (Figure 2.21; 
Figure 2.24). Thus, it will be important to examine if the host cell proteins required to 
mediate CD28 downregulation by these different Vpu proteins are equivalent. Nonetheless, 
the finding that non-NL4.3 Vpu proteins can downregulate CD28 validates that Vpu-
191 
 
mediated downregulation of CD28 could be a universal feature across the epidemic, 
supporting the importance of future research. 
4.1.1.4 The function of CD28 downregulation 
Given the central role of CD28 in signaling to mediating T cell activation, we proposed 
that CD28 downregulation by the viral proteins may impact the activation of T cells. We 
observed that in stimulated cells Nef promoted increased activation, while Vpu inhibited 
activation (Figure 2.23). These effects could be due to changes in the cell surface levels of 
CD28, but may also be attributable to the numerous other effects of the viral proteins on 
immune cell activation, as described in section 1.5.5. Future experiments are necessary to 
more conclusively link downregulation of CD28 to cell activation; however, this is 
challenging given the fact that there are no known mutations in the viral proteins that can 
be made to specifically negate CD28 downregulation without impeding other functions. 
Thus, it is difficult to inhibit CD28 downregulation without hindering other viral protein 
functions which could impact cellular activation. Nevertheless, it would be interesting for 
future experiments to determine if the amount of phosphorylated, and thus signaling 
competent, CD28 differs in stimulated CD4+ T cells infected with virus encoding or lacking 
Nef and Vpu. Overall, we postulate that changes in cell surface CD28 mediated by the viral 
proteins contribute to the overall dysregulation of cellular activation by limiting detection 
of extrinsic stimuli. 
4.1.1.5 Redundancy in CD28 downregulation ability 
The ability of two HIV-1 proteins to counteract the same cell surface molecules 
underscores the importance of this function. In this manner, HIV-1 has a back-up plan to 
ensure that CD28 is downregulated to some extent. Future experiments may be useful to 
determine if there are differences in CD28 downregulation at different times during 
infection. In our experiments in Sup-T1 cells, we examined downregulation at forty-eight 
hours post infection. However, Nef is expressed early during infection, even from 
unintegrated HIV-1 DNA [25], while Vpu is a “late gene”, as its translation is dependent 
on prior expression of the viral Rev protein [26]. Therefore, it would be interesting to 
examine whether the effects of Vpu are more pronounced if the infection proceeds for an 
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increased amount of time, or if downregulation by Nef and Vpu differ over the course of a 
number of days. Moreover, given that vpu and nef genes can compensate for each other, 
we could examine whether there are viruses encoding Nef proteins that poorly 
downregulate CD28, but encode Vpu proteins that compensate for this defect by 
downregulating CD28 more efficiently, or vice-versa. Overall, the ability of multiple viral 
proteins to alter cell surface expression of CD28 suggests that this function is significant.  
4.1.1.6 Summary and future directions 
In taking together the data presented in Chapter 2 and previous findings, we propose a 
model of how Nef and Vpu modulate CD28 within infected CD4+ T cells (Figure 4.1). Nef 
decreases both cell surface and total cellular protein CD28 levels (Figure 2.1; Figure 2.8). 
It remains unknown if Nef targets CD28 at the cell surface, though it has been proposed 
that Nef accelerates the internalization of cell surface resident CD28 [1]. Moreover, it 
remains unclear if Nef mediated downregulation of CD28 occurs through binding to the 
cytoplasmic tail of CD28, similar to how Nef downregulates MHC-I and CD4 [27-29]. We 
observed that mutation of the Nef LL165 or DD175 motifs inhibits the ability of Nef to 
downregulate CD28 (Figure 2.14), suggesting that downregulation of CD28 by Nef may 
require host cellular proteins known to bind to Nef via these motifs, such as AP-2 or v-
ATPase [20, 30]. However, future studies are required to confirm if these proteins are 
necessary for downregulation of CD28. Finally, we observed that in the absence of Nef 
there is less CD28 trafficked to LAMP-1 positive compartments (Figure 2.9), suggesting 
that Nef mediates trafficking to, and potentially degradation of CD28 within, lysosomes. 
Future studies to better map the trafficking pathway and proteins required for CD28 
downregulation by Nef are required. In the case of Vpu, our findings indicate that the S52/56 
motif, which mediates binding to β-TrCP [13], is critical for decreasing cell surface and 
total cellular CD28 protein levels (Figure 2.15). Thus, the mechanism of Vpu-mediated 
CD28 downregulation may require β-TrCP recruitment. However, it remains unknown if 
Vpu is hijacking CD28 at the endoplasmic reticulum, as it does CD4 [13, 31], or at the cell 
surface or intracellular compartments, as it does BST-2 [4, 32]. Moreover, future work is 
needed to determine if Vpu interacts with CD28, to identify additional host cellular proteins 
necessary for Vpu-mediated CD28 downregulation, and to further understand how Vpu 
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contributes to increased lysosomal localization of CD28 (Figure 2.9). Given the importance 
of CD28 in cell activation [33, 34], Nef- and Vpu-mediated decreases in cellular CD28 
levels may play a significant role in altering the activation status of the cell. We observed 
opposite effects of Nef and Vpu on cellular activation (Figure 2.23), which may be a result 
of changes in cellular CD28 levels in addition to the other effects on cellular activation that 
are mediated by the accessory proteins (Section 1.5.5). Overall, changes in cellular 
activation are important, as they can influence antiviral responses and HIV-1 viral gene 
transcription [35-37].     
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Figure 4.1 Models of Nef- and Vpu-mediated CD28 downregulation 
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Proposed models of CD28 downregulation by (a) Nef and (b) Vpu. (A) Newly translated 
CD28 is trafficked to the cell surface via the TGN. In the presence of Nef, CD28 may be 
targeted at the cell surface to increase endocytosis [1], contributing to decreases in cell 
surface levels of CD28. The LL165 and DD175 motifs, which facilitate binding of Nef to 
AP-2 and v-ATPase [20, 30], are critical for CD28 downregulation. In the presence of 
Nef, CD28 localizes to lysosomes. (B) Vpu mediates decreases in cell surface and total 
CD28, but it remains unknown if CD28 is targeted by Vpu shortly after translation in the 
ER, at the cell surface, or at intracellular compartments. The β-TrCP-binding motif of 
Vpu, S52/56, is critical for Vpu-mediated downregulation of CD28. In the presence of 
Vpu, CD28 localizes to lysosomes. 
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4.1.2 Chapter 3: Findings, limitations and future work 
We propose that HIV-1 Nef and Vpu mediate their functions by interacting with host 
cellular membrane trafficking proteins and in Chapter 3 we characterize a novel Nef: host 
protein interaction and examine its importance in Nef-mediated MHC-I downregulation. 
Given the sheer complexity of membrane trafficking, we hypothesized that numerous host 
cell proteins are critical for Nef to downregulate MHC-I, including proteins not yet 
implicated in this process. We were specifically interested in the sorting nexin proteins, 
which stems from our previously published work that illustrates a SNX18: Nef complex is 
formed that localizes to compartments containing AP-1 [38], a trafficking adaptor that Nef 
hijacks to downregulate MHC-I [27].  
4.1.2.1 The Nef: SNX18 interaction interface 
In this chapter, we illustrated for the first time that SNX18 is a direct Nef binding partner 
(Figure 3.1). We have mapped the interaction between SNX18 and Nef to the SH3 domain 
of SNX18 (Figure 3.2). Moreover, the in vitro direct binding, as well as the interaction 
between SNX18 and Nef in cells, was dependent on the Nef PxxP75 motif (Figure 3.3; 
Figure 3.4), which is unsurprising given its documented role in interacting with other SH3 
domain containing proteins [39, 40]. Notably, the interaction between SNX18 and Nef in 
cells, as quantified by BiFC fluorescence intensity, was not completely abolished by 
mutation of the Nef PxxP75 motif (Figure 3.4). This indicates that there may be residues 
within Nef outside of this motif that contribute to this interaction, or that additional host 
cell proteins may facilitate this interaction in cells. A candidate host cell protein that could 
facilitate SNX18 and Nef binding is AP-1, which binds to both SNX18 and Nef [27, 41, 
42], and was previously found to co-localize with the Nef: SNX18 complex in cells [38]. 
Therefore, it would be of interest for future studies to determine if mutation of the Nef 
EEEE65 motif, which mediates AP-1 interactions [27, 43], alters the intensity of the Nef: 
SNX18 BiFC signal. Moreover, it would be interesting to determine if Nef inhibitors such 
as 2c, which targets the Nef PxxP75: SFK SH3 domain interaction interface [44], influence 
the Nef: SNX18 interaction, which could contribute to the ability of these inhibitors to 
block Nef-mediated MHC-I downregulation [44]. In summary, we have identified a novel 
Nef-binding host protein which we posit may facilitate Nef-mediated functions. 
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4.1.2.2 The Nef: SNX18 interaction in MHC-I downregulation 
Overall, we propose that the Nef: SNX18 interaction functions to facilitate Nef-mediated 
MHC-I downregulation. This is supported by our findings that the shRNA knock-down of 
SNX18 reduced Nef-mediated MHC-I downregulation (Figure 3.5). While the inhibition 
of downregulation was consistent, the change was small. However, as discussed in section 
3.3, given that SNX18 and SNX9 exhibit some redundant functions we cannot exclude the 
possibility that despite the lack of a direct SNX9: Nef interaction SNX9 may compensate 
for the loss of SNX18, thereby reducing the effect of SNX18 knock-down on Nef-mediated 
MHC-I downregulation. Future experiments could examine if knock-down of both SNX18 
and SNX9 leads to a greater deficit in Nef-mediated MHC-I downregulation. Moreover, 
while we would like to illustrate that a physical interaction between SNX18 and Nef is 
explicitly required for Nef-mediated MHC-I downregulation it is technically challenging 
given the fact that mutations in the interaction interface also inhibit other protein 
interactions. Indeed, mutation of the Nef PxxP75 motif has already been implicated in 
inhibiting MHC-I downregulation through its abolition of the Nef: SFK interaction [45, 
46]. Nonetheless, our data suggest SNX18 plays a role in decreasing cell surface levels of 
MHC-I in the presence of Nef. 
Given our interest in the role of host cell proteins in the mechanisms of Nef function, we 
sought to define SNX18’s specific role during MHC-I downregulation. Our findings 
indicated that Nef-containing extracellular vesicles are secreted despite reductions in 
SNX18 protein levels (Figure 3.7). Thus, we do not believe that SNX18 is promoting 
decreased cell surface levels of MHC-I by facilitating Nef-mediated secretion of vesicles 
containing MHC-I. However, as described in section 3.3, future experiments to define the 
components within our extracellular vesicle purifications would be beneficial to determine 
the purity of our preparations, as we have not fully defined the characteristics of our 
purified content, nor have we defined the biogenesis pathway from which these vesicles 
originated. This could be completed by electron microscopy or nanoscale flow cytometry 
to determine the size and physical properties of the purified content. In addition, we 
observed that the SNX18: Nef BiFC complex was present at CD63 positive compartments 
(Figure 3.6). Co-localization of the SNX18: Nef BiFC signal with the CD63 marker could 
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suggest that this interaction is occurring at locations where vesicles destined for secretion 
accumulate, however late endosomes marked by CD63 can also contain cargo destined for 
other intracellular compartments. Therefore, the SNX18: Nef interaction may simply be 
occurring at late endosomes, a compartment through which Nef and MHC-I traffic during 
MHC-I downregulation [47]. In this way, SNX18 may function to mediate trafficking of 
MHC-I from the cell surface to the TGN, where MHC-I is sequestered in the presence of 
Nef [44, 47, 48]. Future experiments are necessary to further map the cellular location of 
the SNX18: Nef interaction and examine if Nef-mediated sequestration of MHC-I in the 
TGN is altered in the absence of SNX18. Ultimately, we propose that the binding of Nef 
to SNX18 facilitates Nef-mediated mis-localization of MHC-I within infected cells.  
4.1.2.3 Summary and future directions 
The data presented in Chapter 3 sheds light on the mechanism of how Nef contributes to 
decreases in cell surface levels of MHC-I, which prevents CD8+ cytotoxic T cell detection 
of virally infected CD4+ T cells (Figure 4.2; [49, 50]). Nef promotes endocytosis of cell 
surface MHC-I through an Arf1- or Arf6-dependent mechanism [51, 52]. Trafficking of 
MHC-I away from the cell surface is dependent on Nef’s ability to bind AP-1 and PACS-
1 [53, 54]. This process may be further facilitated by the membrane trafficking mediator 
SNX18, which we have identified as a novel Nef-binding partner (Figure 3.1). This 
interaction is mediated by the PxxP75 motif of Nef binding to the SNX18 SH3 domain 
(Figure 3.2; Figure 3.3). SNX18, like Nef, binds to AP-2 [30]. Upon reductions in SNX18 
protein levels, Nef-mediated MHC-I downregulation is reduced (Figure 3.5). However, 
future studies are needed to confirm the importance of SNX18 in MHC-I downregulation. 
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Figure 4.2 Model of Nef-mediated evasion of cytotoxic T cell responses 
Nef mediates decreases in CD4+ T cell surface levels of MHC-I, preventing detection by 
CD8+ cytotoxic T cells (left; [49, 50]). MHC-I downregulation is facilitated by Arf1- or 
Arf6-mediated endocytosis of cell surface MHC-I (right; [51, 52]). MHC-I is then 
trafficked to the trans-Golgi network in a manner dependent on Nef, PACS-1 and AP-1 
[53, 54]. This trafficking step may be facilitated by SNX18 binding to Nef via a 
PxxP75:SH3 domain interaction.  
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4.2 Significance 
Overall, this thesis provides novel insight into how host cellular receptors are mis-localized 
by the HIV-1 accessory proteins Nef and Vpu. These alterations in the location of host cell 
proteins undoubtedly alter how cells function during HIV-1 infection. In the case of the 
receptors of interest to this work, MHC-I and CD28, the decreases in cell surface levels of 
these immune cell receptors may alter immune responses, despite the effects on these 
receptors being modest. Indeed, it is well established that HIV-1-mediated decreases in cell 
surface levels of MHC-I inhibit detection and killing of virally infected cells [50]. 
Specifically, cells infected with HIV-1 encoding a functional nef gene are more effeciently 
killed by CTLs than by cells infected with HIV-1 enconding Nef unable to downregulate 
MHC-I [50, 55]. Moreover, clinical evidence indicates that MHC-I downregulation ability 
may correlate with HIV-1 disease progression [56, 57]. In contrast, decreases in cell surface 
CD28 likely inhibit CD28 receptor activation. This may contribute to inhibiting the 
responsiveness of cells to external stimuli, in conjunction with the countless other Nef- and 
Vpu-mediated modifications described in section 1.5.5 that influence immune cell 
activation. Changes in cellular activation are important during HIV-1 infection, given that 
HIV-1 transcription is driven by transcription factors that are activated during cell 
activation, thus influencing viral replication (reviewed in [58]). The importance of altering 
the subcellular localization of these receptors during a HIV-1 infection is supported by the 
functional redundancy in Nef and Vpu, whereby both viral proteins contribute to decreases 
in cell surface MHC-I and CD28. In this way, the virus has a contingency plan to ensure 
these functions are fulfilled.  
4.2.1 Implications for HIV-1 treatment 
The functional redundancy of Nef and Vpu emphasizes their significance during infection 
and implies they could be effective therapeutic targets. However, the development of HIV-
1 therapeutics against the accessory proteins Nef and Vpu has been limited. This is likely 
owing to the fact that therapeutics inhibiting Nef and Vpu would need to be utilized in 
combination with other anti-retroviral therapies, as HIV-1 can still replicate in the absence 
of these proteins. Moreover, given that Nef and Vpu are not enzymes, they cannot be 
counteracted by targeting catalytic sites or inhibiting enzymatic activity, as has been done 
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for most of the previously developed anti-retrovirals [59]. However, Nef and Vpu 
functions, including MHC-I and CD28 downregulation, can be targeted based on our 
knowledge of their interactions with host cell proteins. Specifically, as druggable targets 
we can utilize the interaction interfaces between the virus and host proteins that are crucial 
for accessory protein functions. By preventing these binding events through the use of 
small molecule inhibitors, we can prevent Nef- and Vpu-mediated functions. Importantly, 
the Nef and Vpu host cell protein binding motifs are good targets as they are generally 
made up of conserved residues [60-64]. This conservation would allow for targeting of 
these accessory proteins in a manner applicable across the HIV-1 epidemic. 
In addition to being potential targets for new HIV-1 therapeutics, the presence of these 
proteins needs to be accounted for when developing HIV-1 cure strategies, as the functions 
of Nef and Vpu alter the ability of the immune system to detect and eliminate HIV-1 
infection. Obtaining a cure for HIV-1 for those that are currently infected is of importance 
due to the large cost of remaining on life-long anti-retroviral treatment and the co-
morbidities associated with HIV-1 infection [65, 66]. Currently, the greatest challenge to 
curing HIV-1 infections is the presence of latently infected cells which remain “hidden” 
from both the immune system and anti-retroviral therapy by remaining in a resting state 
where HIV-1 gene expression does not occur [67]. Nevertheless, these latently infected 
cells can be reactivated to begin producing virus. Thus, these cells must be eradicated in 
order to eliminate HIV-1 infection. A major approach being used to eliminate latently 
infected cells is reactivating or “shocking” latently infected cells, such that they begin 
expressing viral proteins. This process is followed by elimination or “killing” of these 
reactivated cells via the immune system or viral cytopathic effects [68]. HIV-1 cure 
approaches such as this shock-and-kill method that rely on the immune system to eliminate 
the virus will need to address the fact that if the viral accessory proteins are present, they 
will continue to inhibit the ability of the immune system to eliminate the virus. In this way, 
the use of inhibitors to block the immune evasion capabilities of the accessory proteins has 
been suggested to be critical for successful elimination of latently infected cells [69].  
It has been proposed that molecules such as the Nef: SFK interaction inhibitor 2c, which 
inhibits Nef-mediated MHC-I downregulation [44], are good candidates to consider for 
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preventing immune evasion during attempts to eliminate latently infected cells [69]. 
However, we must also consider the fact that the virus has a back-up plan, with Vpu also 
contributing to MHC-I downregulation [70, 71]. In addition to inhibiting Nef-mediated 
MHC-I downregulation, the targeting of Nef and Vpu’s ability to hide from the immune 
system has also been facilitated through the use of small molecules known as CD4 
mimetics. Specifically, Nef- and Vpu-mediated CD4 downregulation prevents the 
exposure of CD4-induced epitopes on cell surface envelope to ADCC-mediating antibodies 
which serves as a signal for NK cell-mediated lysis of infected cells [72, 73]. CD4 mimetics 
can overcome this process by mimicking the presence of cell surface CD4. Specifically, 
they bind to cell surface envelope and stimulate exposure of CD4-induced epitopes, thereby 
increases NK cell-mediated killing of infected cells [74].  
Ultimately, if we are to successfully cure HIV-1 by eliminating the latent reservoir, we 
need to consider how we can overcome the incredibly effective and redundant abilities of 
the HIV-1 accessory proteins Nef and Vpu to evade the immune system.  
4.2.2 Concluding remarks 
The ability of HIV-1 Nef and Vpu to exhibit functional redundancy is through their shared 
ability to usurp broad cellular mechanisms that determine protein localization within the 
cell. Both Nef and Vpu bind to and hijack host cellular proteins to link their target proteins, 
often cell surface molecules, with the machinery that alter their primary location in the cell. 
This frequently results in the sequestration of target proteins intracellularly or their 
trafficking to sites of protein degradation. The viral proteins facilitate this by mimicking 
canonical host cell protein signals that determine protein localization, such as those that 
mediate binding of membrane trafficking adaptors or the ubiquitin ligase machinery. 
Ultimately, functions similar to those exhibited by HIV-1 Nef and Vpu allow for viruses 
to commandeer host cell machinery to make cells optimally efficient viral production 
factories. 
The study of viruses has broad implications. Notably, researching the fundamental 
mechanisms of clinically relevant viruses is critical to improving prevention, detection and 
treatment of pathogenic viruses. Additionally, since viruses require host cells to replicate, 
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these basic studies also enhance our understanding of fundamental host cell functions. 
Therefore, virology research inevitably leads to an increased understanding of cellular 
biology and biochemistry. In this way, viruses and viral proteins can also serve as research 
tools, effectively expanding our understanding of how cellular processes are mediated in 
the absence of viral infection. 
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